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Introduction
The immune system protects organisms from infectious agents and is involved in 
immune surveillance of malignant cell transformation. Unfortunately, malignant 
cells exploit various mechanisms to evade the immune system resulting in tumor 
outgrowth. In immune therapy, the immune system is reinforced to fight cancer or 
infections. For the treatment of hematological cancers, allogeneic hematopoietic 
stem cell transplantation (allo-SCT) has been established as powerful form of cellular 
immune therapy. The beneficial effect of allo-SCT is a result of the graft-versus- 
tumor (GVT) effect, which is an immunological reaction, mainly executed by donor- 
derived T cells and natural killer cells (NK cells), against tumor cells of the patient. 
Unfortunately, the GVT effect is often accompanied by graft-versus-host disease 
(GVHD), which is an immunological reaction against healthy tissues, resulting is 
considerable morbidity and mortality. In addition, tumor relapses after allo-SCT still 
occur. As a result, novel immunotherapeutic strategies which can induce a powerful 
GVT effect, without the devastating GVHD, are urgently needed. In this thesis, 
we investigated novel cellular immunotherapeutic strategies which aim to enhance 
the GVT effect, without GVHD. The first part explores T cell mediated strategies, and 
in the second part NK cell mediated immunotherapies are investigated. Finally, in 
the last part we illustrate how different forms of immune therapy can be combined 
to maximize their therapeutic potential in multiple myeloma.
Hematological malignancies
Hematological malignancies are clonal diseases originating from a single cell in 
the bone marrow (BM) or peripheral lymphoid tissues, which underwent genetic 
alterations. These alterations result in uncontrolled division of the cell. Depending 
on the affected cell and the genetic alteration, a broad range of diseases with diverse 
clinical features and prognosis can develop. These diseases are generally divided 
into four main groups: acute leukemias, chronic leukemias, lymphomas and plasma 
cell diseases. Hematological malignancies account for 8% of all malignancies in 
Europe.1 This results in 5,600 new patients each year in the Netherlands. Over the last 
century remarkable progress has been made in the treatment of hematological 
malignancies.
 In 1832, Thomas Hodgkin was the first to describe a hematological malignancy 
in medical literature. The disease was later titled Hodgkin’s disease by Samuel Wilks. 
Leukemia was described some years later, in 1845, by Bennett and Virchow. The first 
malignant plasma cell disease, mutiple myeloma (originally called Kahler’s disease), 
was described by Otto Kahler in 1889.2 At that time, no therapies were available to 
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Chapter 1
treat these diseases. Radiotherapy was the first available therapy to treat hema- 
tological malignancies. This therapy was introduced in the beginning of the 20th 
century, mainly to treat Hodgkin lymphoma.3 By 1960 the first patients were cured 
using this treatment. Nowadays radiotherapy is still one of the mainstays in therapy 
of hematological malignancies. Another important therapeutic modality is chemo- 
therapy. The first applications of chemotherapy originate from the 1940s. At that 
time, Louis Goodman and Alfred Gilman found that nitrogen mustard, which had 
been developed for chemical warfare, could induce tumor regression in advanced 
non-Hodgkin lymphoma.4 Nitrogen mustard is a so called alkylating agent, currently, 
modern alkylating agents like cyclophosphamide are still used in the treatment of 
lymphomas and leukemias. In the 1940s, a second approach was developed by 
Sidney Farber. Farber had observed that folic acid stimulated proliferation of acute 
lymphoblastic leukemia (ALL) in children. Therefore, he developed folate analogues 
which could block the function of folate requiring enzymes. These drugs were the 
first drugs to successfully induce remission in children with ALL.5 Unfortunately, 
remissions induced by single agent chemotherapy turned out to be temporary; 
therefore, chemotherapy is currently used as combination therapy. Combination 
chemotherapy with or without radiotherapy can reduce tumor burden and can 
induce long-term remission in some hematological malignancies. For example, multi- 
drug chemotherapy has resulted in overall survival (OS) rates > 90% in childhood 
ALL6 and 5-year OS rates of 88-95% can be reached in Hodgkin lymphoma.7 
In contrast, 5-year OS rates in elderly acute myeloid leukemia (AML) patients are still 
as low as 10%.8 
 In addition to chemotherapy and radiotherapy, in the last decade, targeted 
therapy was added to the therapeutic arsenal. Targeted therapies are directed 
against molecular defects in growth factors, signaling molecules, cell cycle proteins 
or modulators of apoptosis responsible for unlimited cell growth. A well known 
example of a targeted therapy is imatinib, for the treatment of chronic myeloid 
leukemia (CML). This agent inhibits the tyrosine kinase BCR-ABL, which is a product 
of a chromosomal translocation resulting in the Philadelphia chromosome, crucial 
in the pathogenesis of CML. Imatinib has increased 10-year OS from about 20% to 
80-90%.9 DNA methyltransferase inhibitors or hypomethylating agents are another 
promising group of drugs. In recent years, it has become clear that changes in DNA 
methylation play an important role in oncogenesis.10,11 In contrast to genetic changes, 
epigenetic changes are considered to be reversible, making epigenetic changes 
attractive for therapeutic interventions. The hypomethylating agents azacitidine 
and decitabine have shown promising results in myelodysplastic syndrome (MDS) 
and AML patients.12-14 Especially older AML patients, who have a limited benefit with 
current available therapy, may  benefit from these new agents.15,16 Besides targeted 
therapy, immunotherapy can be a powerful therapy by directing the immune 
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system to fight hematological malignancies. A successful example of immune 
therapy is rituximab. Rituximab is an humanized antibody directed against CD20, 
which is expressed on B cells. Addition of rituximab to conventional chemotherapy 
had greatly improved the prognosis of B-cell lymphomas.17 
 Despite the development of these new therapies, many patients still die from 
hematological malignancies. Moreover, therapies are generally toxic, resulting in 
considerable short term and long term morbidity. Therefore, development of more 
effective therapies with reduced side effects is urgently needed. Cellular immuno- 
therapy can potentially induce long-term and specific anti-tumor responses, hence 
this is an attractive adjuvant therapy to cure hematological malignancies. Allo-SCT 
is the oldest and the most effective form of cellular immunotherapy. 
Allogeneic hematopoietic stem cell transplantation
In allo-SCT,  stem cells derived from blood or bone marrow (BM) of a donor are 
transferred to a patient who has been treated with high dosages of chemo- and/or 
radiotherapy. These stem cells home to niches in the BM compartment and form a 
new hematopoietic system. Initially, allo-SCT was performed in patients suffering 
from BM failure after exposure to high dose chemotherapy or irradiation.18 Since BM 
failure is a dose limiting toxicity in high-dose chemotherapy and radiotherapy, SCT 
facilitates the usage of higher dosages of chemotherapy and radiotherapy. 
Interestingly, it was found that transfer of donor stem cells results in better outcomes 
as compared to cryopreserved autologous stem cells or stem cells derived from an 
identical twin donor.19 This is the result of an immunological reaction of donor-derived 
immune cells against residual tumor cells in the patient: the so-called GVT effect.20 
The potency of the GVT effect is further illustrated by induction of durable remissions 
after donor lymphocyte infusions (DLI) in leukemia patients who relapse after 
allo-SCT.21,22 Unfortunately, the GVT effect is often accompanied by an immunological 
reaction against healthy tissues resulting in a multisystem disorder called GVDH.23,24 
Although mild GVHD is associated with a lower relapse rates,20 severe GVHD results 
in considerable morbidity and mortality after allo-SCT. To prevent lethal GVHD, 
HLA-matching is essential in allo-SCT. The HLA system is involved in the presentation 
of antigens to T cells. There are two classes of HLA molecules; HLA-I molecules 
(HLA-A, HLA-B, HLA-C) are present on all nucleated cells, and present peptides to 
CD8+ T cells. HLA-II molecules (HLA-DR, HLA-DQ, HLA-DP) are only present on 
certain immune cells, called antigen-presenting cells (APCs), which present peptides 
to CD4+ T cells. There are many different genetic variants of HLA molecules.25 
To prevent severe GVHD, allo-SCT is preferably performed in donors matched for 
at least eight out of 10 HLA molecules (HLA-DP is not taken into account).26 27 
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Unfortunately, only about 30% of patients have an HLA-matched related donor 
available; in addition, 10-80% of patients (depending on race) have a partially 
matched unrelated donor.28 Currently, alternative donor sources for patients without 
a suitable donor are investigated. Alternative donor sources include haploidentical 
related donors and umbilical cord blood (UCB) stem cell products. A large number 
of phase 2 and observational trials investigating these different donor sources have 
been performed. However, the extensive number of variables including conditioning 
regimen and GVHD prophylaxis strategies make direct comparison of donor sources 
difficult.29 
 In all allo-SCTs, irrespective of donor source, additional interventions to prevent 
GVHD are essential. Since T cells play a major role in the development of GVHD, 
these interventions are mainly directed against T cells. T cells can be depleted from 
the stem cell graft. This can be performed either ex vivo, before transplantation, 
or in vivo, using anti-thymocyte globulin (ATG)30, alemtuzumab31,32 or post-transplant 
cyclo phophamide.33 In addition, immunosuppressive drugs are administered during 
the first period after allo-SCT. Although T cell depletion and immune suppression 
can reduce the risk of GVHD, the desirable GVT effect is also inhibited resulting in 
increased relapse rates.20 Therefore, therapeutic interventions separating GVHD 
from the desired GVT effect are crucially needed. In the next part, we will describe 
the immune biology of the GVT effect, subsequently we will describe potential 
therapeutic interventions maximizing the GVT effect without inducing GVHD. 
Immune biology of the GVT response
After allo-SCT, T cells and NK cells are the main effector cells involved in the GVT 
response. A stem cell transplant will contain low numbers of T cells and NK cells. 
However, T cells and NK cells will develop from donor-derived stem cells.
T cell versus tumor cell
T cells are part of the adaptive immune system, hence every T cell is directed against 
a specific peptide, called an antigen. T cells recognize their cognate antigens 
presented by HLA molecules on the surface of cells, by ligation of this complex by 
the T cell receptor (TCR). Dendritic cells (DCs) are the most professional APCs. 
Immature DCs reside in peripheral tissues where they can capture antigens. Upon 
antigen uptake in an inflammatory environment, DCs start to mature and express 
antigen-HLA complexes.34  Although TCR signal transduction is necessary to activate 
T cells, TCR ligation alone is not sufficient to initiate an immune response. For T cell 
activation, a secondary, so called co-stimulatory signal is needed. The most 
important co-stimulatory signal is provided by interaction of CD28 on the T cell 
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surface with its ligands CD80 and CD86, which are presented on the surface of 
mature APCs. Besides, activated APCs can express several additional co-stimulatory 
receptors like HVEM, CD70, SLAM and OX40L.35,36 In addition to these co-stimulatory 
receptors, T cells can also express co-inhibitory receptors like CTLA-4, PD-1, BTLA and 
TIM-3. These receptors are expressed upon activation, and ligation of these receptors 
to their corresponding ligands on APCs can prevent sustained T cell activation 
resulting in auto-immune diseases (Figure 1).36,37 Interestingly, increased expression 
levels of the co-inhibitory receptor PD-1 on T cells, have been found in patients with 
CLL and adult T-cell leukemia/lymphoma, as compared to healthy controls.38,39 
Figure 1  Co-signaling in T cells
When an antigen presented by an HLA molecule is recognized by its corresponding T cell 
receptor (TCR), the T cell can be activated. However, TCR ligation alone is not sufficient to initiate 
an immune response. For T cell activation, a co-stimulatory signal is needed. The most important 
co-stimulatory signal is provided by ligation of CD28 on the T cell suface, to its ligands CD80 
or CD86 on the antigen presenting cell (APC). In addition, several additional co-stimulatory 
receptors and ligands can be expressed by activated APCs and T cells (depicted in green). 
Interactions between these molecules induce T cell activation. In contrast, APCs and T cells 
can also express co-inhibitory molecules. Interactions between these molecules (depicted in 
red) inhibit T cell effector function, and induce T cell tolerance and apoptosis. Co-inhibitory 
signals are essential to prevent sustained T cell activation resulting in auto-immune diseases.
APC T cell
TCRHLA
CD28CD80/86
LIGHTHVEM
CD27CD70
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OX40L OX40
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PD-1PD-L1/2
HVEM BTLA
TIM3Galectin 9
Co-stimulation
Co-inhibition
514292-L-bw-Roeven
Processed on: 6-10-2017 PDF page: 14
14
Chapter 1
In Hodgkin lymphoma, PD-1 expression on tumor infiltrating lymphocytes was 
also reported;40,41 importantly, high PD-1 expression levels have been associated 
with poor outcome.40 These results suggest that increased expression of these 
co-inhibitory molecules can contribute to the escape from the immune system by 
tumor cells. So blockage of this pathway could be an attractive strategy to enhance 
the GVT effect.
 As mentioned earlier, every T cell is directed against a specific antigen. After 
HLA-matched allo-SCT, GVT effects can be induced by T cell responses toward 
tumor- associated antigens (TAA) or minor histocompatibility antigens (MiHAs). TAA 
are proteins expressed at high levels by tumor cells, but unfortunately, most TAAs 
are also expressed at low levels by healthy tissues, and as a result T cell responses 
against these antigens can potentially induce auto-immune responses.42 MiHAs are 
peptides derived from intracellular proteins, which are presented by HLA molecules. 
MiHAs in recipient cells can differ from those of donor origin due to genetic 
polymorphisms. As a result, donor T cells will recognize these peptides as non-self 
and become activated.43 Numerous MiHAs have been identified, and T cell responses 
against these MiHAs are associated with improved relapse-free survival in several 
studies;44-47 however, not all studies could confirm these results.48,49 Interestingly, 
certain MiHAs are exclusively expressed by hematopoietic cells (e.g. HA1,50 LRH1,51 
ARHGDIB52 and UTA2-153). As a result, boosting T cells against these antigens can 
target leukemia cells, while sparing healthy tissues, thereby separating the GVT 
effect from GVHD. So, these MiHAs are interesting targets for cellular immunotherapy.
Natural killer cell versus tumor cell
NK cells are CD3-CD56+ lymphocytes, which are part of the innate immune system 
and play an important role in the defense against virus-infected and malignant 
cells.54 Activation of these cells and subsequent killing of target cells is regulated by 
a balance in expression levels of numerous inhibitory (e.g. inhibitory killer-cell immuno-
globulin-like receptors (KIRs) and NKG2A) and activating receptors (e.g. DNAX 
accessory molecule-1 (DNAM-1), natural cytotoxicity receptors (NCRs) and NKG2D). 
In homeostasis, NK cells are inhibited by their inhibitory receptors, which recognize 
self HLA class I molecules. An anti-tumor effect can be induced by either up- 
regulation of activating ligands, which is called induced-self activation. On the other 
hand, tumor cells can down-regulate HLA class I molecules, thereby they can escape 
from T cell immunity. In this situation NK cells are not inhibited anymore, and hence 
be activated. This phenomenon is called missing-self activation.54,55 In the setting 
of haploidentical allo-SCT, missing-self activation can contribute to the GVT effect, 
since donor NK cells may lack expression of inhibitory KIRs for recipient HLA class I 
molecules (Figure 2).56 Interestingly, also after HLA-matched allo-SCT, early NK cell 
repopulation has been associated with decreased relapse rates, without increasing 
514292-L-bw-Roeven
Processed on: 6-10-2017 PDF page: 15
15
General introduction
1
GVHD incidence.57,58 Indicating a specific anti-tumor effect independent from KIR 
ligand mismatch. A possible explanation could be the KIR gene-gene model, which 
uses KIR genotype, to predict NK reactivity and clinical outcome after allogeneic 
SCT. KIR genes are located apart from HLA genes on chromosome 16. Two KIR 
genotypes can be distinguished; genotype A, which contains mostly inhibitory KIR 
receptors, and group B, which comprises more activating receptors. Consequently, 
donors and recipients can be categorized as having one of two KIR genotypes: AA 
which is homozygous for group A KIR haplotypes, or Bx, which contains either one 
(AB) or two (BB) group B haplotypes.59 After non-myeloablative HLA-haploidentical 
SCT, it was observed that patients with KIR group A haplotypes showed improved 
overall survival, event-free survival and non-relapse mortality in case the donor had a 
KIR group B haplotype. For patients with KIR group B haplotypes no benefit was 
demonstrated. 60 Furthermore, improved PFS and OS was observed in (AML) patients 
Figure 2  NK cell activation
NK cells are tolerant to healthy cells due to the inhibitory signals provided by their inhibitory 
receptors, which recognize self HLA class I molecules. NK cells can be activated by either by 
induced-self activation or missing-self activation. In induced-self activation infected cells or 
tumor cells can increase expression of activating ligands. Missing-self activation is the result 
of down-regulation of self HLA class I molecules on tumor cells or infected cells. In the setting 
of haploidentical allo-SCT, donor NK cells may lack expression of inhibitory KIRs for recipient 
HLA class I molecules and hence be activated, this is also called missing-self activation. 
NK cell, natural killer cell
NK cell
NK cell
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infected cell
Induced-self activation
Missing-self activation
Tolerance
+
+++
+
-
-
-
-
Killing
Killing
514292-L-bw-Roeven
Processed on: 6-10-2017 PDF page: 16
16
Chapter 1
and relapsed MM patients after HLA-matched SCT when the donor had a group B 
haplotype. This was independent of the patients haplotype. Interestingly, it has been 
shown that early engrafting NK cells after allo-SCT are immature, reflected by a 
reduced cytokine producing capacity.61 As a result, adoptive transfer of functional 
haploidentical donor NK cells, or adoptive transfer of functional donor NK cells after 
HLA-matched allo-SCT could be promising strategies to boost the GVT effect 
without the risk of inducing GVHD.
Cellular immunotherapy in hematological malignancies
Although long-term remissions can be induced after allo-SCT, relapses still occur. 
Therefore, interventions which can enhance GVT effects are needed. In this thesis 
we investigated strategies to boost MiHA-specific CD8+ T cells using dendritic cell 
(DC) vaccines. In addition, we developed NK cell products for adoptive transfer and 
investigated the safety and efficacy of these products. 
T cell based cellular immunotherapy
Since T cells are important effectors after allo-SCT, adoptive transfer of T cells can be 
a strategy to enhance the GVT effect. Adoptive transfer of lymphocytes, including 
T cells, after allo-SCT is called DLI, and it is well known that DLI enhances the GVT 
effect.21,22 However, since unselected T cells are infused, there is a considerable 
risk of inducing GVHD. Therefore, infusion of tumor-specific T cells may be a safer 
treatment. T cells directed against MiHAs selectively expressed by hematopoietic 
tissues will only attack autologous hematopoietic cells including tumor cells, as a 
result, these cells do not induce GVHD. However, the majority of MiHA-specific 
T cells isolated from blood or tumor sites are terminally differentiated effector T cells. 
While these cells are effective killers, they show limited proliferative and no self- 
renewing capacity. This limits their therapeutic potential. It has been shown that less 
differentiated T cell populations like naïve T cells and memory T cell subsets have 
superior in vivo expansion, persistence, and antitumor capacities.62,63 Recently, our 
group has developed a method to generate a MiHA-specific T cell population 
containing a high proportion of T cells with an early memory phenotype. In this 
method, the Akt-pathway is inhibited pharmacologically during culture, resulting in 
MiHA-specific early memory CD8+ T cells, which show a superior expansion capacity 
and a superior antitumor effect as compared to cells generated without Akt-
inhibition.64 Another strategy to generate specific T cells for adoptive transfer is the 
use of T cell receptor-engineered or chimeric antigen receptor (CAR)-engineered 
T cells.65 To generate T cell receptor-engineered T cells, a specific T cell receptor is 
transduced into a T cell. As a result, a T cell population directed against a certain 
514292-L-bw-Roeven
Processed on: 6-10-2017 PDF page: 17
17
General introduction
1
HLA-antigen complex, for example an HLA-MiHA complex, can be generated.66 
CAR-engineered T cells are transduced with a CAR. CARs consist of a tumor antigen- 
binding domain of a single-chain antibody, fused to native human T cell receptor 
CD3ζ signaling domains. Second and third generation CARs have one or more 
additional activating signaling domains derived from co-stimulatory molecules 
such as CD28, 4-1BB, and OX, therefore these CAR-engineered T cells have more 
potent anti-tumor activity as compared to first generation CAR T cells.67,68 Very 
promising results have been obtained by targeting the B-cell lineage restricted 
CD19 molecule in B-cell leukemias and lymphomas, however, CAR T cell adoptive 
transfer can induce severe toxicity.69-71 The generation of CAR T cells targeting 
MiHAs could be a potential therapeutic strategy to treat patients after allo-SCT. 
Although generation of MiHA-specific CAR-engineered T cells has been explored, 
no effective MiHA-specific CAR T cells have been generated yet.72 
 In contrast to the adoptive transfer of T cells targeting tumor cells, endogenous 
T cells can be activated in vivo by DC vaccination. The aim of DC vaccination is to 
induce or boost tumor-specific effector T cells that can reduce the number of tumor 
cells, and can induce an immunological memory response to prevent relapses. DCs 
can be generated ex vivo from monocytes, which are abundant in peripheral blood.73,74 
Next, DCs can be loaded with target antigens, like MiHA antigens. Loading can be 
either exogeneously with short MiHA peptides or DCs can be pulsed with MiHA- 
encoding mRNA. Following mRNA electroporation, diverse MiHA epitopes are 
presented in both HLA-I and HLA-II molecules, which allows activation of a broad 
repertoire of MiHA-specific T cells.75-77  In Chapter 2 of this thesis, we investigated 
MiHA loaded DC vaccines in patients who relapsed after allo-SCT, and did not 
respond to DLI.
 As mentioned before, the GVT effect mediated by T cells can be hampered by 
ligation of co-inhibitory molecules expressed on tumor reactive T cells. An important 
co-inhibitory pathway is the PD1/PD-L1 pathway. We found that PD1/PD-L1 interactions 
contribute to functional impairment of MiHA-specific CD8+ T cells in patients with 
relapsed cancer after allo-SCT.78 In addition, our group has shown that silencing 
of PD-L1 and PD-L2 on MiHA loaded DCs results in more potent DCs, which 
show superior potential to expand MiHA-specific CD8+ T cells.79,80 In Chapter 3 of 
this thesis, we investigated a clinical-grade method to silence PD-L2 and PD-L2 
expression on DC vaccines using siRNA/SAINT-RED transfection. 
Natural killer cell adoptive cell therapy
Besides  T cells, NK cells are important effectors in the GVT response. Therefore, 
NK cell adoptive cell therapy (ACT) can be another attractive strategy to fight 
hematologic malignancies. Miller et al. performed the first clinical trial investigating 
adoptive transfer of allogeneic NK cells in poor-risk AML patients in a non-transplant 
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setting.81 In his study, complete hematologic remission was induced in 5 out of 19 
poor-risk AML patients. Since this study, several studies investigating allogeneic NK 
cell ACT in AML were performed.82-86  These studies found CR rates in poor-risk AML 
patients up to 53% (8/15).86 In NK cell ACT, patients are generally conditioned with a 
cyclophosphamide and fludarabine based immunosuppressive chemotherapy. This 
therapy prevents direct rejection of allogeneic NK cells; besides, it increases 
endogenous cytokine levels, that promote NK cell survival in vivo.81,85 
 For optimal therapeutic effects, NK cell ACT requires sufficient numbers of activated 
NK cells. Moreover, NK cell products need to be free of T cells to prevent GVHD. 
Allogeneic NK cell products used for NK cell ACT are generally enriched from 
peripheral blood from haplo-identical donors, and infused following overnight 
stimulation with IL-2 or IL-15. Using this procedure, relatively low NK cell dosages can 
be generated (3-5x106 cells/kg).83,84,86 In addition, most procedures reported T cell 
dosages of 5x104 up to 2x105 T cells/kg, resulting in an increased risk of GVHD.81,83-86 
For these reasons, our group has developed a good manufacturing practice (GMP)-
compliant, cytokine based culture method for the generation of high numbers of 
highly active NK cells, free of T cells.87,88 In this method, CD34+ human stem and 
progenitor cells (HSPCs) are isolated from umbilical cord blood (UCB). Subsequently, 
these HSPCs are expanded and differentiated into NK cells using different cytokine 
cocktails (Figure 3). Using this method, within 5-6 weeks, an HSPC-NK cell product 
containing > 70% highly activated HSPC-NK cells, free of T cells, can be generated. 
These HSPC-NK cells show cytolytic activity against AML cells in vitro,88 as well BM 
homing capacity and anti-leukemic effects in vivo.89 We performed a phase I clinical 
trial investigating feasibility and safety of these HSPC-NK cell products. Chapter 4 of 
this thesis describes the results of this trial.
 There are several possible methods to further improve allogeneic NK cell ACT. 
We found that the killing potential of our product can be improved by replacing IL-2 
in our culture protocol by IL-12.90 In addition, in vivo survival of NK cells can be 
improved by administration of cytokines, like ALT-803.91 Another example of a 
possible strategy to improve NK cell ACT is to combine NK cell ACT with DNA meth-
yltransferase inhibitors. DNA methyltransferase inhibitors, like azacitidine and 
decitabine are novel agents used to treat AML patients. Recently, it was found that 
NK cells in MDS patients undergoing azacitidine treatment express higher levels of 
KIR, reflecting terminal NK cell differentiation.92 Importantly, these NK cells showed 
higher degranulation and IFN-γ production in response to leukemia cell lines in vitro. 
As a result, combination of NK cell ACT with DNA methyltransferase inhibitors might 
improve NK cell ACT by direct anti-leukemic effects, as well as by potentiating NK 
cell reactivity against AML. In Chapter 5, we compared the impact of azacitidine and 
decitabine on HSPC-NK cells, and investigated their additive and/or synergistic 
anti-leukemic effect in combination with HSPC-NK cell transfer.
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As described earlier, in HLA-matched nonmyeloablative and T cell depleted allo-SCT, 
early NK cell repopulation has been associated with decreased relapse rates, without 
increasing GVHD incidence.57,58 In addition, high NK cell numbers in stem cell grafts 
have been associated with a decreased risk of GVHD.93 Unfortunately, early 
repopulating NK cells are generally immature, reflected by a reduced cytokine 
producing capacity.61 For these reasons, NK cell ACT using high numbers of activated 
NK cells after allo-SCT could be an attractive therapeutic strategy. If NK cells of 
donor origin will be used, these cells will not be rejected, so immunosuppressive 
chemotherapy is not needed. As a result, multiple NK cell infusions can be performed. 
To obtain large numbers of NK cells from donor origin, peripheral blood- or 
BM-derived HSPCs need to be expanded and differentiated into NK cells. However, 
these HSPCs have a lower expansion potential as compared to UCB-derived HSPCs. 
Interestingly, expansion of CD34+ HSPCs can be enhanced by inhibition of the aryl 
hydrocarbon receptor (AhR) using the antagonist StemRegenin1 (SR1).94 In Chapter 6 
of this thesis, we investigated whether addition of SR1 to our NK cell culture method 
could generate large numbers of HSPC-NK cells from peripheral blood-derived 
HSPCs.
Figure 3  Ex vivo generation of NK cells
Representation of the cytokine-based culture protocol used to generate NK cells form UCB- 
derived HSPCs. UCB, umbilical cord blood; HSPCs, hematopoietic stem and progenitor cells; 
NK, natural killer; SCF, stem cell factor; IL, interleukin; Flt3L, FMS-like thyrosine kinase 3 ligand; 
TPO, thrombopoietin
Expansion medium
- Medium + human serum
- SCF, IL-7, Flt3L, TPO
- Heparin
- Low-dose cytokine cocktail
Dierentiation medium 1
- Medium + human serum
- SCF, IL-7, Flt3L, IL-15
- Heparin
- Low-dose cytokine cocktail
Dierentiation medium 2
- Medium + human serum
- SCF, IL-7, IL-15, IL-2
- Low-dose cytokine cocktail
Day 0-9 Day 9-14 Day 14-35
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NK progenitors Mature NK cells
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Outline of this thesis
Although the clinical outcome of many patients suffering from hematological 
malignancies improved due to the development of more effective and less toxic 
therapies over the last decades, still too many patients cannot be cured, or suffer 
from severe toxicity. For these reasons, less toxic treatments with improved 
anti-leukemic effects are urgently needed. Cellular immunotherapy can exploit the 
immune system to fight leukemia. In this thesis, several cellular immunotherapeutic 
strategies targeting various components of the immune system were investigated. 
 Part I of this thesis focuses on DC vaccination targeting hematopoiesis restricted 
MiHA antigens. In Chapter 2, the feasibility, safety and clinical efficacy of MiHA- 
directed DC vaccination in combination with DLI was investigated in patients who 
relapsed after HLA-matched allo-SCT followed by DLI. In this study, DCs were loaded 
with MiHAs, and DC vaccinations were administrated in combination with a DLI. 
The dosage of the DLI was equal to the highest DLI-dose administered to the 
patient, which did not induce GVHD. We concluded that this therapy is feasible and 
safe. We observed an increase in the percentage of MiHA-specific CD8+ cytotoxic T 
cells in peripheral blood in some of the patients investigated. However, these 
promising immunological results did not translate into robust clinical responses. 
Therefore, further improvement of the DC vaccine is needed. In Chapter 3, we 
aimed to improve the efficacy of our DC vaccine by targeting the PD-1/PD-L2/L2 
co-inhibitory pathway. We developed a clinical grade method that uses PD-L siRNA/
SAINT-RED transfection to silence PD-L1/L2 expression on the DC vaccine. By using 
this method, mature and viable DC vaccines with long-term knockdown of PD-L1/
L2 were generated. These vaccines could efficiently stimulate MiHA-specific T cells 
responses. The safety and efficacy of these vaccines is currently investigated in a 
phase I/II clinical trial. In the General discussion and future perspectives section 
some preliminary results of this trial are reported. 
 In Part II of this thesis, we investigated NK cell ACT for the treatment of hema -
tological malignancies. Our group developed a culture method for the generation 
of high numbers of functional NK cells from UCB-HPSCs. In Chapter 4, the feasibility, 
safety, in vivo life span and maturation, and the potential of these cells to reduce 
minimal residual disease (MRD) was investigated in older AML patients. In this clinical 
trial, patients were no candidates for allo-SCT due to age or co-morbidity. We found 
that ACT using these HSPC-NK cell products is feasible with limited toxicity. In addition, 
we demonstrated that these cells can engraft, home to the BM and mature in vivo. 
Interestingly, we found a reduction in MRD in two patients. Notably, these two 
patients had been treated with hypomethylating agent prior to inclusion in the trial. 
Since it was described that NK cells in MDS patients treated with azacitidine show 
higher degranulation and IFN-γ production in response to leukemia cell lines in vitro, 
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we hypothesized that combining azacitidine or decitabine with HSPC-NK cell ACT 
could have an additive and/or synergistic anti-leukemic effect. We investigated this 
hypothesis in Chapter 5.
 Although patients in the clinical trial described in Chapter 4 were no candidates 
for allo-SCT, due to the introduction of non-myeloablative conditioning, allo-SCT is 
currently available for older patients.95,96 Despite the fact that these conditioning 
regimens lead to less non-relapse mortality, the survival benefit is counterbalanced 
by a higher incidence of relapse-related mortality.97-101 Therefore, NK cell ACT may 
be an attractive therapeutic strategy to enhance the GVT response after allo-SCT. 
In that strategy, large numbers of active NK cells of donor origin are needed. For that 
reason, in Chapter 6, we investigated if HSPC-NK cells can also be generated from 
G-CSF mobilized HSPCs. Although G-CSF mobilized HSPCs have a reduced expansion 
potential as compared to UCB-HSPCs, we found that addition of the AhR antagonist 
SR1 to our culture protocol enabled generation of large numbers of highly functional 
HSPC-NK cells. The function and proliferation of these cells was not inhibited by 
cyclosporine A, an immunosuppressive drug normally administered after allo-SCT 
to prevent GVHD. Therefore, these cells provide great promise for effective NK cell 
adoptive immunotherapy after allo-SCT.
 Since malignant cells exploit several strategies to escape from the immune 
system, we assume that multiple therapies need to be combined to cure patients. In 
part III of this thesis, Chapter 7, we use multiple myeloma as an example, to describe 
strategies exploited by malignant cells to escape from the immune system. In 
addition, we illustrate how different immunotherapies targeting multiple myeloma 
are currently developed at the same time. In the near future, these different strategies 
need to be combined to reach an optimal therapeutic effect in patients, while 
minimizing toxicity. 
 Finally, Chapter 8, provides a general discussion and future perspectives regarding 
the research described in this thesis.
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Abstract
Allogeneic stem cell transplantation (allo-SCT) with or without donor lymphocyte 
infusions (DLI) is the only curative option for several hematological malignancies. 
Unfortunately, allo-SCT is often associated with graft-versus-host disease (GVHD), 
and patients often relapse. We therefore aim at improving the graft-versus-tumor 
effect, without increasing the risk of GVHD, by targeting hematopoietic lineage-re-
stricted and tumor-associated minor histocompatibility antigens (MiHAs) using 
peptide-loaded dendritic cell (DC) vaccinations. In the present multicenter study, we 
report the feasibility, safety and efficacy of this concept. We treated 9 multiple 
myeloma (MM) patients with persistent or relapsed disease after allo-SCT and a 
previous DLI, with donor monocyte-derived MiHA-peptide loaded DC vaccinations 
combined with a second DLI. Vaccinations were well tolerated and no occurrence of 
GVHD was observed. In 5/9 patients we were able to show the induction of 
MiHA-specific CD8+ T-cells in peripheral blood. Five out of nine patients showed 
stable disease (SD) for 3.5-10 months (1 patient with an ongoing SD) without the 
need for additional treatment. This study shows that MiHA-based donor mono-
cyte-derived DC vaccination combined with DLI is safe, feasible and capable of 
inducing objective MiHA-specific T-cell responses. Future research should focus on 
further improvement of the vaccination strategy, towards translating the observed 
T-cell responses into robust clinical responses.
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Introduction
Allogeneic stem cell transplantation (allo-SCT) with or without donor lymphocyte 
infusions (DLI) can induce durable remissions due to an allogeneic graft-versus- 
tumor (GVT) effect.1 In an HLA-matched setting, this effect is mainly mediated by 
donor-derived T-cells directed against recipient’s minor histocompatibility antigens 
(MiHAs) presented on malignant cells.2 Unfortunately, allo-SCT is frequently 
associated with severe, sometimes life-threatening graft-versus-host-disease (GVHD). 
In addition, patients may relapse after achieving an initial remission, underscoring 
the need for novel strategies to improve the efficacy and specificity of allo-SCT and 
DLI. There is compelling evidence that the induction of GVT and GVHD crucially 
depends on the presence of professional antigen presenting cells (APCs), in particular 
dendritic cells (DCs), capable of presenting host antigens.3,4 It has been postulated 
that accomplishing strong and specific GVT effects could be possible through 
vaccination of allotransplanted patients with DCs, capable of presenting tumor- 
associated host antigens to donor T cells. We and other investigators previously 
evaluated host DC vaccinations and tumor-associated antigen loaded DC vaccination 
after allo-SCT.5–10 Thus far, these studies revealed that host- or donor-DC vaccination 
after allo-SCT, combined with DLI, is feasible, safe and can induce relevant tumor- 
associated immune responses. Encouraged by the initial studies, we evaluated in a 
multicenter phase I/II trial the feasibility, safety and clinical efficacy of treatment of 
DLI non-responders with a second equivalent dose of DLI combined with a DC 
vaccine, which was generated from donor monocytes and pulsed with peptides of 
hematopoietic-restricted MiHAs. 
Materials and methods
Patients and definitions
The study was approved by the Dutch Central Committee on Research Involving 
Human Subjects (CCMO, ABR 39604, trial EudraCT number: 2012-002435-28) and 
conducted according to the Declaration of Helsinki after informed consent of 
patients and donors.
 Candidates for the study were HLA-A2, -A24, -B7 and/or -B44 positive patients at 
an age of ≥18 years, who did not respond to DLI given for relapsed or residual disease 
after an HLA-matched allo-SCT. Included were patients who showed at least one 
mismatch with their donors for the hematopoietic-restricted MiHAs HA-1, HA-2, 
UTA2-1, LRH-1, ACC-1, ACC-2, PANE-1 and HB-1 in the GVT direction (i.e. patient 
positive, donor negative for the MiHA).11 Main exclusion criteria were WHO 
performance 3-4, rapidly progressive disease despite salvage treatment, concomitant 
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use of immunosuppressive drugs and the presence of acute GVHD > grade 1 or 
extensive chronic GVHD. Maintenance therapy was allowed, but could not be 
started prospectively after DLI. Patients on maintenance therapy had to have stable 
disease (i.e. no ongoing response on maintenance) to allow assessment of the 
response to the study treatment. Included patients received an equivalently dosed 
subsequent DLI combined with DC vaccination. Patients received a total dose of 
45-90 x 106 DCs, administered in three vaccinations with 2-week intervals. In each 
vaccination, 2/3 of the DCs were administered intravenously (i.v.) and 1/3 intradermal 
(i.d.) in the median site of the upper leg. The first DC administration was combined 
with the DLI. Response assessment was performed at week 14 and total follow-up 
was until week 20. Response criteria were based on the International Myeloma 
Working Group (IMWG) uniform response criteria.12,13 Furthermore, for selected 
patients plasma cell chimerism was determined in freshly FACS purified bone 
marrow plasma cells using a previously reported method and used as an additional 
marker of disease activity.14 Time to progression (TTP) was defined as time between 
the start of the first DC vaccination and the occurrence of progression or relapse. 
Toxicity was assessed using the latest available version of Common Toxicity Criteria 
(CTC) for Adverse Events (AE; version 4.0). The GVHD-assessment was done using 
IBMTR criteria, which classifies GVHD according to percentage of involved skin 
surface, level of serum bilirubin and amount of diarrhea in ml per day in 4 classes.15
Vaccine generation
The DC vaccine was generated using a 9-day culture protocol under good 
manufacturing practices (GMP) conditions from CD14+ monocytes enriched from a 
leukapheresis product of the original stem cell donor. Isolation of CD14+ monocytes 
was done using a CliniMACS® procedure. After enrichment, DCs were cultured in 
X-Vivo 15 medium supplemented with 2% Human Serum in the presence of GM-CSF 
(800IU/mL) and IL-4 (500IU/mL). After three days, fresh medium with GM-CSF and 
IL-4 was added, together with keyhole limpet hemocyanin (KLH) protein (20µg/mL). 
At day 7, the DCs were matured ex vivo using IL-6 (15ng/mL), IL-1β (5ng/mL), TNFα 
(600IU/mL) and PGE-2 (1µg/mL). At day 9, the mature DCs were then pulsed with 
10µg/mL of the appropriate MiHA peptide for 2.5-3 hours, after which the cells were 
washed. The peptide-loaded, mature DCs were then cryopreserved for quality 
control testing and release until administration. Cryopreservation had no effect on 
the antigen presenting capacity of the DCs.10 Patients received a total dose of 
45-90x106 peptide loaded DCs, administered in three vaccinations with 2-week 
intervals. A reference vial was thawed and used for quality evaluation determining 
sterility (endotoxin levels <1.6IU/mL; negative for anaerobe and aerobe bacteria, 
fungi and yeast), viability (>70% is 7AAD- on flow cytometry or trypan blue negative 
on light microscopy), purity (<30% expression of CD3 (BD Biosciences), CD14 
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(Beckman Coulter), CD66e (Sanquin), CD19 (Beckman Coulter) and CD56/16 (BD 
Biosciences)) and maturity (>70% of the CD11c+ (BD Biosciences) DCs express CD80, 
CD86, CD83 (all BD Biosciences) and HLA-DR (Biolegend)). Vaccines were 
manufactured locally at the two participating centers. 
Immune monitoring
Next to MiHA-peptides, the DCs were also loaded with the MHC class II restricted 
protein KLH as an adjuvant to provide CD4+ T-cell help for boosting cytotoxic CD8+ 
T-cell responses, and to monitor immunological responses after vaccination. PBMC 
samples obtained from week 0 (baseline), week 1, 2, 4, 6, 8, 10, 14 and week 20 (end 
of follow-up) after vaccination were incubated in vitro with 5µg/mL of KLH peptide 
for 5 days. After five days, cells were washed and proliferation was analyzed by 
staining with Cell Trace™ Violet Cell Proliferation Kit (ThermoFisher) and expressed as 
% of divided cells/total CD3+ T-cells, as measured on a FACS Canto II (BD Biosciences). 
Activation was measured by staining the PBMCs for CD25, CD38 and HLA-DR, and 
depicted as the % of CD3+ T-cells expressing CD25 or co-expressing CD38/HLA-DR 
(all antibodies from BD Biosciences). In addition, the presence of MiHA-specific CD8+ 
T-cells was determined on the obtained PBMC samples. MiHA-specific CD8+ T-cells 
were identified as viable (SYTOX blue negative, ThermoFisher), CD45+ cells double 
positive for APC and PE peptide-MHC tetramers within the CD3+ CD8+ population.
Results
Patient and vaccine characteristics
Between May 2014 and May 2016, nine MM patients were included in the University 
Medical Center Utrecht and the Radboud University Medical Center. Because of 
pre-defined stopping rules, inclusions were stopped after the 9th patient due to 
limited efficacy. Patients had a median age of 56 years (range 40-66) and were 
heavily pre-treated with a median number of previous treatment lines of 5 (range: 
4-7) (Table 1). Patients were intended to receive a minimal dose of 45x106 and a 
maximal of 90x106 DCs. From all donors, we were able to generate sufficient 
MiHA-loaded, pure and highly mature DCs (Table 2). The lowest number of DCs 
administered was 64x106. The vaccine was administered in three courses with 
2-week intervals. In each vaccination, 2/3 of the DCs were administered intravenously 
(i.v.) and 1/3 intradermal (i.d.) in the median site of the upper leg. The first DC 
administration was combined with a DLI. None of the included patients had rapidly 
progressive disease requiring salvage treatment before DLI. Patient 9 mistakenly 
received a DLI dose of 40x106 instead of 5x106, which was reported as a protocol 
violation. This did not lead to any toxicity. 
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Table 1  Patient characteristics and outcome
N Sex Age
(y)
Treatment
lines
M  
protein 
type
Response 
status 
before 
previous 
DLI
Dose 1st 
DLI 106
Response 
status at 
inclusion
Maintenance HLA-  
match
MiHA 
mismatch
DLI 
dose
106
Total  
DC dose
106
Best 
response
TTP
months
Last 
follow up
MiHA 
specific 
T-cells
Anti-KLH 
response
1 M 56 6 IgGκ VGPR 10 VGPR No Sibling LRH-1 10 75 SD 10 PD + +
2 F 48 4 IgGκ CR 1,5 CR No MUD 10/10 UTA2-1 1,5 80 PD 2.2 PD - +
3 F 66 5 κFLC PD 100 PD No Sibling UTA2-1 100 80,3 PD 2 PD + +
4 M 40 4 IgGκ VGPR 10 VGPR No MUD 9/10 HA-1 + LRH-1 10 90 SD 7 PD + +
5 M 52 5 IgGκ PD 1 VGPR No Sibling HA-1 1 76 SD 6 PD + +
6 F 44 7 IgGκ PD 14 VGPR Cyclo/ 
Bortezomib
Sibling UTA2-1 14 83,7 SD 7 SD + +
7 M 64 5 IgGλ PD 10 PD No Sibling HA-1 + LRH-1 10 90 PD 1 PD - +
8 M 66 5 IgGλ PD 10 PD No Sibling UTA2-1 10 77 PD 1.4 PD - +
9 M 66 5 IgA PD 5 PR No Sibling UTA2-1 40 64 SD 3.5 PD - +
Table 2  Generation and characteristics of the DC vaccines
N Pu
ri
ty
 C
D
14
+  
se
le
ct
io
n
Vi
ab
ili
ty
 C
D
14
+
To
ta
l M
iH
A
 
lo
ad
ed
 D
Cs
 1
06
St
er
ili
ty
Vi
ab
ili
ty
 D
Cs
%
 n
on
-D
C
CD
83
CD
80
CD
86
H
LA
-D
R
M
iH
A
1 99% 97% 197 Sterile 93% 0,4% 94% 88% 100% 100% LRH-1
2 100% 97% 210 Sterile 91% 3,3% 98% 91% 99% 99% UTA2-1
3 100% 98% 112,5 Sterile 78% 4,8% 97% 97% 99% 99% UTA2-1
4 100% 95% 140,5 Sterile 89% 1,7% 96% 97% 99% 99% HA-1 + LRH-1
5 88% 96% 65* Sterile 87% 2,0% 99% 99% 100% 72% HA-1
6 100% 98% 297 Sterile 100% 0,4% 99% 95% 100% 100% UTA2-1
7 87% 97% 130 Sterile 89% 1,0% 98% 98% 100% 82% HA-1 + LRH-1
8 90% 97% 155 Sterile 73% 4,0% 98% 97% 99% 94% UTA2-1
9 88% 92% 70 Sterile 83% 3,0% 76% 98% 100% 70% UTA2-1
*  This number is lower than the sum of separately counted thawed DC products upon administration 
(Table 1). This discrepancy is probably caused by a counting error before freezing.
The total DC dose was divided into three doses with a 2-week interval, the first vaccination was 
combined with the DLI. Abbreviations: Cyclo, cyclophosphamide; FLC, free light chains; VGPR, very good 
partial response; CR, complete response; PD, progressive disease; PR, partial response; MiHA, minor 
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Induction of peptide-specific T-cells
Analysis of collected PBMC samples showed a rapid induction of anti-KLH responses 
in all patients after the first vaccination, as shown by in vitro proliferation and 
activation of T-cells upon incubation with KLH (Figure 1A). However, in 7 out of 
9 patients, these responses were lower after the second and third vaccination. 
Analyses of several T-cell subsets, including CD4+, CD8+ and regulatory T-cells did 
not reveal significant changes after vaccination (Supplementary data). Flow 
cytometric analyses of PBMCs with MiHA peptide-MHC tetramers showed the 
induction of MiHA-specific CD8+ T-cells in 5/9 patients, with a very high frequency 
in patient 6 (Figure 1B, C). The percentage and time interval of occurrence varied 
between patients (Figure 1C).
Clinical response
Response assessment was performed at week 14 and total follow-up was until week 
20. No objective clinical responses (≥PR) were observed (Table 1). Median 
time-to-progression (TTP) was 3.5 months (range: 1-10). Three patients were included 
with progressive disease (patient 3, 7 and 8). All of these patients showed ongoing 
progression after vaccination. Five patients remained in stable disease for a median 
of 7 months after vaccination (Pt 1, 4, 5, 6 and 9) (one patient still without signs of 
Table 1  Patient characteristics and outcome
N Sex Age
(y)
Treatment
lines
M  
protein 
type
Response 
status 
before 
previous 
DLI
Dose 1st 
DLI 106
Response 
status at 
inclusion
Maintenance HLA-  
match
MiHA 
mismatch
DLI 
dose
106
Total  
DC dose
106
Best 
response
TTP
months
Last 
follow up
MiHA 
specific 
T-cells
Anti-KLH 
response
1 M 56 6 IgGκ VGPR 10 VGPR No Sibling LRH-1 10 75 SD 10 PD + +
2 F 48 4 IgGκ CR 1,5 CR No MUD 10/10 UTA2-1 1,5 80 PD 2.2 PD - +
3 F 66 5 κFLC PD 100 PD No Sibling UTA2-1 100 80,3 PD 2 PD + +
4 M 40 4 IgGκ VGPR 10 VGPR No MUD 9/10 HA-1 + LRH-1 10 90 SD 7 PD + +
5 M 52 5 IgGκ PD 1 VGPR No Sibling HA-1 1 76 SD 6 PD + +
6 F 44 7 IgGκ PD 14 VGPR Cyclo/ 
Bortezomib
Sibling UTA2-1 14 83,7 SD 7 SD + +
7 M 64 5 IgGλ PD 10 PD No Sibling HA-1 + LRH-1 10 90 PD 1 PD - +
8 M 66 5 IgGλ PD 10 PD No Sibling UTA2-1 10 77 PD 1.4 PD - +
9 M 66 5 IgA PD 5 PR No Sibling UTA2-1 40 64 SD 3.5 PD - +
 histocompatibility antigen; SD, stable disease; MUD, matched unrelated donor; DLI, donor lymphocyte 
infusion; TTP, time-to-progression.
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progression; patient 6, although on maintenance treatment). Patient 2, included 
with minimal residual disease (determined by chimerism analysis on purified plasma 
cells), received radiotherapy on a bone lesion 2.2 months after inclusion, and 
achieved a complete molecular remission (mCR) with 100% donor plasma cell 
chimerism shortly thereafter, and has remained in mCR for 23 months now.
Figure 1   MiHA loaded donor-DC vaccinations induce anti-KLH responses and 
MiHA-specific T-cells in peripheral blood
(A) KLH specific T-cell proliferation and activation is induced by MiHA and KLH-loaded 
donor-derived DC vaccines. Vaccinations were administered at week 0, 2 and 4. DLI was 
administered at week 0. Shown are pooled data of 9 patients, mean +/- SEM. (B) Gating 
strategy of MiHA-reactive CD8 T-cells. The presence of MiHA-specific T-cells was defined as 
the percentage of viable (SYTOX blue negative, ThermoFisher), CD45+ cells double positive 
for APC and PE peptide-MHC tetramers within the CD3+ CD8+ population. (C) Different 
patterns and variable levels of induced MiHA-specific T-cells after vaccination were observed. 
Vaccinations were administered at weeks 0, 2 and 4. DLI was administered at week 0. Results 
for 5 individual patients are shown.
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Toxicity
The vaccinations were well tolerated with only transient induration and erythema at 
the i.d. injection site and grade 2 fever after the second and third vaccination, lasting 
less than 24 hours, in all patients. There was no development of GVHD or any 
life-threatening toxicity. Five severe adverse events (SAE) were reported, four being 
possibly related to the vaccinations: one admission because of high fever and 
abdominal pain after the second vaccination, which resolved spontaneously, and 
three admissions with pneumonia. Other adverse events consisted of diarrhea 
causing hypophosphatemia, flu-like symptoms, liver enzyme elevation, herpes 
simplex infection and a basal cell carcinoma of the skin. All adverse events were CTC 
grade II or III. 
Figure 1   Continued
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Discussion
This study demonstrates the feasibility, safety and efficacy of MiHA peptide loaded 
donor DC vaccination combined with DLI in patients with persistent or relapsed 
disease after allo-SCT and previous DLI. To our knowledge, we are the first to describe 
the use of donor-derived DCs loaded with MiHA peptides as vaccines in combination 
with DLI. 
 In the few vaccination studies performed in the allo-SCT setting, DCs were 
loaded with various antigens using different techniques. The source of DCs 
(autologous or allogeneic) also differed.5–9  Thus far, all these studies have shown 
that the vaccinations were safe and well-tolerated. In none of the studies, except in 
one of our previous studies with autologous DCs10, DC vaccination was combined 
with a second equivalently dosed DLI. We chose this strategy because T cells from 
the first DLI, as they did not induce any sustainable GVT effect, could have been 
anergized or dysfunctional, which is often the case in MM patients.16–20 We did not 
increase the dose of the DLI with the idea that the effect of the first DLI could serve 
as a control for the effect of combinatorial DLI+DC vaccination. Several other 
decisions in the design of this study, such as the dose, administration intervals and 
administration route (i.v.+ i.d.) were based on our previous experience10,21 with the 
intention to keep the variation between this and previous studies minimal. 
Nevertheless, it could well be that in a different design the outcome of DC vaccination 
in these patients could have been different. Therefore, the results of this study need 
to be interpreted within its specific design. 
 In agreement with our previous results, we observed a low toxicity from MiHA 
peptide pulsed donor DC vaccinations, even after combination with a second DLI, 
demonstrating the safety of the approach. The observed immunological responses 
in this trial are also in line with previous studies and provide evidence for the capacity 
of MiHA peptide loaded DCs to induce or boost tumor-reactive cytotoxic 
T-lymphocytes (CTLs). Nonetheless, in virtually all previous studies, not all patients 
developed CTLs. Although it is not well-understood why some patients do and 
some do not mount a CTL response, we can exclude DC related factors, because the 
quality of the DCs was more or less equal in all vaccine products. We observed that 
in our study 3/4 of the patients who failed to induce CTLs (Pt 7,8 and 9) entered the 
study with a response status of PR or progressive disease, while such patients 
represented only 1/5 in the group who did develop CTLs upon vaccination. Although 
these differences did not reach statistical significance it may be, if possible, better 
not to include patients with a progressive disease in future trials. Notably, in this 
study we observed that the developed CTL responses did not translate into robust 
clinical responses and even the induction of a considerably high frequency of MiHA 
UTA2-1 specific CTLs in one patient (Pt 6) did not translate into a clear clinical 
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response. Although not statistically significant, we noted that 4/5 patients (Pt 1,4,5 
and 6) who developed MiHA-reactive CTLs after vaccinations had a longer TTP than 
expected, while the TTP of the patients who did not develop MiHA-specific CTLs 
was much shorter. These observations trigger the discussion why the clinical effects 
of our induced CTLs were not, or at best were hardly, visible. Among several 
possibilities, one could speculate on the limited persistence of the induced T cell 
responses. Are monocyte-derived DCs not capable of inducing stable CTLs? Or are 
the induced CTLs quickly inactivated? Although these mechanisms need to be 
further elucidated in future trials, it seems highly plausible that the expansion or 
even the cytotoxic function of tumor specific CTLs could be actively suppressed by 
tumor (microenvironment)-related factors. In this respect, several well-described 
suppressive cytokines (e.g. TGF-β, IL-10), immune cells (e.g. regulatory T-cells, my-
eloid-derived suppressor cells) and immune checkpoint molecules, such as PD-L1, 
could play a role.22,23 Regarding the latter, we have previously shown that the 
presence of immune-checkpoint molecules on DCs hampers sufficient priming and 
boosting of MiHA-specific T-cells.24,25 Importantly, siRNA-mediated silencing of PD-1 
ligands on DCs increases the immunogenicity of the vaccine and thereby boosts 
the induction of MiHA-specific T-cell responses.26,27 A similar scenario is plausible 
when effector CTLs encounter PD-L1+ tumor cells. Thus, as already suggested by 
others, the use of systemic immune-checkpoint inhibitors may improve the 
outcome of DC vaccination, but has to be used with caution in combination with 
DLI due to the potential risk of eliciting severe GVHD.28,29 In addition to these 
possible future perspectives, our current results point out that patient selection for 
vaccination strategies is crucial. Patients with a low tumor burden and stable disease 
are the best candidates for immune-therapy with DCs. But even in these patients, 
our focus should be on strategies targeting tumor-induced immune suppression, to 
overcome this important barrier to effective anti-tumor immune therapy.
 In conclusion, our findings demonstrate that MiHA-based donor-derived DC 
vaccination is safe and well-tolerated when combined with DLI. In addition, this 
strategy is capable of inducing objective MiHA-specific T-cell responses. These 
findings warrant future investigations, focusing on improvement of the vaccination 
strategy, towards translating the observed T-cell responses into robust clinical 
responses.
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Abstract
Dendritic cell (DC)-based vaccination is an appealing strategy to boost graft-ver-
sus-tumor (GVT) immunity after allogeneic stem cell transplantation (allo-SCT), and 
thereby prevent or counteract tumor recurrence. By exploiting minor histocompat-
ibility antigens (MiHAs) presented on hematopoietic cells, donor CD8+ T cell 
immunity can be selectively targeted to patient’s hematological tumor cells without 
the risk of inducing graft-versus-host disease (GVHD). Previously, we demonstrated 
that silencing RNA (siRNA) silencing of programmed death-ligand 1 (PD-L1) and 
PD-L2 on DCs markedly augments the expansion and function of MiHA-specific 
CD8+ T cells. However, previously applied methods based on electroporation or 
lipid nanoparticles were either incompatible with target antigen mRNA delivery or 
required complex manufacturing compliant to Good Manufacturing Practice (GMP). 
Here, we investigated whether transfection using lipoplexes composed of PD-L1 
and PD-L2 siRNAs plus SAINT-18:DOPE (i.e. SAINT-RED) is an effective and feasible 
clinical-grade method in DC vaccine manufacturing. We observed that a single 
siRNA/SAINT-RED transfection resulted in efficient and long-term knockdown of the 
PD-1 ligands without affecting DC maturation or viability. Furthermore, we 
demonstrated that SAINT-RED can be heat-sterilized without loss of function, 
facilitating its use in  aseptic DC vaccine production. Finally, we showed that the 
established transfection method can be combined with target antigen mRNA or 
peptide loading to efficiently stimulate MiHA-specific T cell expansion and cytokine 
production. Together, these findings indicate that the developed PD-L siRNA/
SAINT-RED transfection protocol in combination with MiHA mRNA or peptide 
loading can be applied in the generation of clinical-grade DC vaccines to boost 
anti-tumor immunity after allo-SCT.
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Introduction
The superiority of dendritic cells (DCs) as professional antigen-presenting cells 
(APCs) has been explored in numerous clinical trials, where ex vivo-generated DCs 
were injected to induce immunity in patients with cancer or infectious diseases.1-3 
Although, in cancer patients durable tumor regression has been observed following 
DC-based vaccination, most studies reported limited clinical responses despite 
induction of detectable antigen-specific T cell immunity. These observations indicate 
the need for enhancement of the magnitude of the immune response, the (poly-)
functionality of the boosted T cells and the induction of long-lived memory T cells. 
Various strategies to improve the potency of DC-based vaccines are being investigated, 
including improvement of the antigen-presenting and co-stimulatory capacity of 
DCs generated from CD14+ monocytes or CD34+ hematopoietic progenitor cells.4,5
 In the autologous tumor immunotherapy setting ex vivo-generated DCs can be 
loaded with tumor-associated antigens (TAAs), whereas in the setting of allogeneic 
stem cell transplantation (allo-SCT) hematopoietic-restricted minor histocompatibility 
antigens (MiHAs) are highly attractive targets. These antigens, expressed by the 
patient’s malignant cells, have been demonstrated to play a key role in graft-versus- 
tumor (GVT) immunity.6-8 Expanding numbers of hematopoietic-restricted MiHAs, 
such as HA-1, LRH-1, UTA2-1 and ARHGDIB, are being identified. As a result, these 
MiHAs can be exploited for adjuvant DC-based immunotherapy in 25% of patients 
transplanted with sibling donor grafts, and 40% with unrelated donor grafts.7 
Previously, we demonstrated that MiHA-encoding mRNA electroporation is an 
efficient method to allow long-lasting presentation of diverse antigenic peptides by 
HLA molecules on mature donor-derived DCs.9 Moreover, we and others observed 
that mRNA-loaded DCs can efficiently activate tumor-reactive T cells in vitro and 
in vivo.9-12 Yet, beside effective loading and presentation of the relevant antigen, 
modulation of co-signaling pathways can further augment DC potency. While ex 
vivo- generated DCs express high levels of co-stimulatory molecules, DC maturation 
also results in up-regulation of co-inhibitory molecules, like Programmed Death 
Ligand-1 (PD-L1) and PD-L2. As these ligands can significantly inhibit expansion and 
function of PD-1 expressing tumor-reactive T cells, it is desirable to specifically 
knockdown their expression on DC vaccines. We have reported that combined 
silencing RNA (siRNA)-mediated down-regulation of PD-L1 and PD-L2 significantly 
augmented the stimulatory potential of DCs.13,14 However, siRNA-mediated silencing 
must be performed at the immature DC (iDC) stage to efficiently prevent PD-L 
up-regulation during maturation,13 while MiHA mRNA loading is optimal at the 
mature DC (mDC) stage.9 Since double electroporation causes substantial loss of 
DC viability and yield, we explored alternative clinical-grade applicable siRNA 
transfection methods based on cationic lipids.
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In this study, we assessed the suitability of lipoplexes composed of PD-L1/L2 siRNAs 
and the SAINT-RED transfection reagent. SAINT-RED consists of the cationic 
amphiphilic lipid SAINT-18 (1-methyl-4-(cis-9-dioleyl)methyl-pyridinium-chloride) 
and the neutral helper-lipid dioleoylphosphatidylethanolamine (DOPE) in a 1:1 
molar ratio. It is a well established and potent delivery reagent for nucleotides and 
proteins15-17. Importantly, SAINT-RED can be produced compliant to Good 
Manufacturing Practice (GMP) and can be easily incorporated in our clinical-grade 
DC generation protocol. This paper describes the development of an optimal 
non-toxic siRNA/SAINT-RED protocol for efficient and long-lasting knockdown of 
PD-L1 and PD-L2 in conjunction with MiHA mRNA delivery by electroporation in 
monocyte-derived DCs (moDC). Importantly, PD-L silenced MiHA mRNA-loaded 
DCs generated using this method showed enhanced MiHA-specific T cell activating 
potential. Therefore, these improved DC vaccines hold great promise for immuno-
therapeutic applications in cancer patients. In the near future, we will start a clinical 
trial investigating these superior DC vaccines in patients with hematological 
malignancies after allo-SCT.
Materials and Methods
Donor material
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor buffy 
coats (Sanquin Blood Bank, Nijmegen, the Netherlands) or allo-SCT donor apheresis 
material. All cells of healthy donors or allo-SCT donors were obtained after written 
informed consent. Furthermore, we used PBMCs from 2 patients who developed 
a HA-1-specific T cell response after allo-SCT. Patient 1 suffered from follicular 
non-Hodgkin lymphoma, cells were collected two years after allo-SCT. Patient 2 
suffered from multiple myeloma, in this patient cells were collected one year after 
donor lymphocyte infusion.
siRNAs targeting PD-L1 and PD-L2
PD-L1 and PD-L2 siRNAs were kindly provided by dr. Anna Borodovsky from Alnylam 
Pharmaceuticals, and produced as described previously.14,18 The duplex sequences 
were as follows: PD-L1, 5’AGAccuuGAuAcuuucAAAdTsdT-3’  (sense), 5’-UUUGAAAGu-
AUcAAGGUCUdTsdT-3’(anti-sense); PD-L2, 5’-AuAAcAGccAGuuuGcAAAdTsdT-3’(sense), 
5’-UUUGcAAACUGGCUGUuAUdTsdT-3’(anti-sense). As a negative control a siRNA 
duplex for Luciferase was used, with the sequence 5’-cuuAcGcuGAGuAcuucGAdTs-
dT-3’ (sense) and 5’-UCGAAGuACUcAGCUcAGCGuAAGdTsdT-3’(anti-sense). Small 
case represent 2’-O-methyl modified residues. 
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DC culture and PD-L silencing
The DC generation protocol including PD-L silencing and antigen loading is 
summarized in Figure 1. Monocytes were isolated from PBMCs via plastic adherence 
in tissue culture flasks (Greiner Bio-One, Alphen a/d Rijn, the Netherlands). Immature 
DCs (iDCs) were generated by culturing monocytes in X-VIVO-15 medium without 
phenol red and gentamicin (Lonza, Verviers, Belgium),  supplemented with 2% 
human serum (HS; PAA laboratories, Pasching, Austria), 500 U/mL IL-4 and 800 U/mL 
GM-CSF (both Immunotools, Friesoythe, Germany). After 3 days, iDCs were harvested, 
and 1x106 DCs were plated per well in 6-well plates and incubated with siRNA/
SAINT-RED lipoplexes at a 1:10 w/v ratio in a total volume of 1 mL serum-free 
X-VIVO-15. 1-5 µg luciferase (negative control) or PD-L1/L2 siRNA (in a w/w ratio of 
2:1) had been pre-complexed for 15 minutes with 0.75 mM SAINT-RED (Synvolux 
Therapeutics, Groningen, The Netherlands), after which serum-free X-VIVO-15 was 
added to a total volume of 200 µL. After 4 hours of incubation with the siRNA/
SAINT-RED lipoplexes at 37˚C, 1 mL X-VIVO-15/4% HS medium containing 1000 U/mL 
IL-4 and 1600 U/mL GM-CSF was added. At day 7, maturation was induced in 
X-VIVO-15/2% HS containing 5 ng/mL IL-1β, 15 ng/mL IL-6, 20 ng/mL TNF-α 
(all Immunotools) and 1 µg/mL PGE2 (Pharmacia & Upjohn, Bridgewater, NJ, USA). 
At day 9, mDCs were harvested, analyzed for viability using trypan blue exclusion 
and either exogenously loaded with 5 µM LRH-1 peptide or electroporated with 
20 µg P2X5-encoding mRNA or HMHA1 encoding mRNA  (produced as described 
earlier)14 at 200 Volt, 150 µF in a Biorad Genepulser II (Biorad, Hercules, CA, USA) 
according to previously described protocols.14
Figure 1  Schematic overview of DC generation protocol
Monocytes were isolated from PBMCs by means of plastic adherence, and subsequently 
cultured for 3 days to generate intermediate DCs. At day 3, PD-L siRNA/SAINT-RED lipoplexes 
were added to the DCs to allow siRNA delivery and release. At day 7, at the immature DC 
stage, maturation was induced by addition of maturation cytokines. Finally, at day 9, PD-L 
silenced mature DCs were harvested and subsequently loaded with MiHA-encoding mRNA 
or short MiHA peptides.
Monocytes Intermediate DCs Immature DCs Mature DCs
Day 0 Day 7 Day 9 Day 3 
Plastic 
adherence 
isolation 
PD-L1/PD-L2 
knockdown using  
siRNA/SAINT-
RED 
MiHA mRNA 
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loading 
IL-4 
GM-CSF 
IL-4 
GM-CSF 
IL-6, IL-1β
TNF-α, PGE2 
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Flow cytometry
Phenotype and maturation state of DCs was analyzed by staining with the following 
antibodies: CD14 (clone HCD14), CD80 (clone 2D10), CD83 (clone HB15e), CD86 (clone 
IT2.2), CD11c (clone Bu15), CD40 (clone 5c3), CCR7 (clone G043H7), CD25 (clone BC96), 
HLA-ABC (clone B6/32), HLA-DR (clone L243, all Biolegend, San Diego, CA, USA), 
PD-L1 (clone MIH1) and PD-L2 (clone MIH18, both Beckton Dickinson (BD), Franklin 
Lakes, NJ, USA) and isotype controls IgG1-FITC (clone MOPC-21), IgG1-PE (clone 
MOPC-21), IgG2a (clone MOPC-173, all Biolegend). The ΔMFI was calculated by 
subtraction of the mean fluorescence intensity (MFI) of the isotype control from the 
PD-L MFI, subsequently the relative PD-L knockdown efficiency was calculated as 
follows: (ΔMFI PD-L siRNA treated DC/ΔMFI control siRNA treated DCs) x 100. 
Cells were analyzed using the Coulter FC500 flow cytometer (Beckman Coulter, 
Fullerton, CA, USA). 
 HA-1-specific T cells were detected by staining cell suspensions with PE-labeled 
and APC-labeled tetramers containing HA-1/HLA-A2 (VLHDDLLEA). Tetramers were 
kindly provided by prof. dr. Frederik Falkenburg (Department of Hematology, Leiden 
University Medical Center, Leiden, the Netherlands). T cell cultures were incubated 
with 0.15-0.2 µg tetramer for 15 minutes at room temperature. Subsequently, cells 
were labeled with the appropriate concentrations of anti-CD8 (clone B9.19, Beckman 
Coulter) and anti-CD3 (clone UCHT1, Biolegend) for 30 minutes at 4°C. After washing 
with PBS/0.5% BSA, cells were resuspended in washing buffer containing 1:5000 
diluted Sytox blue (Invitrogen, CA, Carlsbad, USA). Cells were analyzed using a Gallios 
flow cytometer (Beckman Coulter). 
Allogeneic mixed lymphocyte reactions (Allo-MLRs)
Allogeneic CD4+ and CD8+ T cells were isolated from PBMCs by direct magnetic 
labeling with the appropriate MicroBeads (Miltenyi Biotec, Bergisch, Gladbach, Germany) 
following the manufacturer’s instructions. In the proliferation assays, T cells were 
labeled with 1.25 µM carboxyfluorescein diacetate succinimidyl ester (CFSE; 
Molecular Probes Invitrogen, Eugene, OR, USA) for 10 minutes at 37°C. The reaction 
was terminated by adding an equal volume of HS and cells were washed. T cells 
were resuspended in Iscove’s modified Dulbecco’s medium (IMDM, Life Technologies, 
Carlsbad, CA, USA) supplemented with 10% HS. In the proliferation assays, 7.5x104 
T cells were stimulated for 4 days with mature DCs at various T cell:DC ratios, 
as indicated, in a 96-well round-bottom plate (Corning Incorporated, NY, USA). 
To examine cytokine production, 25x104 T cells were stimulated with mature DCs 
at a ratio of 1:0.1 in a 48-well flat bottom plate (Cellstar; Greiner Bio-one) and 
supernatant was collected at days 1-4 for cytokine analysis. All allo-MLR assays were 
performed in 4-fold. At day 4, CFSE-labeled T cells were harvested and labeled with 
anti-CD8 (clone HIT8a) or anti-CD4 (clone OKT4, both from Biolegend) for 30 minutes 
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at 4°C. After washing, T cells were resuspended in PBS/0.5% bovine serum albumin 
(BSA; Sigma, St Louis, MO, USA) containing 0.1% 7-amino-actinomycin D (Sigma) and 
T cell proliferation was analyzed using a Gallios flow cytometer (Beckman Coulter). 
MiHA-specific CTL stimulation assays
LRH-1-specific CTL clone RP1 was isolated from a patient as described previously.6,19 
The cells were cultured in IMDM supplemented with 10% HS at a concentration of 
0.1x106 cells/mL. 100 µL cell suspension was subsequently plated per well, in six fold, 
in a 96-wells round-bottom plate and co-cultured with 5,000 DCs in a total volume 
of 200 µL per well. The next day, supernatant was harvested for cytokine analysis.
 To examine MiHA-specific T cell expansion, HA-1 specific CD8+ effector memory 
T cells, present in PBMCs of allo-SCT patients 1 and 2, were stimulated for one week 
ex vivo with HA-1 mRNA loaded DCs from a HLA-A2+ HA-1- donor. PBMCs and DCs 
were co-cultured at a T cell:DC ratio of 1:0.1 in 2 mL IMDM/10% HS in 24-well plates 
(Corning-Costar). After 5 days, 100 U/mL IL-2 (Chiron, Emeryville, CA, USA) and 5 ng/
mL IL-15 (Miltenyi) was added. At day 7, cells were harvested, counted, and the 
percentage of MiHA-specific CD8+ T cells was determined using double color 
tetramer-based flow cytometry.
Cytokine analysis
Interferon-γ (IFN-γ) levels in culture supernatants were analyzed using enzyme-linked 
immunosorbent assays (ELISA; Pierce Endogen, Rockford, IL, USA) according to the 
standard protocol. Release of IL-2, IL-4, IL-5, IL-10, TNF-α and IFN-γ by the T cells was 
simultaneously determined in pooled supernatant using a Th1/Th2 BDTM cytometric 
bead array (BD) following the manufacturer’s protocol and measured on a Navios 
flow cytometer (Beckman Coulter).
Statistical analysis
Statistical significance of differences in IFN-γ secretion between T cells stimulated 
with PD-L knockdown DCs was analyzed using One-way ANOVA. P-values <0.05 
were considered significant.
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Results
Efficient PD-L1 and PD-L2 knockdown can be obtained using  
siRNA/SAINT-RED lipoplexes
We previously showed that PD-L silenced DCs induce superior activation and 
proliferation of antigen-experienced T cells compared to control DCs.13,14 These 
results indicate that PD-L silencing could greatly improve the potency of ex 
vivo-generated DCs in cancer immunotherapy. In previous work, we showed 
efficient, specific and long-term silencing of PD-L1 and PD-L2 in ex vivo-generated 
DCs using either electroporation or LNP-based transfection methods. However, 
these methods were either incompatible with target antigen mRNA delivery or 
required complex GMP-compliant manufacturing, respectively. Therefore, we 
investigated an alternative method for PD-L siRNA delivery and knockdown using 
the transfection reagent SAINT-RED, composed of the lipids SAINT-18 and DOPE. 
First, we determined the optimal dose and timing of siRNA/SAINT-RED transfection 
within the moDC culture protocol. Therefore, day 3 immature DCs (iDCs) were 
transfected with increasing dosages of PD-L1 or PD-L2 siRNA/SAINT-RED lipoplexes 
at a siRNA/SAINT-RED w/v ratio of 1:10. At day 9, PD-L1 and PD-L2 protein expression 
on the DCs was analyzed by flow cytometry. Interestingly, siRNA/SAINT-RED 
transfection at day 3 was sufficient to achieve efficient PD-L knockdown on mature 
DCs. Furthermore, we observed decreased PD-L1 and PD-L2 expression levels with 
increasing dosages of siRNA/SAINT-RED lipoplexes. The optimal dose was 4 µg 
siRNA complexed with 40 µL 0.75 mM SAINT-RED, which resulted in <15% PD-L1 
expression and <5% PD-L2 expression on the DCs (Figure 2A-B). The use of higher 
amounts of either siRNA or SAINT-RED did not further improve PD-L knockdown 
efficacy. As PD-L2 has lower basal expression levels on mature DC, less siRNA was 
required for efficient PD-L2 knockdown as compared to PD-L1. Therefore, in later 
experiments, PD-L1 and PD-L2 siRNAs were mixed at a ratio of 2:1, 4 µg in total per 
1x106 DC. These data demonstrate that we can effectively silence PD-L1 and PD-L2 
on moDC vaccines using the clinical-grade applicable SAINT-RED transfection 
reagent for siRNA delivery.
SiRNA/SAINT-RED lipoplexes induce long-lasting silencing of PD-L1 
and PD-L2 without affecting DC viability or maturation 
To study the influence of SAINT-RED mediated siRNA delivery on DC characteristics, 
we assessed knockdown efficiency, viability and phenotype following transfection. 
Combined delivery of PD-L1 and PD-L2 siRNA (2:1 w/w ratio) resulted in efficient 
knockdown of both PD-1 ligands (i.e. 83.9 ± 1.5 % for PD-L1 and 82.3 ± 3.8 % for 
PD-L2, n=6; Figure 3A). For the generation of a DC vaccine with superior efficacy in 
vivo, sustained PD-L knockdown is essential. Therefore, duration of PD-L silencing 
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was determined by analyzing PD-L protein levels in time using flow cytometry. We 
observed that PD-L1 and PD-L2 expression levels remained low up to day 4 after 
induction of maturation (Figure 3B), indicating that PD-L knockdown can also persist 
in vivo after administration of the vaccine. In contrast to siRNA transfection by elec-
troporation or lipid nanoparticles (LNP),13,14 this transfection method had no adverse 
effects on DC viability (Figure 3C). Furthermore, PD-L silenced DCs expressed low 
Figure 2   Efficient PD-L1 and PD-L2 knock-down can be induced using  
siRNA/SAINT-RED lipoplexes
Intermediate DCs were transfected with 4 µg PD-L1/PD-L2 siRNA (2:1 w/w ratio) or control 
siRNA complexed with 40 µl 0.75 mM SAINT-RED w/v ratio 1:10. At day 7, maturation was 
induced by addition of IL-6, IL-1β, TNF-α and PGE2. At day 9, PD-L1 and PD-L2 protein 
expression on the DCs was analyzed by flow cytometry. (A) PD-L1 and PD-L2 protein 
expression in DCs transfected with PD-L siRNA (solid black lines) or control siRNA (dotted 
black lines) as compared to isotype control (grey histograms). The numbers in the plot 
represent the mean fluorescence intensity (MFI). Data of 1 representative donor is shown. (B) 
The percentage of PD-L1+ or PD-L2+ DCs after treatment with increasing dosages of siRNA/
SAINT-RED lipoplexes was determined by flow cytometry. Relative PD-L knockdown 
efficiency was calculated as follows: (ΔMFI PD-L siRNA treated DC/ΔMFI control siRNA treated 
DCs) x 100%. The data are expressed as mean ± SEM of 2 different donors.
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levels of CD14 and high levels of CD11c, CD83, CD80, CD86, CD25, CD40 and HLA 
class I and II molecules, similar to non-transfected and control DCs, indicating 
preservation of their highly mature and stimulatory phenotype (Figure 3D).20 
Moreover, PD-L siRNA/SAINT-RED transfection did not affect CCR7 expression levels, 
which is important for trafficking of DCs to the lymph nodes (Figure 3D).21,22 Taken 
together, these data show that durable PD-L1 and PD-L2 knockdown can be 
Figure 3   SiRNA/SAINT-RED lipoplexes induce long-term silencing of PD-L1 and 
PD-L2 without affecting DC viability or maturation
Intermediate DCs were not transfected or transfected with 4 µg PD-L1/PD-L2 siRNA (2:1 w/w 
ratio) or control siRNA complexed with 40 µl 0.75 mM SAINT-RED w/v ratio 1:10. At day 7, 
maturation was induced by addition of IL-6, IL-1β, TNF-α and PGE2 for 2 days (A, C, D) or 1-4 days 
(B). DC viability was determined by trypan blue exclusion. PD-L1 and PD-L2 protein expression 
and phenotype was analyzed by flow cytometry. (A) PD-L1 and PD-L2 protein expression was 
calculated relative to control siRNA-transfected cells. Data are expressed as mean ± SEM of 
6 donors. (B) Percentage of PD-L1+ or PD-L2+ DCs over time was determined by flow cytometry. 
The percentage of PD-L+ DCs transfected with control siRNA was set to 100%. Data are expressed 
as mean ± SEM of 2 donors. (C) The percentage of viable DCs was determined by trypan blue 
exclusion. Data are expressed as mean ± SEM of 2 donors. (D) Expression of maturation and 
co-stimulatory molecules was analyzed using flow cytometry. Data are expressed as mean ± 
SEM of 2 donors.
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achieved using our siRNA/SAINT-RED transfection protocol without affecting DC 
viability as well as their  stimulatory and migratory phenotype.
Heat sterilization of SAINT-RED does not impair PD-L knockdown 
efficacy 
For clinical exploration of our optimized siRNA/SAINT-RED transfection method in 
DC vaccine generation, all materials should be clinical-grade available or produced 
compliant to GMP regulations. Importantly, SAINT-RED reagent can be heat-steril-
ized without affecting concentration and functional activity (data not published). To 
investigate the effect of heat sterilization of SAINT-RED on DC transfection efficacy, 
we compared PD-L silencing following siRNA transfection with regular SAINT-RED 
versus autoclaved SAINT-RED of the same batch. In these experiments, we observed 
similar PD-L knockdown efficiencies; respectively, for PD-L1 79.1  ± 2.6% vs. 81.2 ± 
1.1%, and for PD-L2 82.3 ± 1.1% vs. 83.9 ± 1.4% (Figure 4). This demonstrates that 
heat-sterilized SAINT-RED can be applied in our clinical-grade DC generation protocols. 
Besides using a sterile functional reagent, it is also important to evaluate the risks of 
residual SAINT-RED in our washed DC end product. In our protocol per 1x106 DC, 30 
nmol SAINT-RED is added, which is equal to 21 µg of SAINT-RED. In our clinical trial, 
patients will receive 3 vaccinations of 0.25 x 106 DCs/kg. So in case of 100% uptake 
by the DC, the maximum administered dose of SAINT-18 will be 5.25 µg SAINT-RED/
kg body weight of the patient per vaccination. However, it is likely that the actual 
dose is lower as residual siRNA/SAINT-RED lipoplexes will be efficiently removed 
Figure 4   Heat sterilisation does not affect transfection efficacy using SAINT-RED
Intermediate DCs were transfected with 4 µg PD-L1/PD-L2 siRNA (2:1 w/w ratio) or control 
siRNA complexed with 40 µl 0.75 mM SAINT-RED w/v ratio 1:10. At day 7, maturation was 
induced by addition of IL-6, IL-1β, TNF-α and PGE2. At day 9, PD-L1 (A) and PD-L2 (B) protein 
expression was analyzed by flow cytometry. Data are expressed as mean ± SEM of 3 donors.
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during DC processing prior to injection (harvesting, electroporation, washing). 
In mice the No Observed Adverse Effect Level (NOAEL) of SAINT-RED is 0.5 mg/kg 
(unpublished observation). Based on this NOAEL we will administer at least  >95x less 
SAINT-RED to our patients, indicating that the toxicity risks of SAINT-RED are limited. 
Collectively, these results and considerations indicate that we can generate a safe 
and GMP-compliant DC vaccine using this transfection method. 
Figure 5   PD-L silenced DCs augment cytokine producing capacity of T cells in 
allogeneic MLR assays
Intermediate DCs were transfected with 4 µg PD-L1/PD-L2 siRNA (2:1 w/w ratio) or control 
siRNA complexed with 40 µl 0.75 mM SAINT-RED w/v ratio 1:10. At day 7, maturation was 
induced by addition of IL-6, IL-1β, TNF-α and PGE2 for 2 days. At day 9, DCs were co-cultured 
with allogeneic CD4+ or CD8+ T cells, which had been selected from PBMCs. (A) CD4+ and 
CD8+  T cells were stained with CFSE. After four days of co-culture, T cell proliferation was 
analyzed based on CFSE dilution. Data are depicted as mean percentage of proliferating T 
cells ± SEM for 3 different donors. (B) IFN-γ levels were measured in the supernatant after four 
days of co-culture. Data are depicted as mean ± SD, and are 1 representative example of 3 
different donors. (C) Cytokines produced by CD4+ and CD8+ T cells of the same donor 
stimulated with allogeneic DCs at a ratio of 1:0.1 were analyzed simultaneously at day 1-4 of 
co-culture. Statistical analysis was performed using One-way ANOVA followed by a Bonferroni 
post-hoc test. *P< 0.05, **P<0.01, ***P<0.001.
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PD-L silenced DCs augment cytokine producing capacity of T cells  
in allo-MLR assays
To investigate whether PD-L siRNA/SAINT-RED transfected DCs augment T helper 
(Th)1/Th2 and CD8+ T cell responses, we performed allo-MLR assays. In these assays, 
PD-L knockdown DCs or control DCs were co-cultured with allogeneic T cells for 
four days, thereafter T cell proliferation and cytokine production was analyzed. 
As reported previously,13 we did not observe enhanced T cell proliferation (Figure 5A), 
while IFN-γ production was significantly enhanced after stimulation with PD-L 
knockdown DCs (Figure 5B). CD4+ T cell-mediated IFN-γ production doubled after 
co-culture with PD-L knockdown DCs, moreover allogeneic CD8+ T cells even 
produced four times more IFN-γ upon stimulation with PD-L silenced DCs. 
In addition, we investigated Th1/Th2 skewing and CD8+ T cell activation following 
culture with PD-L silenced DC by analysis of various cytokine levels in time (Figure 5C). 
We observed increased production of IFN-γ, IL-2 and TNF-α in both in CD4+ 
and CD8+ T cells. Notably, although increased IL-5 production was observed upon 
co-culture with allogeneic DCs, no effect of stimulation with PD-L knockdown DC 
was observed. We did not observe IL-4 nor IL-10 production (data not shown). 
Furthermore, no effects of stimulation with PD-L knockdown DC on CD4+ and 
CD8+ T cell activation and differentiation phenotype were observed (data not shown). 
Together, these data demonstrate that our PD-L knockdown DCs preferentially 
stimulate cytotoxic T cell and Th1 responses, which are highly important for effective 
anti-tumor immunity.
Figure 5   Continued
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PD-L silenced DCs can be efficiently loaded with MiHA-encoding mRNA 
and show superior stimulation of MiHA-specific T cell responses
To investigate the potential of PD-L siRNA/SAINT-RED transfected DCs to boost 
MiHA-specific CTL expansion and function, we stimulated CTLs specific for the hema-
topoietic-restricted MiHA LRH-1 with PD-L knockdown DCs either electroporated 
Figure 6   PD-L knockdown DCs can be loaded with MiHA-encoding mRNA and 
effectively stimulate MiHA-specific T cell responses
Intermediate DCs were transfected with 4 µg PD-L1/PD-L2 siRNA (2:1 w/w ratio) or control 
siRNA complexed with 40 µl 0.75 mM SAINT-RED w/v ratio 1:10. At day 7, maturation was 
induced by addition of IL-6, IL-1β, TNF-α and PGE2 for 2 days. Then, mature DCs were 
electroporated with or without 20 µg P2X5 mRNA encoding the MiHA LRH-1 or HMHA1 
encoding the MiHA HA-1. Alternatively, DCs were exogenously loaded with 5 µM LRH-1 
peptide. (A) LRH-1-specific CTLs were stimulated with PD-L knockdown or control DCs at an 
E:T ratio 1:0.05 for 5 days. IFN-γ levels were measured in the supernatant by means of ELISA. 
Data are depicted as mean ± SD and are representative for 2 different donors. ND, not 
detectable. (B-D) PBMCs containing HA-1-specific CD8+ T cells were stimulated with PD-L 
knockdown or control DCs at an E:T ratio of 1:0.1. After one week, the percentage of 
HA-1-specific T cells was determined by flow cytometry. (B) Percentage of HA-1 specific T 
cells in the total CD8+ T cell population of patient 1. (C-D) Total number of HA-1-specific CD8+ 
T cells after one week of stimulation, (C) patient 1 and (D) patient 2.
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with LRH-1 encoding mRNA or exogenously loaded with the LRH-1 peptide. After 
overnight incubation, we measured production of IFN-γ by LRH-1-specific CTLs in 
the culture supernatants (Figure 6A). As shown previously,9 stimulation with MiHA 
mRNA-electroporated DCs resulted in significantly increased IFN-γ production by 
these LRH-1-reactive CTLs as compared to peptide-loaded DCs. Importantly, PD-L 
knockdown DCs significantly augmented IFN-γ production as compared to control 
DCs. No significant IFN-γ production was measured when LRH-1-specific CTL were 
stimulated with unloaded MiHA- DCs. Subsequently, we investigated the potential 
of MiHA mRNA pulsed PD-L siRNA/SAINT-RED transfected DCs on boosting the 
expansion of patient-derived MiHA-specific effector memory T cells. Therefore, we 
co-cultured PBMCs of two allo-SCT patients with mRNA-loaded PD-L silenced or 
control DCs. At start, these PBMCs contained <0.01 % HA-1-specific CD8+ effector 
memory T cells. After one week, the percentage of HA-1-specific CD8+ T cells in 
patient 1 had expanded to 3.5% after stimulation with PD-L knockdown DCs as 
compared to 1.6% in case of control DCs (Figure 6B). In absolute numbers the 
increase in HA-1-specific CD8+ T cells was even more evident, resulting in 4.6 and 
33.4 times more HA-1-specific CD8+ T cells in patient 1 and patient 2, respectively, 
as compared to stimulation with control DC (Figure 6C-D). These data demonstrate 
that siRNA/SAINT-RED-mediated PD-L knockdown followed by pulsing with MiHA- 
encoding mRNA results in a highly potent DC vaccine with enhanced capacity to 
boost MiHA-reactive T cell proliferation and cytokine production in allo-SCT patients.
Figure 6   Continued
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Discussion
Although it is well known that tumors can induce tumor-reactive T cell responses, 
these T cell responses are often insufficient due to low T cell numbers or poor T cell 
functionality. Therefore, tumor-reactive immunity should be boosted to prevent 
tumor progression and induce regression of tumors.23,24 Since DCs are professional 
APCs, which efficiently take up and present antigens to T cells and in addition 
express high levels of co-stimulatory molecules,25 DC vaccination is considered to 
be a highly attractive approach to boost tumor-reactive T cell immunity in patients. 
Although durable clinical responses have been observed after DC vaccination in 
some patients,26 clinical responses are most often limited, so further improvement 
of DC vaccine potency is urgently warranted.25 
 Due to their abundance in peripheral blood, monocytes are an attractive and 
easily available cell source for DC generation. After isolation, monocytes can be 
differentiated into iDCs using GM-CSF and IL-4. Subsequently, addition of pro- 
inflammatory cytokines such as IL-1β, IL-6, PGE2 and TNF-α results in generation of 
mDCs, expressing high levels of co-stimulatory receptors.27 To induce tumor-specific 
T cell immunity in the autologous immunotherapy setting, these ex vivo-generated 
moDCs can be loaded with tumor-associated antigens (TAAs). Nevertheless, after 
allo-SCT MiHAs play a dominant role in the induction of anti-tumor T cell 
immunity.28,29 Especially, using hematopoietic-restricted MiHAs, a potent anti-tumor 
T cell response can be induced without the risk of inducing GVHD.7-9 DCs can be 
either exogenously loaded with short MiHA peptides or pulsed with MiHA-encoding 
mRNA. Following mRNA electroporation in mature DCs, diverse MiHA epitopes are 
presented in both HLA-I and HLA-II molecules, which allows activation of a broad 
repertoire of MiHA-specific T cells.30 Moreover, we and others have shown that 
mRNA-loaded DCs can induce expansion of tumor-reactive T cells in vitro and in 
vivo.9-12 So effective and tumor-specific DC vaccines can be generated using moDCs 
loaded with hematopoietic-restricted MiHAs. However, while moDCs express high 
levels of co-stimulatory receptors, co-inhibitory receptors are also expressed on 
these cells and may limit their stimulatory potential. Therefore, interference with 
these co-inhibitory pathways is an appealing strategy to further improve the 
immunogenicity of moDC vaccines. 
 Previously, we explored whether DC vaccines could be improved by siRNA- 
mediated silencing of the co-inhibitory molecules PD-L1 and PD-L2 in immature 
moDCs. Activation of MiHA-experienced CD8+ T cells from allo-SCT patients with 
PD-L silenced DCs demonstrated that these DCs indeed have superior potential 
induce expansion of MiHA-specific cytotoxic T cells.13,14 siRNA was delivered using 
either electroporation or LNP. However, to allow in vivo induction and boosting of 
GVT-specific T cell responses by our DC vaccines, PD-L/PD-1 blockade should be 
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combined with hematopoietic-restricted MiHA loading. To prevent loss of viability 
due to double electroporation, we assessed the suitability of lipoplexes composed 
of PD-L1/L2 siRNAs and the clinical grade available SAINT-RED transfection reagent. 
This SAINT-RED is composed of the cationic amphiphilic lipid SAINT-18 (1-methyl-4-
(cis-9-dioleyl)methyl-pyridinium-chloride) in a 1:1 molar ratio with the neutral 
helper-lipid DOPE, and is a highly efficient and non-toxic transfection reagent for 
delivery of nucleotides and proteins into target cells.16 Recent studies showed 
efficient gene silencing in vitro and in vivo using SAINT-18.15,17 In contrast to the 
LNP-based method for siRNA delivery we explored earlier,14 SAINT-RED can be easily 
produced in compliance with GMP guidelines. Furthermore, we found that it can be 
heat-sterilized without affecting its functionality. In addition, we calculated that the 
maximum amount of SAINT-RED that will be administered to our patients is >95x 
below the NOAEL. So, this transfection method is safe and can easily be incorporated 
in clinical-grade DC-generation protocols.  Therefore, we developed and optimized 
a protocol for the generation of a MiHA-specific PD-L knockdown DC vaccine using 
SAINT-RED. Using this DC generation protocol, we observed efficient, specific and 
long-lasting down-regulation of PD-L1 and PD-L2 expression levels. Importantly, DC 
viability was not affected by this transfection method. Furthermore, expression of 
high levels of maturation markers was maintained. In concordance with results 
obtained with earlier PD-L siRNA delivery strategies, PD-L knockdown DCs  loaded 
with MiHA augmented activation of MiHA-specific CD8+ T cells.13 These findings 
designate our PD-L silenced DC a highly promising vaccination strategy to boost 
Th1 and tumor-reactive CD8+ T cell responses in cancer patients and prevent tumor 
progression or relapse. The first safety/toxicity study with these DC vaccines will 
involve patients with hematological malignancies after allo-SCT, to enhance 
GVT-reactive T cell responses. As patients post allo-SCT are in a highly activated 
immunological state, the risk of eliciting or aggravating GVHD by systemic therapy 
with PD-1 or PD-L1 blocking antibodies is substantial. Importantly, the risk of 
inducing auto-immune responses with the PD-L silenced DC vaccines will be 
limited, as DC vaccines will be loaded with hematopoietic-restricted MiHA. Thereby, 
only T cell responses selective for these antigens will be boosted. 
 Besides, application in ex vivo moDC vaccine generation, the here described 
transfection protocol for DC vaccine generation could be easily adapted for other 
immunotherapeutic approaches. Since this method is not limited to moDC vaccines, 
siRNA-mediated knockdown of PD-L1/L2 on naturally occurring DC subsets or DCs 
generated from CD34+ hematopoietic stem cells is an interesting approach to 
explore. Importantly, DC vaccines could be loaded with TAAs; thereby this vaccine 
will also be applicable for solid tumors such as melanoma and renal-cell carcinoma. 
 In conclusion, in this study we developed a protocol for the generation of a 
highly effective clinical-grade DC vaccine by combining PD-L siRNA delivery via 
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SAINT-RED with MiHA-encoding mRNA pulsing. This resulted in highly efficient, 
specific and long-lasting silencing of PD-L1/L2 without affecting DC viability or 
phenotype. Furthermore, these MiHA mRNA pulsed PD-L silenced DC showed 
superior stimulatory potential to boost MiHA-specific T cell proliferation and cytokine 
production. By application of this new siRNA transfection method, we can generate 
highly potent clinical-grade DC vaccines to selectively boost GVT responses after 
allo-SCT. 
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Abstract
Purpose: Older acute myeloid leukemia (AML) patients have a poor prognosis, 
therefore novel therapies are needed. Allogeneic natural killer (NK) cells have been 
adoptively transferred with promising clinical results. Here, we report the 
first-in-human study exploiting an unique scalable NK cell product generated ex 
vivo from CD34+ hematopoietic stem and progenitor cells (HSPCs) from partially 
HLA-matched umbilical cord blood units. 
Experimental Design: Ten older AML patients in morphologic complete remission 
received an escalating HSPC-NK cell dose (between 3 and 30x106/kg body weight) 
after lymphodepleting chemotherapy without cytokine boosting. 
Results: HSPC-NK cell products contained a median of 75% highly activated NK cells, 
with <1x104 T cells/kg and <3x105 B cells/kg body weight. HSPC-NK cells were well 
tolerated and no graft-versus-host disease nor toxicity was observed. Despite no 
cytokine boosting was given, transient HSPC-NK cell persistence was clearly found in 
peripheral blood up to 21% until day 8, which was accompanied by augmented IL-15 
plasma levels. Moreover, donor chimerism up to 3.5% was found in bone marrow. 
Interestingly, in vivo HSPC-NK cell maturation was observed, indicated by the rapid 
acquisition of CD16 and KIR expression, while expression of most activating receptors 
was sustained. Notably, two out of four patients with minimal residual disease (MRD) 
in bone marrow before infusion became MRD negative (<0.1%), which lasted for 6 
months. 
Conclusions: These findings indicate that HSPC-NK cell adoptive transfer is a 
promising, potential “off-the-shelf” translational immunotherapy approach in AML.
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Introduction
Acute myeloid leukemia (AML) is prevalent in older adults with a mean age of 
69 years.1 Current treatment consists of intensive chemotherapy, hypomethylating 
agents, low-dose cytarabine or supportive care.2,3 Although morphologic complete 
remission (CR) can be achieved in 40-60% of older patients,4-6 most patients relapse 
resulting in a 5-year overall survival (OS) of about 10%. This poor outcome can be 
attributed to unfavorable cytogenetic and molecular features, and increased 
incidence of multidrug resistance.7 Intensive treatment modalities, such as allogeneic 
stem cell transplantation (allo-SCT) are often limited due to co-morbidities.8 
However, non-myeloablative conditioning regimens has made allo-SCT feasible for 
older and medically less fit patients.9,10 Unfortunately, net results in terms of OS has 
not improved, because reduction of non-relapse mortality (NRM) is counterbal-
anced by higher incidence of relapse-related mortality.11-15 Hence, relapse is still the 
leading cause of treatment failure in AML patients, who are consolidated with 
allo-SCT, after having achieved morphologic CR.10,13,14 Persistent minimal residual 
disease (MRD) has been associated with increased relapse rates and decreased OS in 
both myeloablative and non-myeloablative allo-SCT.16-18 Therefore, improved and 
tolerable conditioning therapies are needed to reduce or eradicate MRD in older 
AML patients.
 Adoptive cell therapy (ACT) exploiting allogeneic natural killer (NK) cells can 
exert anti-AML activity without inducing graft-versus-host disease (GVHD) and is 
clinically well-tolerated.19-22 Allogeneic NK cell ACT is performed following cyclo-
phosphamide and fludarabine (Cy/Flu) based lymphodepleting chemotherapy, 
thereby preventing immediate rejection of transferred allogeneic NK cells. Moreover, 
it eliminates tolerogenic immune cells and promotes cytokine availability for in vivo 
NK cell persistence and expansion.20,23 Most previous studies combined NK cell 
infusion with administration of IL-2 to boost in vivo expansion.19-24 However, high 
doses of IL-2 resulted in significant toxicity. Furthermore, an increase in regulatory 
T cells (Tregs) was found after IL-2 administration even at lower dosage, which could 
inhibit NK cell functionality.23-25 Interestingly, studies at the University of Minnesota 
showed that poor-prognosis AML patients with relapsed/refractory disease achieved 
hematologic CR after NK cell therapy in 26% (5/19) and 53% (8/15) of cases without 
or with prior IL2-diphtheria toxin fusion protein (IL2DT) treatment to deplete Tregs, 
respectively.20,24 This increased CR rate allowed several patients to become eligible 
for potentially curative allo-SCT.24 Although NK cell ACT is a promising therapy in 
AML patients, the desired clinical effect needs further enhancement of the NK 
cell-mediated anti-tumor effect.
 Effective ACT requires NK cells to be appropriately activated, available in 
sufficient numbers, have appreciable persistence in vivo, home to the tumor site and 
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effectively kill tumor cells. Generally, allogeneic NK cell products have been enriched 
from the peripheral blood (PB) of haplo-identical donors followed by stimulation 
with IL-2 or IL-15. However, this cellular product is a heterogeneous mixture of cells. 
CD3+ T cell and CD19+ B cell depletion results in a cell product with 23-70% of infused 
cells being NK cells.20,23,24 CD3 depletion followed by CD56 positive selection can result 
in higher percentages of NK cells (66-97%), but relatively low NK cell dosages of 
3-5x106 cells/kg can be generated using these methods.21,22,24 Moreover, these 
procedures reported T cell dosages of 5x104/kg up to 2x105/kg in adult patients, 
resulting in an increased risk of GVHD. Therefore, development of more homogeneous 
and well-defined allogeneic NK cell products is preferable for adoptive immuno-
therapy. Previously, we reported a good manufacturing practice (GMP)-compliant 
culture method for the ex vivo generation of highly active NK cells.26 In this system, 
CD34+ human stem and progenitor cells (HSPCs) isolated from allogeneic umbilical 
cord blood (UCB) are expanded and differentiated into NK cells in the presence of 
IL-15 and IL-2, resulting in a clinically relevant dose of NK cells with a purity >85%.26,27 
These allogeneic HSPC-NK cells show cytolytic activity against AML cells in vitro26 
as well as bone marrow homing capacity and anti-leukemic effects in vivo.28
 Here, we describe the first-in-human phase I study investigating ACT with 
escalating dosages of UCB-derived HSPC-NK cells in older AML patients. HSPC-NK 
cell infusion was performed without IL-2 administration in order to investigate IL-15 
driven homeostatic NK cell persistence and tolerability after infusion, and to avoid 
IL-2-mediated Treg expansion potentially affecting donor NK cell functionality. We 
demonstrate that ACT using this scalable and potentially “off-the-shelf” HSPC-NK cell 
product results in transient donor NK cell persistence, homing to the bone marrow 
and further in vivo maturation in older AML patients following lymphodepleting 
chemotherapy. HSPC-NK cells were well tolerated and no GVHD nor toxicity was 
induced. Two out of four patients with detectable MRD before infusion became 
MRD negative after HSPC-NK cell ACT. Although we cannot separate the effect of the 
NK cell infusion from the effect of immunosuppressive chemotherapy on MRD, our 
results indicate that HSPC-NK cell ACT represents an innovative and promising 
strategy for patients with AML.
Materials and Methods
Study design
Older AML patients who achieved morphologic CR after remission induction 
chemotherapy or hypomethylating agents were included. Inclusion criteria were: 
AML, age ≥ 55 years and contraindication for allo-SCT, no HLA-antibodies, CR after 
first or second line chemotherapy, World Health Organization (WHO) performance 
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score ≤ 1 and life expectancy > 6 months. The study protocol has been approved by 
the national medical ethical committee (CCMO registration NL31699.00020; EudraCT 
number 2010-018988-41) and the study was registered at the Dutch clinical trial 
registry (NTR 2818). All subjects gave written informed consent in accordance with 
the Declaration of Helsinki.
UCB selection
HLA typing of eligible AML patients was performed by the Luminex method using 
the LABtype SSO kit (OneLambda, Canoga Park, USA). Subsequently, a suitable 
allogeneic UCB unit displaying the highest HLA match for HLA-A, -B and -C was 
selected for HSPC-NK cell product manufacturing (see for details supplementary 
information). KIR typing of UCB units was performed with the KIR SSO genotyping 
test (OneLambda, Canoga Park, USA). A total of 350 UCB units within the Cord Blood 
Bank Nijmegen containing a mean of 874 ± 439 x106 (range 230-3,070 x106) viable 
nucleated cells and 4.66 ± 3.64 x106 (range 2.00-33.95 x106) viable CD34+ HSPC were 
available. The UCB requirements as drug substance for HSPC-NK product 
manufacturing were negative for viral, bacterial and fungal contamination, and 
presence of ≥ 2.0x106 viable CD34+ HSPCs. 
HSPC-NK cell infusion
To favor HSPC-NK cell persistence, patients received non-myeloablative chemo- 
therapy with cyclophosphamide (Cy) 900mg/m2/day and fludarabine (Flu) 30mg/
m2/day from day -6 to -3. Following premedication with acetaminophen (500 mg) 
and clemastine (2 mg), HSPC-NK cells were administered intravenously (IV) three 
days after conditioning (day 0). Except for patient 1, all patients received a single 
dose of Pegfilgrastim (6 mg) on day 8 to prevent long-term neutropenia. According 
to the local guidelines for severe immunocompromized patients all patients were 
treated ciprofloxacin 500 mg twice daily and fluconazol 400 mg once daily during 
neuropenia. In addition, patients were treated with cotrimoxazol 480 mg once daily 
and valaciclovir 500 mg twice daily until one year after Cy/Flu conditioning. 
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Results
Patient characteristics
In this study, we investigated the feasibility, safety, and biological properties of 
allogeneic HSPC-NK cell infusion following lymphodepleting chemotherapy in older 
(≥ 55 years) AML patients, who were not eligible for allo-SCT because of age or 
co-morbidity. A total of 17 patients were enrolled (Figure 1A). All included patients 
had a WHO-performance status of 0 to 1. Four patients were excluded after consent 
signing: two patients had anti-HLA class I antibodies, one patient did not reach 
morphologic CR, and one patient withdrew informed consent. For 13 patients 
HSPC-NK cell product manufacturing was initiated. One production was interrupted 
because of relapse during culturing. Another patient developed a relapse just before 
the start of lymphodepleting chemotherapy, and was not treated (UPN12; NK cell 
production was completed). Eleven remaining patients received Cy/Flu conditioning, 
and ten out of eleven HSPC-NK cell products generated met the release criteria. 
Eventually, 10 patients were treated with escalating dosages of HSPC-NK cells (Figure 1B). 
Dosages were based on previous studies with enriched NK cell products from PB 
ranging from 1-5x106/kg using the CD3-depletion/CD56-enrichment method21 and 
2-15x106/kg using the CD3/CD19 depletion method20. The intended HSPC-NK 
dosages were 3, 10 and 30 x106/kg in cohorts of 3 patients. Patient characteristics 
and their UCB-donor are displayed in Table 1. Median age of patients was 72 years 
(range 68-76 years). Patients were all in morphologic CR after one (n=1), two (n=4) or 
three (n=2) courses of standard intensive chemotherapy (Table 1). Three patients 
were in morphologic CR after intensive chemotherapy followed by treatment with 
hypomethylating agents (UPN7, 8 and 9). 
HSPC-NK cell products
For the generation of allogeneic NK cell products, partially HLA-matched UCB units 
were selected based on the HLA type of the patient. Matching for HLA-A, -B and -C 
for the 10 treated patients was 6/6 for one patient, 3/6 for five patients, 2/6 for three 
patients and 1/6 for one patient. Although KIR mismatch was not prioritized in this 
study, seven out of 10 patients had a KIR receptor-ligand mismatch, where the UCB 
donor possessed inhibitory KIR genes for which the HLA ligand was lacking in the 
patient (Table 1). KIR genotype of the used UCB units is reported in Table 1. Cell 
numbers at each step of the manufacturing process are shown in Supplementary 
Table 1. After thawing and CD34 selection, a median of 2.63x106 CD34+ cells (range, 
1.15-8.13) were placed in culture. The mean purity of the CD34+ cell product was 
74±13% (range 46% - 86%). After 42 days of culture, a median of 2,341x106 total 
nucleated cells (TNC; range 563-5,842) were recovered. Purity of CD56+CD3- NK cells 
in the generated cell products was 75±12% (range 40-85) with a median viability of 
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Figure 1   Patient inclusion and study scheme
(A) Patient inclusion scheme. (B) Patients in CR were included in the study. After informed 
consent, an UCB was selected and HSPC-NK cells were generated. Patients received cyclo-
phosphamide 900 mg/m2/day IV and fludarabine 30 mg/m2/day IV (Cy/Flu day -6 to -3). 
Escalating dosages of HSPC-NK cells were infused at day 0. Patients were monitored for 
toxicity, GVHD, MRD, and in vivo HSPC-NK cell expansion and maturation.
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Table 1   Demographic, hematologic and UCB donor characteristics of enrolled 
AML patients.
UPN Age 
(years)
Sex WHO type Karyotype Risk group1 Previous 
therapy
Disease  
status at 
HSPC-NK 
infusion
KIR  
ligand- 
ligand
mismatch
KIR  
receptor-
ligand 
mismatch
Donor KIR 
haplotype
Infused
HSPC-NK cells
(x106/kg) 
Total infused
HSPC-NK cells
( x106)
1 72 M AML with NPM1 
mutation
46 XY Good/ 
intermediate
Intensive 
chemotherapy,
3 courses
CR1 C1 C1 AA 3 220
2 68 M AML 46 XY Intermediate Intensive 
chemotherapy,
2 courses 
CR1 Bw4 Bw4 AB 3 324
3 73 F Therapy related AML Complex Very poor Intensive 
chemotherapy,
2 courses
CR1 C1 C1 AB 3 189
4 70 F AML 46 XX Very poor Intensive 
chemotherapy, 
2 courses
CR1 C1 C1 AA 10 650
5 72 F AML with MDS-related 
features
46 XX Poor Intensive 
chemotherapy,
3 courses
CR1 - - AB 10 530
6 76 M AML with MDS-related 
features
ND Poor Intensive 
chemotherapy,
2 courses
CR1 C1 C1 AA 10 770
7 75 F AML with MDS-related 
features
46 XX
+13
Poor Intensive 
chemotherapy,
1 course, azacitidine 
1 course
CR1 - - AB 30 1693
8 71 M AML 46 XY
inv(12)
Very poor Intensive 
chemotherapy,
1 course, decitabine 
3 courses, azacitidine 
5 courses
CR1 - C2,Bw4 AA 17 1191
9 71 M AML 46 XY Very poor Intensive 
chemotherapy,
4 courses, azacitidine 
17 courses
CR3 - - AA 6 510
10 73 M AML 47 XY
+19+8
Poor Intensive 
chemotherapy,
1 course
CR1 - C2 AB 30 2190
Abbreviations: CR1, first complete remission; CR3, third complete remission; HSPC-NK, hematopoietic stem 
en progenitor cell-derived Natural killer cell; KIR, killer-cell immunoglobulin-like receptor; F, female, 
ND, not determined; M, male.
1  Risk group classification was determined using criteria defined by the Dutch-Belgian Cooperative Trial 
Group for Hematology Oncology (HOVON).
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Table 1   Demographic, hematologic and UCB donor characteristics of enrolled 
AML patients.
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therapy
Disease  
status at 
HSPC-NK 
infusion
KIR  
ligand- 
ligand
mismatch
KIR  
receptor-
ligand 
mismatch
Donor KIR 
haplotype
Infused
HSPC-NK cells
(x106/kg) 
Total infused
HSPC-NK cells
( x106)
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CR1 - - AB 10 530
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1 course
CR1 - C2 AB 30 2190
Abbreviations: CR1, first complete remission; CR3, third complete remission; HSPC-NK, hematopoietic stem 
en progenitor cell-derived Natural killer cell; KIR, killer-cell immunoglobulin-like receptor; F, female, 
ND, not determined; M, male.
1  Risk group classification was determined using criteria defined by the Dutch-Belgian Cooperative Trial 
Group for Hematology Oncology (HOVON).
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94% (range 88-99). The percentage of CD3+ T cells and CD19+ B cells was very low to 
absent, i.e. 0.03±0.04% (range 0.00-0.16) and 0.16±0.21% (range 0.00-0.65), 
respectively (Figure 2A). The mean frequency of CD16 and NKG2A positivity on 
CD56+CD3- cells was 21±10% (range 5-34) and 84±10% (range 63-94), respectively 
(Figure 2A). All CD56+CD3- cells expressed high levels of the activating receptors 
NKG2D (mean 89±10%), NKp30 (mean 86±10%), NKp44 (mean 83±10%), NKp46 
(mean 80±9%) and 2B4 (mean 93±4%) (Figure 2B). CD56+CD3- cell products killed 
K562 cells with 82±7% lysis at an E:T ratio of 3:1 (Supplementary Figure 1; 
Supplementary Table 2). CD107a-based degranulation assays showed a mean 
frequency of CD107a+ degranulating NK cells of 28±5%. The mean frequency of 
IFNγ+ NK cells was 2.9±2.3%. For three patients, we could evaluate the capacity of 
the generated HSPC-NK cells to induce lysis of primary patient-derived AML cells 
obtained at diagnosis (Figure 2C). Notably, patients’ primary AML cells were 
substantially killed within 24 and 48 hours of co-culture with the corresponding 
HSPC-NK cell products. 
 Eleven out of 12 manufactured products met the release criteria. The total 
infused HSPC-NK cell dose ranged from 189 to 2,190x106 CD56+CD3- cells (Table 1 
and Supplementary Table 1). In the twelve manufactured HSPC-NK products the 
mean number of CD19+ B cells was 0.32 ±0.37x105/kg. Importantly, the median 
number of CD3+ T cells was <0.01x105/kg. One product (for UPN11) failed release 
due to exceeding the CD3+ T cell impurity criteria of <0.1x105/kg (i.e. 0.43x105/kg), 
although the percentage T cells was only 0.16%. This product was not infused to 
avoid risk of inducing GVHD. These results demonstrate the feasibility to generate 
GMP-compliant CD34-derived HSPC-NK cell products with potent functional activity 
against leukemia cells meeting lot release criteria for infusion.
 
Safety of HSPC-NK cell infusion
Patients were monitored for toxicity and GVHD at specified time-points. Administration 
of Cy/Flu conditioning and infusion of HSPC-NK cells was well tolerated and no NK 
cell infusion-related toxicities were seen. Furthermore, we did not observe any 
signs of GVHD. Importantly, no clinical signs of cytokine release syndrome or other 
unexpected toxicities were observed. Furthermore, no significant increase in IL-6 
nor ALT levels was observed (data not shown). Cy/Flu conditioning did result in 
expected hematologic toxicity. The median time to neutrophil count of >0.5x109/L 
and to platelet count >25x109/L was 21 and 29 days, respectively. Two patients had 
a neutropenic period  >30 days, and four patients had a platelet count <25x109/L 
for >30 days. Six patients developed febrile neutropenia, but all recovered well with 
antibiotic treatment. An overview of all adverse events >grade 2 is shown in 
Supplementary Table 3.
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Figure 2   HSPC-NK cell products express high levels of activating ligands and  
show potent functional activity
HSPC-NK cells were generated for patients included in the study according to our GMP-grade 
culture protocol. The phenotype of a representative HSPC-NK cell product at the day of 
infusion (day 0) was determined by FCM. (A) CD45+/7AAD- lymphocytes were analyzed for 
their expression of CD56, CD3, CD19 and CD34. CD45+/CD56+ HSPC-NK cells were analyzed 
for their expression of a repertoire of receptors important for NK cell activation and 
maturation. (B) Expression of NK cell receptors on CD45+/CD56+ HSPC-NK cells at the day of 
infusion. Data represented as mean percentage positive cells ± SD on 9-12 HSPC-NK cell 
products. (C) HSPC-NK cell products, which had been cryopreserved at the day of infusion, 
were thawed and cultured for six days in basal medium supplemented with 10% HS, 1000 U/
ml IL-2 and 20 ng/ml IL-15. Thereafter, NK cells were washed and incubated with CFSE-labeled 
AML blasts in the presence of 50 ng/ml IL-3, 20 ng/ml SCF, 20 ng/ml Flt3L, 20 ng/ml G-CSF 
and 5 ng/ml IL-15. Specific killing of AML blasts in diagnosis samples from UPN 1, 2 and 4 after 
24 and 48 hours of co-culture with their corresponding HSPC-NK cell products was analysed 
in a FCM-based killing assay. Data are displayed as mean ± SD of triplicate wells.
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Donor HSPC-NK cell persistence
As anticipated, Cy/Flu conditioning induced lymphocytopenia in all patients 
(Supplementary Figure 2A). Temporary lymphodepletion is essential to facilitate NK 
cell persistence and proliferation in vivo. Absolute numbers of CD4+ T cells, CD8+ T 
cells and CD56+CD3- NK cells were depleted to <0.1x109/L at the time of infusion 
(Supplementary Figure 2, B-D). Relatively, depletion of CD8+ T cells was more 
profound as compared to CD4+ T cells (Supplementary Figure 2, E and F). From day 
eight onward, repopulation of patient’s NK cells and T cells was observed. 
Endogenous IL-15 plasma level, which is essential for in vivo survival and expansion 
of infused NK cells, increased after Cy/Flu conditioning. We observed a six-fold 
increase in IL-15 concentration from baseline (18 ± 5 ng/ml) with a peak at day six 
after Cy/Flu and NK cell infusion (mean 49 ± 16 ng/ml; Figure 3A). Although patients 
did not receive IL-2 injections, a relative increase in the percentage of Tregs within 
the CD4+ T cell population was observed (Figure 3B). However, the mean absolute 
number of Tregs was not augmented.
 Successful donor chimerism was detectable in all patients after infusion. At day 
6-8, we found chimerism up to 21% in PB and up to 3.5% in bone marrow (BM) 
(Figure 3, C and D). Donor chimerism tend to increase when more HSPC-NK cells 
were infused, although the patient that reached the highest chimerism at day 6 did 
not receive most NK cells (i.e. UPN5 who received 10x106/kg). Notably, this patient 
did reach the highest amount of endogenous IL-15. These data demonstrate that 
HSPC-NK cells transiently persist in PB and BM following Cy/Flu conditioning in the 
absence of additional cytokine boosting. 
Transferred HSPC-NK cells mature in vivo by acquisition of CD16  
and KIR expression
To investigate HSPC-NK cell phenotype after infusion, multi-color flow cytometry 
(FCM) analysis was performed at specified time-points. Ex vivo-generated HSPC-NK 
cells express higher levels of CD56, as compared to endogenous CD56dim and 
CD56bright NK cells, so these cells could be readily detected by FCM in vivo. 
Interestingly, the phenotype of infused NK cells of three patients (UPN5, 7 and 8) 
could be analyzed (Figure 4A). In these patients, a clear population of CD3-CD56very-
bright HSPC-NK cells was observed. This population increased in time, and this 
increase reflected the measured donor chimerism. Interestingly, CD16 expression on 
donor HSPC-NK cells increased after infusion resulting in frequencies up to 30-60% 
at day 6-8 (Figure 4B and Supplementary Figure 3A). As reported previously,29 IL-15/
IL-2 expanded HSPC-NK cell products express low levels of KIRs (<5%; Figure 2B). 
However, FCM analysis revealed that HSPC-NK cells rapidly acquire KIRs after infusion 
(Supplementary Figure 3B). In addition to NK cell maturation, preservation of an 
activation phenotype is essential for NK cell reactivity in vivo. Importantly, we did not 
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observe a significant decrease in the expression of NKp30, NKp46 or NKG2D; 
however, expression of NKp44 did decrease after infusion (Figure 4C). These results 
demonstrate that in vivo persisting HSPC-NK cells further mature into KIR+CD16+ NK 
cells while preserving an activated phenotype in vivo after adoptive transfer. 
Figure 3   HSPC-NK cells engraft in PB and BM after Cy/Flu conditioning
Patients were conditioned with Cy/Flu from day -6 to day -3. HSPC-NK cells were infused at 
day 0. Blood was collected at day -7, day 0, day 1, day 2, day 6, day 8, day 14 and day 28. BM 
aspirations were performed before and day 7 after HSPC-NK cell infusion. (A) Plasma IL-15 
levels of each individual patient measured by ELISA. (B) The percentage of Tregs (defined as 
CD4+CD25+FOXP3+ cells) in the CD4+ population and the absolute Treg count (determined 
by measuring the percentage of Tregs within the lymphocyte population) were determined 
by FCM at day -7 and day 14 in peripheral blood. (C-D) Donor chimerism was determined by 
real-time quantitative PCR using single nucleotide polymorphisms (SNPs) and/or the SMCY 
gene. The percentage of donor chimerism in PB (C) and in BM (D) for each individual patient 
is shown.
Plasma IL-15 Regulatory T cells
Donor chimerism (PB) Donor chimerism (BM)
A B
C D
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Figure 4   HSPC-NK cells expand and further mature in vivo
The phenotype of infused NK cells was determined by FCM at different time points in UPN 5, 
7 and 8. (A) The percentage of CD3-CD56verybright NK cells, a phenotype which corresponds 
to our HSPC-NK cell product, increased in time in PB and BM. Gated on CD45+ lymphocytes. 
(B) The percentage of CD16+ cells within the CD3-CD56verybright NK cell population at different 
time points in UPN5, 7 and 8. (C) Expression of activating receptors on HSPC-NK cell products 
before infusion within the CD3-CD56verybright NK cells in PB at day 6, and BM at day 8 after 
infusion in three patients (mean ± SD) are shown. *P < 0.05, one-way analysis of variance with 
Bonferroni post-hoc test.
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Clinical outcome and effect on MRD
At the time of HSPC-NK cell infusion, all patients were in morphologic CR (Table 1). 
Currently, four of the 10 treated patients are disease free for 60, 52, 22 and 16 months, 
respectively. The other six patients relapsed after a mean duration of 364 days after 
Cy/Flu and HSPC-NK cell infusion. In most patients, investigations to detect MRD 
were performed by FCM using leukemia-associated phenotypes (LAPs) and/or 
molecular analysis (Table 2). Before HSPC-NK cell infusion, UPN3 and UPN5 showed a 
positive q-PCR MRD signal in BM and PB for the TP53 and IDH2 mutation, respectively 
(Table 2). After infusion, the signals remained detectable and patients relapsed after 
four (UPN3) and six (UPN5) months. Furthermore, FCM could detect MRD at day -14 
in two patients (UPN7 and 8). This could be confirmed in UPN8 by a positive q-PCR 
detection in BM and PB of a RUNX1 mutation. Notably, we observed a clear decrease 
in the FCM-based MRD signal in UPN7 and 8 (Figure 5 A and B; Table 2). Both patients 
had been treated with azacitidine before start of the study. UPN7 had been treated 
with one course of chemotherapy, and subsequently received two courses of 
azacitidine (50mg/m2, 5 days, last dose day -26). At day -14, MRD of 6.7% was 
measured in BM by FCM (Figure 5B; upper panel). This patient was treated with Cy/
Flu followed by infusion of 30x106/kg HSPC-NK cells. At day 90 after infusion, MRD in 
BM was <0.01% (Figure 5, A and B). Thereafter, MRD remained low in BM until day 
180. However, UPN7 relapsed shortly thereafter, at day 194. Azacitidine therapy was 
started, but could not be continued due to infectious complications, and the patient 
died at day +306. UPN8 had received one course of chemotherapy followed by 3 
courses of decitabine (20mg/m2, 5 days). Because of persisting disease during 
decitabine therapy, he was considered ineligible for allo-SCT. Subsequently, therapy 
was switched to azacitidine (75mg/m2, 7 days for 4 cycles, followed by 50mg/m2, 
5 days, last dose day -17). Despite this therapy, MRD of 6.1% was measured at day -20 
in BM by FCM (Figure 5B; lower panel), and 6% RUNX1-mutated cells in BM and PB 
were detected by q-PCR (Table 2). This patient was treated with Cy/Flu and 17x106/
kg HSPC-NK cells. At day 90, MRD in BM was reduced to 0.04% (Figure 5B; lower 
panel), and RUNX1-mutated cells were <0.1% in PB (Table 2). UPN8 relapsed thereafter 
at day 181, and treatment with Selinexor was started. However, blast counts rapidly 
increased despite therapy and the patient passed away at day +301. Collectively, 
these findings suggest that immunosuppressive chemotherapy followed by a high 
dose of HSPC-NK cells exerted a transient anti-leukemic effect. 
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Table 2  Clinical outcome in HSPC-NK treated AML patients.
UPN Risk group Molecular 
aberrations
Disease 
status  
before  
NK cell 
infusion
FCM MRD 
status  
before  
NK cell 
infusion1
Molecular  
MRD status  
before  
NK cell  
infusion2
Date of 
infusion
MRD status
Day +7
MRD status
Month +3
MRD status
Month +6
Time to 
relapse 
(months)
Therapy  
after relapse
Survival
1 Good/ 
intermediate
NPM1 CR1 ND NPM1: BMNEG,PBNEG 21-12-2011 NPM1: BMNEG,PBNEG NPM1: PBNEG NPM1: BMNEG,PBNEG No relapse No Alive 55 months after 
infusion
2 Intermediate IDH1 CR1 ND IDH1: BMNEG,PBNEG 4-9-2012 IDH1: BMNEG,PBNEG IDH1: PBNEG IDH1: BMNEG No relapse No Alive 47 months after 
infusion
3 Very poor TP53 CR1 ND TP53: BMPOS,PBPOS 23-10-2012 TP53: BMPOS,PBPOS TP53: PBPOS Relapse 4 Azacitidine 
(8 months)
14 months
4 Very poor IDH2, RUNX1 CR1 BMNEG IDH2: BMNEG,PBNEG 18-12-2012 IDH2: BMNEG,PBNEG IDH2: BMNEG,PBNEG IDH2: BMNEG,PBNEG
FCM:BMNEG
35 Decitabine,  
planned for  
allo-SCT
Alive 43 months after 
infusion
5 Poor IDH2, 
DNMT3A
CR1 ND IDH2: BMPOS,PBPOS 7-5-2013 IDH2: PBPOS NE Relapse 6 Azacitidine
(12 months)
22 months
6 Poor No known 
mutations
CR1 BMNEG NE 4-6-2013 NE FCM: BMNEG FCM: BM0.1% 14 No therapy 15 months
7 Poor IDH1 CR1 BM6.7% NE 20-8-2014 NE NE
FCM: BMNEG
NE
FCM: BM0.05%
6 Azacitidine
(1 month)
10 months
8 Very poor ASXL1,
RUNX1
CR1 BM6.1% RUNX1: 
BMPOS,PBPOS
17-2-2015 RUNX1: BMPOS,PBNEG RUNX1: PBNEG
FCM: BM0.04%
RUNX1: BMPOS
FCM: BM3.5%
6 Selinexor (2 months), 
azacitidine (2 months)
10 months
9 Very poor FLT3-ITD CR3 BMNEG NE 10-3-2015 NE NE NE No relapse No Alive 17 months after 
infusion
10 Poor No known 
mutations
CR1 ND NE 11-8-2015 NE NE NE No relapse No Alive 12 months after 
infusion
Note: MRDpos or relapse is depicted in bold text 
Abbreviations: allo-SCT, allogeneic stem cell transplanatation; BMneg, negative in bone marrow; CR1, 
first complete remission; CR3, third complete remission; FCM, flow cytometry; MRD, minimal residual 
disease; ND, not determined; NE, not evaluable; NK, natural killer; PBneg, negative in peripheral blood.
1  Molecular MRD: POS is >0.1% mutated cells and NEG is ≤ 0.1% mutated cells (detection limit q-PCR 
assays is 0.1%).
2  FCM MRD: POS is >0.01% LAP+ cells and NEG is ≤ 0.01% LAP+ cells (detection limit FCM MRD assays is 
0.01%).
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NK cell 
infusion
FCM MRD 
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before  
NK cell 
infusion1
Molecular  
MRD status  
before  
NK cell  
infusion2
Date of 
infusion
MRD status
Day +7
MRD status
Month +3
MRD status
Month +6
Time to 
relapse 
(months)
Therapy  
after relapse
Survival
1 Good/ 
intermediate
NPM1 CR1 ND NPM1: BMNEG,PBNEG 21-12-2011 NPM1: BMNEG,PBNEG NPM1: PBNEG NPM1: BMNEG,PBNEG No relapse No Alive 55 months after 
infusion
2 Intermediate IDH1 CR1 ND IDH1: BMNEG,PBNEG 4-9-2012 IDH1: BMNEG,PBNEG IDH1: PBNEG IDH1: BMNEG No relapse No Alive 47 months after 
infusion
3 Very poor TP53 CR1 ND TP53: BMPOS,PBPOS 23-10-2012 TP53: BMPOS,PBPOS TP53: PBPOS Relapse 4 Azacitidine 
(8 months)
14 months
4 Very poor IDH2, RUNX1 CR1 BMNEG IDH2: BMNEG,PBNEG 18-12-2012 IDH2: BMNEG,PBNEG IDH2: BMNEG,PBNEG IDH2: BMNEG,PBNEG
FCM:BMNEG
35 Decitabine,  
planned for  
allo-SCT
Alive 43 months after 
infusion
5 Poor IDH2, 
DNMT3A
CR1 ND IDH2: BMPOS,PBPOS 7-5-2013 IDH2: PBPOS NE Relapse 6 Azacitidine
(12 months)
22 months
6 Poor No known 
mutations
CR1 BMNEG NE 4-6-2013 NE FCM: BMNEG FCM: BM0.1% 14 No therapy 15 months
7 Poor IDH1 CR1 BM6.7% NE 20-8-2014 NE NE
FCM: BMNEG
NE
FCM: BM0.05%
6 Azacitidine
(1 month)
10 months
8 Very poor ASXL1,
RUNX1
CR1 BM6.1% RUNX1: 
BMPOS,PBPOS
17-2-2015 RUNX1: BMPOS,PBNEG RUNX1: PBNEG
FCM: BM0.04%
RUNX1: BMPOS
FCM: BM3.5%
6 Selinexor (2 months), 
azacitidine (2 months)
10 months
9 Very poor FLT3-ITD CR3 BMNEG NE 10-3-2015 NE NE NE No relapse No Alive 17 months after 
infusion
10 Poor No known 
mutations
CR1 ND NE 11-8-2015 NE NE NE No relapse No Alive 12 months after 
infusion
Note: MRDpos or relapse is depicted in bold text 
Abbreviations: allo-SCT, allogeneic stem cell transplanatation; BMneg, negative in bone marrow; CR1, 
first complete remission; CR3, third complete remission; FCM, flow cytometry; MRD, minimal residual 
disease; ND, not determined; NE, not evaluable; NK, natural killer; PBneg, negative in peripheral blood.
1  Molecular MRD: POS is >0.1% mutated cells and NEG is ≤ 0.1% mutated cells (detection limit q-PCR 
assays is 0.1%).
2  FCM MRD: POS is >0.01% LAP+ cells and NEG is ≤ 0.01% LAP+ cells (detection limit FCM MRD assays is 
0.01%).
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Figure 5   Decreased AML blasts in BM after HSPC-NK cell therapy
In two patients, the percentage of AML blasts in BM was measured at different time points by 
FCM using consensus leukemia associated phenotypes (LAPs). (A) Graphic representation of 
subsequent treatments and their effect on the percentage of AML blasts in the BM in UPN7 
and UPN8. (B) Decrease in the percentage of LAP+ AML cells of UPN7 (CD45±CD34+CD133+CD117- 
cells) and UPN8 (CD45±CD34+CD133+CD7+ cells) in BM at day 90 after HSPC-NK cell therapy, 
as compared to day -14 (UPN 7) or day -20 (UPN8).
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Discussion
Here, we investigated the safety, toxicity and biologic properties of ACT with 
escalating dosages of ex vivo-generated, UCB-derived HSPC-NK cells without 
additional cytokine administration in older AML patients (EudraCT number 2010-
018988-41). This is the first time that UCB-derived HSPC-NK cell ACT has been 
explored in humans. A major advantage of using widely available UCB units for 
generating NK cells compared to haplo-identical PB donors is the selection of the 
most optimal NK donor based on KIR haplotype B and KIR-L (HLA) genetics. Using a 
limited number of 350 UCB units, we were able to select a partially HLA-matched 
UCB unit for most AML patients with either a KIR receptor-ligand mismatch and/or 
KIR B haplotype (Table 1). Ten older AML patients in morphologic CR were successfully 
infused with alloreactive HSPC-NK cells (between 3 and 30x106/kg body weight) 
after Cy/Flu chemotherapy. We found that this was safe with limited toxicity. In line 
with earlier studies investigating ACT with allogeneic NK cells products, we did not 
observe GVHD or severe infections.19-24 As expected, conditioning with Cy/Flu 
Figure 5   Continued
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induced hematologic toxicity. The median time to absolute neutrophil and platelet 
count recovery was comparable to the cytopenic period reported earlier by Curti 
et al.21,22 In our study, two patients had a neutropenic period >30 days, and four 
patients had a platelet count below 25x109/L for >30 days. So while the majority 
of patients did recover quickly, heavily pretreated older AML patients are at risk 
to develop prolonged cytopenia. These results suggest the need for a careful 
evaluation for the eligibility for Cy/Flu plus NK cell therapy, which should be proposed 
only to patients with sufficient BM reserve.
 Patients in the current study were not eligible for allo-SCT at the time of study 
inclusion. At the start of the study, allo-SCT was not performed in patients >65 years 
of age at our center. Currently, four out of 10 treated patients (UPN1, 2, 9 and 10) are 
still alive and disease free at 60, 52, 22 and 16 months after NK cell infusion. Moreover, 
one patient (UPN4) was disease free for 35 months, and two out of four (very) poor 
risk patients with detectable MRD, became negative (<0.1%) lasting for 6 months. 
Some of these patients would currently be eligible for allo-SCT, as during our study, 
NMA allo-SCT was introduced in medical fit AML patients >65 years of age.8,30 
We observed that HSPC-NK cell infusion following Cy/Flu conditioning can at least 
temporarily decrease MRD. Although in this study the therapeutic effect of HSPC-NK 
cells cannot be separated from a Cy/Flu effect, we believe this therapy could be an 
attractive strategy to reduce MRD before NMA allo-SCT in patients with morphologic CR. 
Especially since prolonged cytopenia will not be a limiting factor using this strategy 
due to the donor stem cell rescue. In addition, HSPC-NK cell therapy could also be 
applied for consolidating medical less fit younger patients with (very) poor risk AML 
that undergo NMA allo-SCT. 
 In this phase I study, we performed HSPC-NK cell infusion without IL-2 
administration. This study design allowed us to separate toxicity induced by Cy/Flu 
conditioning and HSPC-NK cell infusion from IL-2-mediated toxicity, which can be 
considerable.31 Besides, it has been reported that Tregs, capable of suppressing NK 
cell function, are relative resistant to cytotoxic therapy and expand rapidly after IL-2 
administration.23,25,32,33 Although we did observe a relative increase in Tregs at day 
14 after HSPC-NK cell infusion, the absolute Treg number before and after treatment 
was unchanged. Importantly, HSPC-NK cells were detectable up to 21% in PB and 
3.5% in BM until day 8 in patients infused with >10x106/kg. Regarding the HSPC-NK 
cell dose, 3 patients received 1x106/kg, 1 received 6x106/kg, 3 received 10x106/kg, 1 
received 17x106/kg and 2 received 30x106/kg. Furthermore, for two of the included 
patients (UPN 11 and 12), who were not infused due to T cell impurity in the product 
(UPN 11) or relapse before the start of cy/flu conditioning (UPN 12), the achievable 
HSPC-NK cell dose was 23 and 30x106/kg, respectively. The highest HSPC-NK cell 
dose that was given in this study was 30x106/kg. This is 7.5-fold higher than the 
medium infused dose of 4x106/kg CD3-depleted/CD56-enriched PB-NK cells22 and 
514292-L-bw-Roeven
Processed on: 6-10-2017 PDF page: 91
91
NK cell therapy in older AML patients
4
in the same range of the highest PB-NK cell doses (mean 26 ± 15x106/kg) using the 
CD3/CD19 depletion method.24 However, HSPC-NK cell products hardly contain 
allogeneic T cell impurity avoiding the chance of inducing GVHD. The future 
perspective of exploiting HSPC-NK cell therapy is at least the infusion of 30x106 
HSPC-NK cells/kg, which could be increased by further optimizing the culture 
protocol.
 Notably, donor NK cell chimerism could be detected in all patients, but NK cell 
numbers did not exceed an absolute level of 100 cells/mL in PB. Miller et al.20 showed 
that an in vivo NK cell persistence and expansion of >100 cells/mL at day 7 to 14 after 
infusion and IL-2 boosting is correlated with achievement of CR in relapsed/refractory 
AML patients. This indicates that this surrogate endpoint could be used to evaluate 
clinical efficacy of NK cell therapy products. Since we did not reach this surrogate 
endpoint in the current study, further improvement of our therapy is needed, such 
as boosting in vivo expansion using cytokines. As mentioned earlier, IL-2 has been 
used in most reported studies to stimulate NK cell expansion in vivo.19-22,24 However, 
since IL-15 is crucial for NK cell survival, proliferation and effector function,34,35 and in 
contrast to IL-2 does not promote Treg expansion,36,37 it is a very attractive cytokine 
to boost NK cell expansion. Clinical grade IL-15 is available, though its efficacy might 
be limited by its short half life and poor bioavailability in lymphoid organs.38 Hence, 
IL-15 superagonist complexes with enhanced biological activity have been 
developed.39 A promising IL-15 superagonist is ALT-803, which includes an activating 
mutation in IL-15, a IL-15Ra sushi domain to increase trans-presentation, and an IgG1 
Fc domain to increase in vivo half-life and stability.38 A phase I trial, investigating 
ALT-803 in patients with relapsed hematological malignancy after allo-SCT revealed 
no dose limiting toxicity.40 In addition, a dose dependent increase in NK cell 
proliferation was observed. For these reasons, the combination with ALT-803 is a 
promising strategy to boost HSPC-NK cell expansion in future clinical studies.
 Next to boosting in vivo expansion, the killing potential of HSPC-NK cell products 
could be further improved in order to maximize clinical efficacy. Recently, we 
published an improved HSPC-NK cell generation protocol.29 In this protocol, IL-2 is 
replaced by IL-12 during ex vivo NK cell generation. Addition of IL-12 to the culture 
protocol resulted in superior IFNg production and cytolytic activity of HSPC-NK cells 
towards AML cells in vitro. Importantly, these NK cells demonstrated improved 
anti-leukemic responses in mice bearing human AML cells.29 Furthermore, we 
showed both in mice,28,29 and now also in patients that HSPC-NK cells rapidly gain 
CD16 expression in vivo. This facilitates the combination with monoclonal antibodies 
directed against antigens expressed on leukemic blasts such as CD33, CD123 and 
CLEC12A to exploit antibody-dependent cellular cytotoxicity as well as with TriKEs 
composed of single-chain scFv against CD16 and CD33 in combination with a 
modified IL-15 cross-linker.41 Another way to make HSPC-NK cells more antigen 
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specific is the redirection toward target antigens expressed by leukemic blasts by 
chimeric antigen receptors (CARs).42 This is particular interesting for HSPC-NK cells 
since transduction efficacy of expanding CD34+ cells is much more effective 
compared to viral transduction of PB-derived NK cells. Consequently, HSPC-NK cell 
products with improved anti-tumor potential have great promise for immunotherapy 
in AML and other cancers.
 Altogether, we found that ACT using HSPC-NK cell products in older AML 
patients following lymphodepleting chemotherapy is tolerable with limited toxicity. 
In addition, we demonstrate that HSPC-NK cells transiently persist, home to the BM, 
and undergo in vivo maturation into anti-leukemic effector cells. Interestingly, we 
found a reduction in MRD in some poor risk AML patients with morphologic CR. This 
HSPC-NK cell-based immunotherapy could be an adjuvant therapy to decrease or 
eradicate MRD in AML patients following intensive chemotherapy or treatment with 
hypomethylating agents, and serve as a consolidating therapy or even as therapeutic 
bridge towards NMA allo-SCT. Furthermore, HSPC-NK cell based therapy hold great 
promise to induce CR in relapsed/refractory AML patients. 
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Supplementary information
Supplementary materials and methods
GMP-compliant manufacturing of the HSPC-NK cell products
In all UCB units, the red blood cell count had been reduced before storage using 
standard EloHAES® separation, and the mononuclear cells had been washed, 
cryopreserved and stored in liquid nitrogen.1 On day -42 before infusion, the 
selected UCB unit was thawed at 37°C and resuspended in thawing buffer consisting 
of CliniMACS PBS/EDTA buffer (Miltenyi Biotech, Bergisch Gladbach, Germany), 
5% human serum (HS; Sanquin blood bank, Amsterdam, the Netherlands), 3.5 mM 
MgCl2 (Pharmacy Department, RUNMC, Nijmegen, The Netherlands) and 100 U/ml 
Pulmozyme (Roche, Almere, The Netherlands) as described previously.2 After 
thawing, CD34+ HSPCs were enriched using the CliniMACS Cell Selection Device 
(Miltenyi) and directly used for NK cell generation according to the culture method 
described previously.2 Briefly, the cells were cultured in the Radboudumc clean 
room facility under GMP conditions in VueLifeTM culture bags (Cellgenix, Freiburg, 
Germany) in Glycostem Basal Growth Medium (GBGM®; Glycostem Therapeutics, 
‘s-Hertogenbosch, The Netherlands) supplemented with 10% HS (Sanquin 
Bloodbank, Nijmegen, the Netherlands), a low-dose cytokine cocktail consisting of 
GM-CSF (Neupogen; Amgen, Breda, the Netherlands), G-SCF and IL-6 (both 
Cellgenix). At day 0-9, the medium was additionally supplemented with a high-dose 
cytokine cocktail containing SCF, Flt3L, TPO and IL-7 (all CellGenix), and between day 
10 and 14 TPO was replaced by IL-15. After 14 days cells were differentiated by 
replacing Flt3L by IL-2 (Proleukin®; Chiron, München, Germany). During the first 
14 days of culture, low molecular weight heparin (LMWH; Clivarin®; Abott, Wiesbaden, 
Germany) was added to the media. Around day 14 cells were transferred to the 
WAVE BioreactorTM System 2/10 (GE Health, Uppsala, Sweden). The conditions of the 
bioreactor were as follows: temperature 37°C, CO2 5%, airflow 0.1-0.2 L/min, rocking 
rate 10/min, rocking angle of 6°. After 42 days, NK cell products were harvested and 
washed. A sample of the final product was used for lot release testing. Before lot 
release, the product was required to have > 70% CD56+CD3- cells, > 70% viability 
(7AAD-) of CD56+CD3- cells, > 30% positivity for NKG2A, NKp30, NKp44, NKp46 and 
NKG2D+ on CD56+CD3- cells, < 1x104 CD3+ T cells/kg,  < 3x105 CD19+ B cells/kg and 
negative in-process bacterial and fungal cultures. Sterility testing was performed 
on the final products and reported 14 days after conditional release by the QP. 
All manufactured HSPC-NK products were negative for bacterial and fungal 
contamination.
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Chimerism assay
PB and BM chimerism was determined by real-time quantitative PCR using single 
nucleotide polymorphisms (SNPs) and/or the SMCY gene as described previously.3 
Briefly, UCB units and AML patients were screened for discriminating SNPs. 
Quantification was based on real-time PCR with allele-specific primers for DNA 
sequences containing the discriminating SNP and target DNA-specific probes. 
Quantitative analysis was performed by generating calibration functions from cycle 
thresholds (Ct) obtained by real-time PCR of DNA serially diluted in water. The 
detection limit of the used assays were 0.1%. Donor chimerism was expressed as the 
percentage of donor cells within total PB or BM cells. 
Immunophenotyping
The cell count, purity, and viability of the HSPC-NK cell product was determined 
using a single-platform FCM assay with the following antibodies CD45-ECD (J33), 
CD3-FITC (SK7), CD19-FITC (J3-119), CD34-PE (581) (all Beckman Coulter, Woerden, the 
Netherlands), CD56-PE (NCAM16.2), CD3 (SK7) (both BD Biosciences, San Jose, CA, 
USA), 7AAD (Sigma, St Louis, MO, USA) and counting beads (Beckman Coulter). 
Ten-color analysis was used to determine the phenotype of HSPC-NK cell products 
as well as PB/BM samples from patients before and after treatment. The following 
monoclonal antibodies were used in the appropriate concentration: CD16-FITC 
(NP15, BD-bioscience, Franklin Lakes, NJ, USA), CD336-PE (Z231), CD3-ECD (UCHT-1), 
CD337-PEcy5 (Z25), CD355-PEcy7 (BAB281), CD314-APC (ON72), CD244-APC700 (C1.7), 
CD56-APC750 (N901), CD159a-PB (Z199), CD45-KO (J.33), CD85j-PEcy5.5 (HP-F1), 
CD158b-PEcy7 (GL183), CD158e-APC (Z27.3.7), CD158a-APC700 (EB6B), CD45RA-FITC 
(ALB11), HLA-DR-PE (Immu-357), CD45RO-ECD (UCHL1), CD5-PEcy5.5 (BL1a), 
CD27-PEcy7 (1A4CD27), CD56-APC (N901), CD8-APC700 (B9.11), CD3-APC750 (UCHT-1), 
CD4-PB (13B8.2) (all Beckman Coulter) and CD159c-PE (134591, R&D systems, 
Minneapolis, MN, USA). Treg numbers were determined using anti-human FoxP3 
Staining Kit (BD Biosciences) according to the manufacturer’s instructions. The 
acquisition was perfomed on the NaviosTM flow cytometer and the data were further 
analyzed using KaluzaTM software (both from Beckman Coulter).
Serum cytokine concentrations 
IL-15 concentrations were determined on frozen plasma by ELISA (R&D systems, 
Abingdon, Oxon, UK) as described previously.2
Flow cytometry based cytotoxicity and degranulation assay
Functional analysis of HSPC-NK cell products was assessed retrospectively using 
cryopreserved cells which were thawed and cultured for six days before use in basal 
medium supplemented with 10% HS, 1000 U/ml IL-2, and 20 ng/ml IL-15. Flow 
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cytometry based cytotoxicity assays were performed as previously described.4 
Briefly, CFSE-labeled target cells were resuspended in IMDM/10% FCS to a final 
concentration of 1-3 x 105/ml. HSPC-NK cells were washed with PBS and resuspended 
in IMDM/2% HS to a final concentration of 1-10 x 105/ml. Target cells were co-cultured 
at different E:T ratios in 96-well flat-bottomed plates. NK and target cells alone were 
plated as controls. After 24 or 48 hr incubation at 37oC, cells were harvested and the 
number of viable target cells was quantified by flow cytometry. Target cell survival 
was calculated as follows: % survival = (absolute number of viable CFSE+ target cells 
co-cultured with NK cells / absolute number of viable CFSE+ target cells cultured in 
medium)*100. The percentage of specific killing was 100 minus % survival. 
Co-cultures of NK with primary AML cells were supplemented with IL-3 (50 ng/mL; 
Cellgenix), SCF (20 ng/mL; Immunotools), Flt3L (20 ng/mL; Cellgenix), G-CSF (20 ng/
mL; Amgen), and IL-15 (5 ng/mL). Killing of K562 cells was measured following 
overnight incubation with HSPC-NK cells using increasing E:T ratios. In addition, 
killing of primary AML blasts was analyzed for three HSPC-NK product/patient pairs 
for which BM cells collected and cryopreserved at diagnosis were available. 
Degranulation of HSPC-NK cells during co-culture was measured by cell surface 
expression of CD107a. After 18 hrs of incubation at 37oC, the percentage of CD107a+ 
cells was determined by FCM.
MRD analysis
FCM-based detection of MRD was performed using consensus leukemia-associated 
(immune)phenotypes (LAPs) as described previously.5 LAPs were established in 
newly diagnosed AML in a two-step approach. In the first step, FCM panels were 
used to define the immunophenotype of the blasts in whole BM or PB at diagnosis. 
In this so-called first run, aberrant expression patterns of individual antigens were 
defined, and from these runs relevant antigens for the putative LAPs for MRD 
assessment (one LAP per tube) were defined and tested in a second run. Sensitive 
LAPs were used for MRD detection.
 AML patients were standard analyzed for NPM1, FLT3-ITD and CEPBA mutations. 
In addition, AML patients without these molecular aberrations were screened 
with the Ion AmpliSeq™ AML panel and subsequent sequencing on the Ion Torrent 
PGM (ThermoFisher Scientific, Waltham, MA, USA), according to manufacturer’s 
instruction. This panel utilizes 237 amplicons to analyze 19 genes implicated in AML 
(entire coding regions: CEPBA, DNMT3A, GATA2, TET2, TP53; hotspot regions: ASXL1, 
BRAF, CBL, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, NPM1, NRAS, PTPN11, RUNX1, WT1). Molecular 
MRD quantification was performed by real-time PCR with allele-specific primers for 
DNA sequences containing the patient-specific mutation and target DNA-specific 
probes. Quantitative analysis is performed by generating calibration functions from 
cycle thresholds (Ct) obtained by real-time PCR of DNA from the AML patient at 
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diagnosis serially diluted in DNA from healthy donor BM DNA. The detection limit of 
the assays was 0.1%. Molecular MRD was expressed as the percentage of mutated 
cells within total PB or BM cells.
Statistical analysis
Results are presented as median values, ranges and/or mean ± SD. To compare 
expression of activation receptors before and after infusion the one-way analysis of 
variance with Bonferroni post-hoc test was used. A P-value of <0.05 was considered 
statistically significant.
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Supplementary Table 1  Characteristics of HSPC-NK cell products
UPN Cryopreserved UCB After thawing After CD34 selection HSPC-NK products after expansion and preparation
Total  
NC
(x106)
Total 
CD34+
( x106)
Total  
NC
( x106)
Total  
CD34+
( x106)
CD34+ 
Recovery  
(%)
Total  
CD34+
( x106)
Purity
CD34+
(%)
Total  
NC
(x106)
Purity
CD56+CD3-
(%)
Viability
CD56+CD3-
(%)
Infused
CD56+CD3-
( x106)
CD56+CD3-
per kg
( x106/kg)
CD3+
per kg
(x105/kg)
CD19+
per kg
( x105/kg )
1 2122 4.14 1137 2.78 67 2.68 81 2012 75 93 220 3 0.01 0.00
2 1415 2.90 690 2.07 71 1.76 85 563 81 99 324 3 0.00 0.00
3 545 2.02 313 1.47 73 1.21 71 3343 71 99 189 3 0.00 0.00
4 1133 5.55 633 3.04 55 3.47 82 3173 58 99 650 10 0.00 0.05
5 1221 5.55 561 3.14 57 2.58 86 4984 74 94 530 10 0.00 0.48
6 1106 3.37 511 1.64 49 1.57 52 2069 74 97 770 10 0.03 0.62
7 545 6.22 566 6.33 102 4.30 83 2156 79 93 1693 30 0.00 0.80
8 460 4.19 350 3.11 74 1.95 65 1820 65 96 1191 17 0.00 0.47
9 2147 15.90 1305 9.27 58 8.13 77 1198 40 88 510 6 0.05 1.10
10 1020 10.04 659 8.56 85 7.41 82 5842 79 91 2190 30 0.07 0.10
11 680 3.40 429 1.93 57 1.15 46 2525 85 94 Not infused due to 
exceeding the CD3+ T cell 
impurity criteria;  
achieved manufacturing 
dose 23x106/kg 
0.43 0.02
12 3070 11.05 1984 6.35 57 6.58 82 3832 77 94 Not infused due to relapse
prior Cy/Flu conditioning; 
achieved manufacturing 
dose 30x106/kg
0.00 0.20
Median 1120 4.87 600 3.08 63 2.63 82 2341 75 94 NA NA 0.00 0.15
Mean ± SD 1289
±793
6.19
±4.11
 762 ± 485 4.14 ± 2.75 67 ± 15 3.57
±2.49
74 ± 13  2793
± 1528
75
±12
95
±3
NA NA 0.05
±0.12
0.32
±0.37
Abbreviations: HSPC-NK, hematopoeitic stem and progenitor cell derived natural killer cell; NC, nucleated 
cells; NA, not applicable; SD, standard deviation; UBC, umbilical cord blood.
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Supplementary Table 1  Characteristics of HSPC-NK cell products
UPN Cryopreserved UCB After thawing After CD34 selection HSPC-NK products after expansion and preparation
Total  
NC
(x106)
Total 
CD34+
( x106)
Total  
NC
( x106)
Total  
CD34+
( x106)
CD34+ 
Recovery  
(%)
Total  
CD34+
( x106)
Purity
CD34+
(%)
Total  
NC
(x106)
Purity
CD56+CD3-
(%)
Viability
CD56+CD3-
(%)
Infused
CD56+CD3-
( x106)
CD56+CD3-
per kg
( x106/kg)
CD3+
per kg
(x105/kg)
CD19+
per kg
( x105/kg )
1 2122 4.14 1137 2.78 67 2.68 81 2012 75 93 220 3 0.01 0.00
2 1415 2.90 690 2.07 71 1.76 85 563 81 99 324 3 0.00 0.00
3 545 2.02 313 1.47 73 1.21 71 3343 71 99 189 3 0.00 0.00
4 1133 5.55 633 3.04 55 3.47 82 3173 58 99 650 10 0.00 0.05
5 1221 5.55 561 3.14 57 2.58 86 4984 74 94 530 10 0.00 0.48
6 1106 3.37 511 1.64 49 1.57 52 2069 74 97 770 10 0.03 0.62
7 545 6.22 566 6.33 102 4.30 83 2156 79 93 1693 30 0.00 0.80
8 460 4.19 350 3.11 74 1.95 65 1820 65 96 1191 17 0.00 0.47
9 2147 15.90 1305 9.27 58 8.13 77 1198 40 88 510 6 0.05 1.10
10 1020 10.04 659 8.56 85 7.41 82 5842 79 91 2190 30 0.07 0.10
11 680 3.40 429 1.93 57 1.15 46 2525 85 94 Not infused due to 
exceeding the CD3+ T cell 
impurity criteria;  
achieved manufacturing 
dose 23x106/kg 
0.43 0.02
12 3070 11.05 1984 6.35 57 6.58 82 3832 77 94 Not infused due to relapse
prior Cy/Flu conditioning; 
achieved manufacturing 
dose 30x106/kg
0.00 0.20
Median 1120 4.87 600 3.08 63 2.63 82 2341 75 94 NA NA 0.00 0.15
Mean ± SD 1289
±793
6.19
±4.11
 762 ± 485 4.14 ± 2.75 67 ± 15 3.57
±2.49
74 ± 13  2793
± 1528
75
±12
95
±3
NA NA 0.05
±0.12
0.32
±0.37
Abbreviations: HSPC-NK, hematopoeitic stem and progenitor cell derived natural killer cell; NC, nucleated 
cells; NA, not applicable; SD, standard deviation; UBC, umbilical cord blood.
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Supplementary Table 2  Functional activity of HSPC-NK cell products
UPN % Killing E:T ratio 3:1 % CD107a+ NK cells % IFN-γ+ NK cells
1 72% 23 0.3
2 69% 28 1.0
3 82% 30 2.5
4 84% 24 0.6
5 84% 41 6.4
6 94% 29 1.5
7 81% 25 2.3
8 ND ND ND
9 ND ND ND
10 87% 24 2.9
11 84% 27 4.0
12 N/A 29 7.0
Median 84 % 28 % 2.4 %
Mean ± SD 82 ± 7 28± 5 2.9  ± 2.3
Functional activity of HSPC-NK cell products, which had been cryopreserved at the day of infusion, was 
analyzed after thawing and re-culture. For this, cells were thawed and cultured for six days in basal 
medium supplemented with 10% HS, 1000 U/ml IL-2 and 20 ng/ml IL-15. At day 6, NK cells were washed 
and specific killing of K562 cells by HSPC-NK cells was analysed after overnight co-culture in a FCM-based 
killing assay. The percentages of degranulating (CD107a+) and IFN-γ-producing HSPC-NK cells were 
determined following 4 hr stimulation with K562 cells at the single cell level by FCM. ND, not determined.
Supplementary table 3  Adverse events associated with Cy/Flu regimen
Event Number of treated patients (N=10)
Grade 3 Grade 4
Neutropenia 10 (100%)
Trombocytopenia 10 (100%)
Anemia 9 (90%)
Febrile neutropenia 6 (60%)
Hypokalemia 3 (30%)
Urticaria (before infusion of HSPC-NK cells) 1 (10%)
Flank pain (before infusion of HSPC-NK cells) 1 (10%)
Syncope 1 (10%)
ALAT increased (149 days after infusion) 1 (10%)
Abbreviations: Cy, cyclophosphamide; Flu, fludarabine; HSPC, hematopoietic stem and progenitor cell; 
NK, natural killer; ALAT, alanine aminotransferase.
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Figure S1   Functional activity of HSPC-NK cell products
Functional activity of HSPC-NK cell products, which had been cryopreserved at the day of 
infusion, was analyzed. Cells were thawed and cultured for six days in basal medium 
supplemented with 10% HS, 1000 U/ml IL-2 and 20 ng/ml IL-15. Cells were incubated with 
K562 cells. Specific killing of K562 cells by HSPC-NK cells after overnight co-culture was 
analysed in a FCM-based killing assay.
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Figure S2   Cy/Flu conditioning induces temporary lymphocytopenia
(A) Lymphocyte numbers were measured in PB at different time points between day -7 and 
day 90. (B-D) The absolute NK cell (B), CD4+ T cell (C) and CD8+ T cell (D) count was determined 
by measuring the percentage within the lymphocyte population by FCM. (E-F) The 
percentage of CD4+ (E) and CD8+ (F) T cells within the lymphocyte population was 
determined by FCM. Mean ± SD of 10 patients. < depicts the threshold of detection of 
lymphocyte count.
A
B
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Figure S2   Continued
C
D
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Figure S2   Continued
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Figure S3   HSPC-NK cells mature in vivo
After NK cell infusion, the phenotype of CD3-CD56verybright NK cells, a phenotype which 
corresponds to our HSPC-NK cell product, was determined by FCM at different time points in 
UPN 5, 7 and 8. (A) The percentage of CD16+ cells within the CD56verybright population at 
different time points in patient 5, 7 and 8. (B) KIR (CD158a, b and e) expression within the 
CD3-CD56verybright cell population at day 2 and 8 after infusion in UPN5 and UPN8.
CD16
17% 29% 40%
23% 37% 56%
10%
27% 32% 50% 58%
Day 0+4h Day 2 Day 6 Day 8
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Abstract
 
Combining NK cell adoptive transfer with hypomethylating agents (HMA) is an 
attractive therapeutic approach for patients with acute myeloid leukemia (AML). 
However, data regarding the impact of HMA on NK cell functionality are mostly 
derived from in vitro studies with high non-clinical relevant drug concentrations. 
Here, we report a comparative study of azacitidine and decitabine in combination 
with allogeneic NK cells generated from CD34+ hematopoietic stem and progenitor 
cells (HSPC-NK cells) in in vitro and in vivo AML models. In vitro, low-dose HMA did not 
impair HSPC-NK cell viability. Furthermore, low-dose decitabine preserved HSPC-NK 
killing, proliferation and IFN-γ production capacity, while azacitidine diminished 
their proliferation and reactivity. Importantly, we showed that HMA and HSPC-NK 
cells can synergize to target AML cell lines and patient AML blasts. In vivo, both 
agents exerted a significant delay in AML progression in NOD/SCID/IL2Rgnull mice, 
while the persistence of adoptively transferred HSPC-NK cells was not affected. 
Infused NK cells showed sustained expression of most activating receptors, 
up-regulated NKp44 expression and remarkable KIR acquisition. Most importantly, 
only decitabine potentiated HSPC-NK cell anti-leukemic activity in vivo. Interestingly, 
besides up-regulation of NKG2D and DNAM-1 activating ligands on AML cells, 
decitabine enhanced mRNA expression of inflammatory cytokines, perforin, and 
TRAIL by HSPC-NK cells. In addition, treatment resulted in increased numbers of 
HSPC-NK cells in the bone marrow compartment, suggesting that decitabine could 
positively modulate NK cell activity, trafficking and tumor targeting. These data 
provide a rationale to explore combination therapy of adoptive HSPC-NK cells and 
decitabine in AML patients.
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Introduction
 
Harnessing natural killer (NK) cells against cancer is an emerging therapeutic 
approach, increasingly being explored for both hematological malignancies and 
solid tumors. Next to activation of patient’s own NK cells by means of cytokine 
administration or redirection through treatment with tumor-targeting antibodies, 
current research also invests in ex vivo NK cell generation and expansion methods 
for adoptive cell therapy. Previously, we reported on GMP compliant, cytokine-based 
culture systems for the generation of NK cell products from CD34+ hematopoietic 
stem and progenitor cells (HSPC-NK cells).1-3 Using this platform, we conducted a 
first-in-human phase I study in older patients with acute myeloid leukemia (AML) 
who were ineligible for allogeneic stem cell transplantation.4  In this study, escalating 
dosages of ex vivo-generated HSPC-NK cells were infused following lymphodepleting 
chemotherapy. Importantly, we demonstrated that infusion of up to 30 million 
allogeneic HSPC-NK cells per kg body weight was feasible, well-tolerated and safe, 
without inducing graft-versus-host disease nor non-hematological toxicities. 
Although this study included older AML patients in morphological complete 
remission, two patients showed persistent minimal residual disease (MRD) before 
treatment. Interestingly, MRD decreased below the detection level by day 90 after 
HSPC-NK cell infusion, emphasizing a possible therapeutic activity of adoptively 
transferred HSPC-NK cells. Likewise, promising anti-tumor responses have been 
reported worldwide from cancer patients undergoing NK cell adoptive immuno- 
therapy.5-10 However, responses are mostly transient and concern a minority of the 
patients. Therefore, efforts have to be made to further maximize tumor targeting 
efficacy and NK cell responsiveness in vivo, likely through combinatorial treatment 
strategies.11 In the context of AML, an attractive approach resides in the combination 
of HSPC-NK cells with generally well-tolerated hypomethylating agents (HMA).12 
 Azacitidine (Vidaza®, AZA) and decitabine (Dacogen®, DAC) are two HMA 
currently used for the treatment of AML and myelodysplastic syndromes (MDS).13 
These HMA are cytidine nucleoside analogs that incorporate into the DNA during 
cell replication and division. While at higher dosages these agents exert direct 
toxicities towards myeloid cancer cells through DNA damage, at lower dosages, they 
can modulate gene expression due to hypomethylating activity. Particularly, their 
potential in upregulating NK-activating molecules, like NKG2D ligands, on tumor 
cells through their epigenetic modulation, and thereby sensitizing tumors to NK 
cell-mediated killing has been reported in several studies and for different cancers, 
including AML.14-17  Nonetheless, direct impact of HMA on NK cell functionalities has 
not been well established yet. Conflicting data has been reported, describing either 
advantageous or deleterious effect on NK cells.15, 18-22 Moreover, these data are 
mostly derived from in vitro studies, often performed at high drug concentrations 
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that do not reflect plasma levels achieved in patients. Therefore, it remains unclear 
whether application of HMA therapy can augment NK cell-mediated anti-tumor 
responses in AML patients.
 In this report, we address the possibility to combine HSPC-NK cell therapy with 
HMA. Through in vitro and in vivo studies, we performed head-to-head comparison 
of AZA and DAC to evaluate their impact on HSPC-NK viability and functionalities, 
as well as their capacity to potentiate HSPC-NK cell reactivity towards AML. Most 
importantly, we demonstrate that DAC, but not AZA, positively modulates the 
in vivo anti-leukemic potential of adoptively transferred HSPC-NK cells through AML 
cell sensitization, enhancement of NK cell maturation and cytolytic functions, as well 
as improves on NK cell trafficking and accumulation at the tumor site. Furthermore, 
our study reveals that HSPC-NK cells and DAC can potently cooperate to eradicate 
AML, providing a strong rationale to explore this combination strategy in AML 
treatment. 
Methods 
HSPC-NK cell generation
NK cell products were generated from CD34+ HSPCs derived from umbilical cord 
blood obtained after normal full-term delivery and written informed consent (CMO 
2014/226). The culture protocol was adapted from Cany et al.2 and Roeven et al.23 
and combined the use of the aryl hydrocarbon receptor antagonist StemRegenin-1 
for the expansion of CD34+ HSPCs, together with IL-15 and IL-12 for the differentiation 
of NK cells. Briefly, MACS-isolated CD34+ cells (Miltenyi Biotec) were expanded for 
9-10 days in the presence of SCF, IL-7, Flt3L, and TPO (all 25 ng/ml, Immunotools). 
Thereafter, TPO was replaced by IL-15 (50 ng/ml, Immunotools) for 5 days. From day 
14-15 onwards, cell differentiation and expansion was performed in the presence of 
SCF (20 ng/ml), IL-7 (20 ng/ml), IL-15 (50 ng/ml) and IL-12 (0.2 ng/ml, Miltenyi Biotech). 
Medium was supplemented with 2 µM StemRegenin-1 (Cellagen Technology) from 
day 0 to day 21. All media were prepared with basal CellGro DC medium (Cellgenix) 
and supplemented with 10% or 2% pooled human serum (Sanquin Blood Bank 
Nijmegen) during the expansion and differentiation phase, respectively. The cell 
density and CD56 acquisition was checked twice a week by flow cytometry (details 
described in supplemental information) and adjusted to 1.5 - 2.5 x106 cells/ml by 
addition of new medium. HSPC-NK cells were used at the end of the culture process 
with >80% CD56+ cell purity, which was typically achieved within 5-6 weeks of culture.
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Hypomethylating agents
5-Azacytidine (AZA) and 5-Aza-2’-deoxycytidine (DAC) were purchased from Sigma 
Aldrich. For in vitro studies, both drugs were dissolved in NaCl 0.9% to 0.1-1 mM, 
aliquoted for single use, and stored at -20ºC. Drugs were used immediately after 
thawing and treatment of the cell cultures were performed with limited light 
exposure. In vitro, HMA were used at concentrations similar to those achieved in 
plasma of HMA-treated patients24, 25, with daily refreshments due to short half-life of 
these agents.26 For in vivo studies, 2-4 mg HMA was kept on ice protected from light, 
and dissolved using NaCl 0.9% just before mice injection. Treatments were also 
applied daily in line with current clinical practice.
In vivo studies
All animal experiments were conducted in immune-deficient NOD-scid IL2Rgnull 
(NSG) mice originally purchased from Jackson Laboratories. Mice were housed and 
bred in the Radboudumc Central Animal Laboratory and were used in experiments 
at 6 to 12 weeks of age (20-30 g body weight). Studies were approved by the Animal 
Experimental Committee of the Radboudumc and conducted in accordance with 
institutional and national guidelines under the University permit number 10300. 
The preclinical xenograft model for AML was established by intra-femoral injection 
of the THP-1 cells, engineered to express the GFP and luciferase reporter genes 
(THP-1.LucGFP cells) for longitudinal tumor load monitoring by bioluminescence 
imaging, as previously described.2 In adoptive transfer studies, HSPC-NK cells were 
resuspended in PBS and injected intravenously via the tail vein. Survival of HSPC-NK 
cells in vivo was supported by subcutaneous administration of recombinant human 
IL-15 (1 µg per mouse; Immunotools), every 2-3 days following HSPC-NK cell infusion. 
Alternatively (for data shown in Figure 5), ALT-803, kindly provided by Dr. Hing Wong 
and Dr. Sarah Alter from Altor BioScience Corporation (FL, USA), was administered 
subcutaneously at 0.2 mg/kg every 3-4 days. The experimental designs employed 
for the treatment of mice with HMA were based on current clinical practice (dosage, 
duration, and route of administration). The dosages applied in humans (mg/m2) 
were translated for mouse studies (mg/kg) based on Reagan-Shaw et al.27 (see 
Supplementary Figure S4 for calculation). During treatment with HMA, mice were 
given wet food to improve feeding and tolerability of the drugs. Mice were carefully 
monitored for weight and general conditions, and sacrificed according well defined 
end-points. Ex vivo FCM analysis and gene expression profiling (details described in 
supplemental information) were performed on cells isolated from spleen, bone 
marrow or liver using erythrocyte lysis solution or lympholyte-M (Cedarlane).
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Statistical analysis
Statistical analyses were performed using Graphpad Prism 5 software. Student 
t-tests, one- and two-way analysis of variance (ANOVA) were used when appropriate, 
as indicated in the figure legends. Differences were considered to be significant for 
p values <0.05.
Results
HMA augment HSPC-NK efficacy against AML in vitro
To investigate the possibility to combine HSPC-NK cells with HMA therapy, we first 
tested the effect of AZA and DAC alone on two AML cell lines. THP-1 and KG1a cells 
were treated daily with HMA using concentrations similar to those in plasma of 
treated patients24, 25. As expected, the number of viable AML cells decreased in a 
time- and dose-dependent manner compared to untreated cells (Supplementary 
Figure S1). AZA at 0.1-1 µM and DAC at 0.01-0.1 µM had moderate impact on AML cell 
viability and proliferation and, therefore, these concentrations were selected for 
subsequent studies.
 Next, we determined whether pre-treatment of AML cells with HMA influenced 
their susceptibility to HSPC-NK cell-mediated killing. Therefore, THP-1 and KG1a cells 
were cultured in the presence or absence of HMA for 2 days, and then used as 
targets for HSPC-NK cells with or without washout of the drugs (Figure 1A). At start 
of the co-culture, equal numbers of viable AML cells were plated in each experimental 
condition. Interestingly, absolute AML cell count analysis showed that the effect of 
HMA and HSPC-NK cells was additive for the higher HMA concentrations, but 
synergized NK-mediated killing at low concentrations (Figure 1A-F). Following 
co-culture with HSPC-NK cells, the survival of THP-1 cells decreased from 60% 
without HMA pre-treatment to 30 - 40% for pre-treated cells (Figure 1B, p<0.001 for 
all HMA groups vs. no HMA pre-treatment). Because AML cell counts were only 
slightly diminished with the HMA in the absence of NK cells (Figure 1B), these data 
translated into a significant increase in NK-specific killing for each treatment 
condition analyzed independently (Figure 1C). Notably, the effect of HSPC-NK cells, 
defined using the absolute number of AML cells actually killed by NK cells, was 
significantly increased when THP-1 cells were pre-treated with the lower concentrations 
of HMA (Figure 1D). These data support the hypothesis that HMA can sensitize AML 
cells to HSPC-NK cell-mediated killing. The combination treatment of HMA and 
HSPC-NK cells was also studied over time for KG1a cells, without drug wash-out 
(Figure 1E-F).  Interestingly, HMA synergized with HSPC-NK cells in killing KG1a cells 
and resulted in potent reduction of AML cell numbers when combined together.
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Figure 1   HMA can sensitize AML cells to NK cell-mediated killing
(A) Experimental design: THP-1 and KG1a cells were cultured in the presence of AZA or DAC 
at the indicated concentrations. Two days later, cells were harvested and used as targets for 
HSPC-NK cells with or without drug wash-out. The same numbers of viable AML cells were 
plated for each condition. The numbers of viable AML cells were determined by FCM after 
1 to 3 days of co-culture, and were used for calculation of AML cell survival, NK specific killing 
for each independent treatment, and overall effect of NK cells, as indicated. (B-D) Effect of 
HMA pre-treatment and HSPC-NK cells on THP-1 cells at day+1. Data were obtained after 
drug wash-out, and depicted as the mean ± SEM of 3 independent experiments (one-way 
ANOVA, ** p<0.01). (E-F) Effect of HMA pre-treatment and HSPC-NK cells on KG1a cells. Data 
were obtained without drug wash-out, and depicted as the mean ± SEM of 3 independent 
experiments. Data shown in E were obtained at day+1, and in F are depicted the relative 
numbers of viable AML cells quantified from day 0 to day+3.
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Based on these findings, we next co-cultured HSPC-NK cells and patient-derived 
primary AML cells in the absence or presence of clinically relevant HMA concentrations 
(Figure 2A). We confirmed a robust and dose-dependent effect of HMA on primary 
AML cell viability and proliferation (Supplementary Figure S2), while HSPC-NK cell 
survival is not affected (Figure 2B). Interestingly, combined treatment demonstrated 
sustained killing of primary AML cells by HSPC-NK cells at all drug concentrations 
tested. Importantly, the combination with 1 µM AZA and 0.1 µM DAC showed superior 
AML killing efficacy compared to NK cell treatment alone (Figure 2C). As seen with 
AML cell lines, the HMA can synergize with HSPC-NK cells in killing primary AML cells 
(Figure 2D), and the effect of NK cells increased in the presence of HMA, particularly 
with DAC (as illustrated for pAML#4, Figure 2E). These data demonstrate that HMA 
differentially affect AML and HSPC-NK cells in vitro, and that HSPC-NK cells maintain 
potent anti-leukemic activity during HMA exposure. Most importantly, our findings 
demonstrate that HMA can potentiate HSPC-NK cell killing activity, suggesting that 
the combination of HPSC-NK cells with HMA therapy could result in a double attack 
against AML.
Exposure to low dose HMA concentrations does not impair HSPC-NK 
cell cytolytic activity in vitro
To further study the impact of HMA on NK cell functionalities, HSPC-NK cells were 
cultured either under proliferative (i.e. 20 ng/ml IL-15 plus 1000 IU/ml IL-2) or 
steady-state (i.e. 5 ng/ml IL-15) conditions and treated with HMA for 6 consecutive 
days (Figure 3A). HMA treatment did not affect HSPC-NK cell viability (data not 
shown), however 1 µM AZA significantly decreased NK cell proliferation (Figure 3B). 
DAC had a minor impact, even at the highest concentration tested. Next, we 
Figure 1  Continued
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Figure 2   HSPC-NK cells in combination with HMA potently combat primary  
AML cells in vitro
(A) Experimental design: primary AML cells obtained from 5 different patients at diagnosis 
were stained with CFSE and cultured in the presence of AZA or DAC using the indicated 
concentrations (5x104 AML cells per well).  One day after, HSPC-NK cells (2.5x105 cells per well) 
were added and the drug were refreshed daily. The numbers of viable AML cells were 
determined by FCM at day+3 of coculture. (B) Median HSPC-NK cell survival at day+3 
(combined data obtained with 5 different primary AML samples). The number of NK cells 
quantified without HMA was set at 100%. (C) Median AML cell survival at day+3 (combined 
data obtained with 5 different primary AML samples). The number of AML cells quantified 
without HMA and NK cells is set at 100%. Data depicted in B and C represent combined data 
obtained with 5 different primary AML samples, and were analyzed using one-way ANOVA. 
***p<0.001, **p<0.01, n.s. not significant. (D-E) The survival of AML cells from 2 different 
patients (pAML#4 and pAML#5) and corresponding effect of NK cells quantified at day+3 are 
depicted as the mean ± SEM of data obtained with 4 different HSPC-NK cell donors. Data 
were analyzed using two-way ANOVA. ***p<0.001, *p<0.05, n.s. not significant.
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Figure 3   Low dose HMA does not impair HSPC-NK cell viability, proliferation and 
cytolytic functions
(A) Experimental design: CFSE-labeled HSPC-NK cells were culture under proliferative (high 
dose IL-15 and IL-2) or steady-state (low dose IL-15) conditions in the presence of AZA or DAC 
refreshed daily at the indicated concentrations. Cell proliferation, viability, and absolute 
numbers, as well as functionality and phenotype were analyzed by FCM after 6 days-
treatment. (B) Percentages of proliferating HSPC-NK cells under steady-state (left panel) and 
proliferative (right panel) conditions. Combined data from 3 independent experiments 
(mean ± SEM) are shown. (C) Specific killing of K562 and THP-1 cells by HSPC-NK cells 
pre-treated with HMA. The same numbers of viable NK cells were plated in each experimental 
well after wash-out of the drug, and the killing of K562 and THP-1 cells was determined after 
overnight co-culture using 1:1 E:T ratio. Data obtained with NK cells treated either under 
proliferative or steady-state conditions and performed with 6 different HSPC-NK cell donors 
are combined and depicted as mean ± SEM. (D) NK cell reactivity upon K562 stimulation and 
analyzed at the single cell level by FCM. Representative dot plots of HSPC-NK cells cultured 
under proliferative conditions and treated with AZA1 µM, DAC 0.1 µM, or without HMA are 
shown. NS, not stimulated. (E) Expression level of the maturation markers NKG2A, CD16, and 
KIRs on HSPC-NK cells following culture upon proliferative condition in the presence of DAC 
0.1 µM, or without HMA. Mean ± SD of 6 HSPC-NK cell donors are shown. (F) Representative 
dot plots of HSPC-NK cell IFNγ production capacity with respect to KIR expression following 
DAC 0.1 µM or no HMA treatment under proliferative condition. Statistical analyses were 
performed using one-way (B-C) and two-way (E) ANOVA.
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analyzed the cytolytic activity of HMA-treated HSPC-NK cells against MHC-Ineg K562 
cells and MHC-Ipos THP-1 cells. Target cell killing was only diminished following 
HSPC-NK pre-treatment with the highest dosages of AZA and to a lesser extent with 
DAC (Figure 3C). These observations were confirmed at the single cell level using 
CD107a degranulation and intracellular IFN-γ staining. As depicted in Figure 3D, the 
proportion of CD107a+ HSPC-NK cells upon K562 stimulation was only negatively 
affected with 1 µM AZA, but not with 0.1 µM DAC. The percentages of IFN-γ+ 
HSPC-NK cells remained similar, although slightly increased upon exposure to the 
highest HMA concentrations.
 In addition, we examined the phenotype of HSPC-NK cells cultured in the 
presence of HMA. Overall, HMA did not influence expression levels of activating 
receptors, adhesion molecules, death receptors nor maturation markers (NKG2A and 
CD16) in vitro (Supplementary Figure S3). Only the frequency of KIR+ HSPC-NK cells 
increased, particularly following exposure to HMA under proliferative conditions 
(Figure 3E). We showed previously that NKG2A+KIR+ HSPC-NK cells display higher 
IFN-γ production capacity over NKG2A+KIR- cells.2 Therefore, the increase in KIR 
expression likely explains the elevated proportions of IFN-γ+ HSPC-NK cells upon 
K562 stimulation (Figure 3F). These data confirm that AML and HSPC-NK cells are 
Figure 3   Continued
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differently affected by HMA, and that low drug concentration of HMA preserves 
HSPC-NK cell anti-leukemic activity.
Decitabine, but not azacitidine, potentiates HSPC-NK cell 
anti-leukemic efficacy in vivo
To investigate combinatorial HMA and HSPC-NK cell therapy against AML, we 
conducted in vivo studies using our established intra-femoral THP-1 mouse model.2 
First, we tested the tolerability of HMA-treatment in mice by daily application of 
de-escalating dosages, which were defined based on current practice in patients 
(i.e. 75 and 20 mg/m2 for AZA and DAC, respectively). Here, we identified 12.5 mg/m2 
AZA x 7 injections, and 5 mg/m2 DAC x 5 injections as the highest tolerated dose in 
NSG mice based on body weight loss, and reduced THP-1 cell progression 
(Supplementary Figure S4). To further lower HMA dosages we subsequently tested 
7.5 mg/m2 AZA and 2.0 mg/m2 DAC, which are 10x lower to current dosages applied 
in patients. These dosages were well tolerated and still reduced THP-1 growth (see 
Figure 4A, HMA titration#1). However, AZA given at 7.5 mg/m2 exerted a limited 
anti-leukemic effect, while 2.0 mg/m2 DAC strongly reduced tumor growth. Based 
on these observations, we further refined the treatment schedule to give the highest 
tolerated dose of AZA (12.5 mg/m2) for 7 consecutive days, and lowered the dosage 
of DAC to 1.25 mg/m2 over 5 days (see Figure 4A, HMA titration#2). Finally, these 
dosages resulted in a similar and intermediate effect on THP-1 cells in vivo, and were 
employed to test the efficacy of combination therapy with HSPC-NK cells. 
 To assess the impact of HMA on NK cells in vivo, infusions of HSPC-NK cells plus 
rhIL-15 were applied at the start of HMA treatment (Figure 4B). Of note, treatment 
with HSPC-NK cells only was not included as this is ineffective in this highly stringent 
THP-1 AML mouse model.2 Interestingly, bioluminescence imaging revealed lower 
tumor load in mice treated with HSPC-NK cells in combination with DAC, compared 
to DAC monotherapy (Figure 4C). Although transient, this reduction in tumor 
progression was significant two weeks after treatment (Figure 4D). In contrast, no 
difference was observed in AZA-treated mice. These differential effects could not be 
attributed to defective HSPC-NK cell persistence upon AZA vs. DAC treatment, as 
similar numbers of HSPC-NK cells were detected in peripheral blood and spleen of 
mice subjected to these treatment schedules (Figure 4E, Supplementary Figure S5).
 To validate these findings and further improve anti-leukemic potency, we performed 
a new experiment applying the same approach but with 2-treatment cycles (Figure 5A). 
In addition, we employed ALT-803 instead of rhIL-15 to support NK cell persistence 
in vivo. ALT-803 is an IL-15 super-agonist complex comprised of an IL-15 mutant 
(N72D) bound to sushi domain of IL-15Rα fused to IgG1 Fc. This complex has been 
shown to display higher stability and enhanced biological activity on NK cells 
in vivo as well as superior localization to the lymphoid organs when comparated 
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Figure 4   Decitabine, but not azacitidine, potentiates HSPC-NK cell anti-leukemic 
effect in vivo
(A) Adult NSG mice injected in their femur (IF) with luciferase-expressing THP-1 cells were treated 
with HMA using dosages as indicated in the figure (in mg/m2) and monitored for tumor load 
progression every 3 to 4 days by bioluminescence imaging. Treatment was applied daily 
from day 4 to day 9 in titration#1, and from day 2 to 8, and day 4 to 8 for AZA and DAC 
respectively in titration#2. AZA was injected subcutaneously and DAC intravenously based 
on current clinical practices. Data are depicted as mean ± SD including 8-10 mice per group. 
Dotted lines indicate upper detection limit for tumor load monitoring (signal saturation). 
(B-D) THP-1 bearing mice were treated with HMA using the same dosages as described in 
titration#2, and with a single infusion of HSPC-NK cells, applied at day 4. Survival of NK cells 
in vivo was supported by recombinant human IL-15, given subcutaneously every 2 to 3 days. 
(B) Experimental design. (C) Median tumor load at day 17. (D) Fold increase in tumor load 
after 2 weeks treatment with DAC alone or in combination with HSPC-NK cells (calculated as 
the ratio between day 17 and day 3 signals). (E) Absolute numbers of circulating NK cells in 
mice without treatment vs. following treatment with AZA (12.5 mg/m2) or DAC (1.25 mg/m2). 
Data were analyzed using unpaired, two-tailed t test in D, and one-way ANOVA in E.
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to rhIL-15.28, 29 The effects of ALT-803 on HSPC-NK cells was validated in vitro 
(Supplementary Figure S6). In this experimental model, treatment with two DAC 
cycles not only inhibit engraftment of THP-1 cells, but further slowed down AML 
progression (Figure 5B). Notably, we showed that 2 cycles of combined DAC, 
HSPC-NK cells and ALT-803 treatment resulted in significantly reduced THP-1 
progression for up to 4 weeks compared to DAC-treatment only (Figure 5C). These 
data demonstrate that DAC does not impair HSPC-NK cell targeting in vivo, and that 
this combination strategy can boost the reactivity of adoptively transferred HSPC-NK 
cells against AML.
Decitabine enhances HSPC-NK cell cytolytic functions and trafficking 
to the bone marrow in vivo
To understand how DAC potentiates NK cell reactivity against AML occurs in vivo, we 
further analyzed the phenotype of THP-1 cells and HSPC-NK cells following DAC 
treatment of the mice. First, we examined activating ligands and death receptors on 
THP-1 cells by FCM (Figure 6). While only slight differences were seen for ULBP1, 
MIC-A/B, CD112, TRAIL receptors and Fas, the expression levels of ULBP2 and CD155 
were evidently increased with DAC, supporting our finding that HMA can sensitize 
AML cells to HSPC-NK cell-mediated killing. On HSPC-NK cells, we observed sustained 
expression of DNAM-1, NKp46, TRAIL and CD69 (Figure 7A). However, the NKG2D 
level diminished on NK cells while expression of NKp44 was significantly increased. 
Similar phenotypical changes were observed with AZA (Supplementary Figure S7). 
Furthermore, in line with our previous report(2), HSPC-NK cells maintained high 
expression of NKG2A following adoptive transfer into NSG mice, and acquired CD16 and 
KIR expression as compared to the infused product prior to infusion (data not shown). 
Figure 4   Continued
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Figure 5   Treatment with HSPC-NK cell infusions and decitabine improves control 
of AML in vivo
(A) Experimental design: THP-1 bearing mice received 1 or 2 cycles of DAC (1.25 mg/m2), with 
or without HSPC-NK cells, which were infused the first day from each cycle. Survival of 
HSPC-NK cells in vivo was supported by ALT-803 (an IL-15 super-agonist complex), which was 
given subcutaneously every 3 to 4 days till day 35 (0.2 mg/kg per injection). (B) Impact of DAC 
on tumor load progression. Median tumor load from untreated mice, and mice treated with 
1 or 2 cycles of DAC are shown. (C) Impact of HSPC-NK cell infusions on tumor load progression 
in mice co-treated with 2 cycles of DAC. Data are shown as mean + SD and were analyzed 
using two-way ANOVA. One mouse in each DAC x2 and DAC+NK x2 group die at day 17 and 
day 15 respectively likely due to DAC-related toxicities (weight loss > 20% following second 
treatment cycle). These mice were excluded from the complete data set shown in this figure.
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Moreover, DAC further increased the frequency of KIR+ HPSC-NK cells. By RT-qPCR, 
we also demonstrated enhanced gene expression of inflammatory cytokines, perforin 
and TRAIL following DAC treatment, which are important players in NK cell-mediated 
killing (Figure 7B). Notably, no or less up-regulation of these inflammatory and 
cytolytic mediators was seen with AZA (Supplementary Figure S7). Finally, we 
examined HPSC-NK cell counts in the bone marrow compartment. In three 
independent experiments (data of two independent experiments shown in Figure 7C), 
we repeatedly found increased numbers of HSPC-NK cells in mouse bone marrow 
Figure 6   Decitabine treatment upregulates NK-inducing ligands on THP-1 cells in vivo
THP-1 bearing mice were treated with DAC (1.25 mg/m2) for 5 consecutive days. One week 
after the start of treatment, mice were sacrificed and bone marrow cells were isolated for ex vivo 
analysis of THP-1 cells. Data obtained from 5 individual mice per treatment group were pooled 
to reach enough events by FCM (500-900 single and viable THP-1 cells acquired per test). 
The relative expression level of NKG2D and DNAM-1 ligands, as well as death receptors are 
depicted in A, and overlay plots with mean fluorescence intensities are shown in B. Iso, isotype 
control; ND, no drug; DAC, decitabine.
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following DAC treatment, while the numbers of circulating NK cells were either 
similar (day+7) or lower (day+14) in peripheral blood as compared to control mice. 
Altogether, these data strongly support that low dose DAC can potentiate the 
anti-leukemic reactivity of HSPC-NK cells towards AML via modulation of gene 
expression and phenotype in AML and NK cells, and by influencing cell trafficking 
and tumor targeting in vivo.
Figure 7   Decitabine enhances the anti-leukemic potential of HSPC-NK cells 
through modulation of their maturation, activation, cytolytic functions 
and trafficking to the bone marrow
Adult NSG mice were infused with HSPC-NK cells and treated with DAC (1.25 mg/m2) for 
5 consecutive days. Persistence of NK cells in vivo was supported by subcutaneous 
administration of IL-15 (1 µg/injection) every 2-3 days. Mice were sacrificed one or two weeks 
after NK cell infusion for detailed ex vivo analysis. (A) Phenotype of HSPC-NK cells analyzed 1 
week after the start of decitabine treatment. Analysis was performed on cells isolated from 
spleen including 5 mice per treatment group. The relative expression of various maturation 
and activation markers, as well as adhesion molecules and homing receptor (right panel) and 
representative dot plots (left panel) are shown. (B) Gene expression profiling for the cytolytic 
machinery of NK cells, analyzed by RT-qPCR on cells isolated from livers, including 5 mice per 
treatment group. Data were normalized to human β-Actin. (C) Absolute numbers of HSPC-NK 
cells were determined in peripheral blood (absolute no. per ml) and mouse bone marrow 
either 1 week (experiment#1) or 2 weeks (experiment#2) after the start of treatment. Two 
femurs per mouse were combined in experiment#1, while experiment#2 was performed in 
IF THP-1 bearing mice and absolute NK cell counts were determined in each femur, with 
(Tumor BM) or without (NBM) tumor. Data shown in A were analyzed using two-way ANOVA 
and data from panels B and C using unpaired, two-tailed t test.
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Discussion
Here, we investigated the capacity of AZA and DAC to enhance HSPC-NK cell reactivity 
against AML. To the best of our knowledge our study is the first head-to-head 
comparison of AZA and DAC in promoting NK cell-mediated anti-leukemic reactivity 
in vivo. In line with previous reports, we showed that these HMA exert direct effects 
on AML cell viability, proliferation, and phenotype that eventually result in a greater 
susceptibility to NK cell mediated-killing. Furthermore, we also found increased 
expression of NKG2D and DNAM-1 ligands on THP-1 AML cells following treatment 
with HMA. In contrast to the AML cells, exposure to HMA had minimal impact on 
HSPC-NK cell viability and proliferation. Moreover, our data demonstrated that DAC 
can potentiate HSPC-NK cell functionalities and anti-leukemic activity, both in vitro 
and in vivo. Notably, combined HSPC-NK cell and DAC treatment resulted in improved 
control of THP-1 AML in NSG mice, while the combination with AZA did not yield an 
additive anti-leukemic effect. In vitro this may be attributed to a more pronounced 
inhibitory effect of AZA on NK cell proliferation and degranulation capacity. But in 
vivo, the difference between both HMA could rely on multiple factors. For instance, 
AZA showed only minor influence on the cytolytic machinery of HSPC-NK cells, and 
Figure 7   Continued
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had a lower impact on NK cell trafficking and accumulation in the bone marrow 
compartment compared to DAC. We believe this is not due to different dosing of 
the HMA in our mouse studies as we carefully titrated AZA and DAC treatment for 
exerting the same direct effect on THP-1 cells in vivo. 
 Interestingly, increased NK cell anti-leukemic activity could already be demonstrated 
in DAC-treated mice following a single infusion of HSPC-NK cells, but was further 
enhanced by application of two treatment cycles. It is important to underline that 
this intra-femoral THP-1 AML model is very stringent. On the one hand due to the 
fast and aggressive THP-1 cell progression in vivo,2 and on the other hand because 
it requires effective NK homing to the tumor site following intravenous infusion.30 
In this model, treatment with DAC did not eradicate THP-1 cells in vivo but allowed 
indolent disease progression, thereby favoring HSPC-NK cell responses to less bulky 
and residual disease. Increased HSPC-NK cell numbers were seen in bone marrow of 
particularly DAC-treated mice. Shortly after infusion HMA treatment may favor NK 
cell homing to the bone marrow as a result of transient leukopenia in HMA-treated 
mice. Moreover, two weeks after NK cell transfer to tumor-bearing mice, HSPC-NK 
cell numbers were particularly increased within the tumor bed rather than in normal 
bone marrow, suggesting a specific NK cell homing to the tumor site. In this regard, 
we also observed higher levels of inflammatory cytokine production by HSPC-NK 
cells following DAC treatment. These observations are in line with a recent 
publication by Wang et al. describing a dual effect of DAC on inflammation and 
lymphocyte trafficking at the tumor site in a mouse ovarian cancer model.31 They 
showed that low-dose DAC treatment increases the expression of chemokines that 
recruit NK cells and CD8+ T cells as well as promotes their production of IFN-γ and 
TNF-α. Interestingly, we also observed that AML cells, including THP-1, can secrete 
the inflammatory chemokines CXCL9, CXCL10 and CXCL11 upon IFN-γ and TNF-α 
exposure (data not shown), and that HSPC-NK cells maintain high CXCR3 expression 
in vivo.2 In addition, it has been recently shown that HMA can activate endogenous 
retroviruses (ERVs), thereby eliciting an IFN type I and III response, which subsequently 
leads to secretion of CXCL9 and CXCL10.32 Finally, the DAC-induced IFN response 
may positively impact HSPC-NK cell activity and function as seen by the up-regulation 
of immune mediators such IFN-γ, TNF-α and perforin. Therefore, we believe that, 
besides its direct anti-leukemic activity, DAC can potently maximize HSPC-NK cell 
responses presumably via epigenetic modulation. Besides sensitizing AML cells to 
NK cell-mediated killing, our data support that DAC can boost HSPC-NK cell cytolytic 
functions, enhance inflammatory responses and up-regulate expression of the 
activating receptor NKp44. This could result in a self-stimulatory loop further 
promoting NK cell recruitment to the tumor site and sustained AML control.
 Altogether, our findings provide a strong rationale to investigate HMA therapy 
in patients not only prior to adoptive NK cell immunotherapy, but also concomitantly 
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with HSPC-NK cell infusion to exploit superior efficacy of these two treatment 
regimens. Potential clinical applications are broad. For AML, current remission 
induction and consolidation regimens could be complemented with adoptive 
transfer of allogeneic HSPC-NK cells combined with low or increasing doses DAC as 
an adjuvant consolidation or bridge-to-transplant strategy. Furthermore, combining 
DAC and HSPC-NK cell infusion with the IL-15 superagonist ALT-803, which has shown 
enhanced biological activity and better half-life in vivo compared to rhIL-15,28 ,29 
is a promising combinatorial approach to maximize the anti-leukemic effect. 
This combination could further eradicate minimal residual disease, and ultimately 
improve outcome of allogeneic stem cell transplantation.33, 34 We cannot affirm that 
the same findings will occur in patients, and treatment dosages are particularly 
difficult to translate from human to animal beings and vice-versa. In our model we 
applied 5-day DAC treatment, whereas in patients it has been observed that 10-day 
treatment is more efficacious.35-37 Furthermore, our mouse studies revealed that 
2 cycles with combined DAC, HSPC-NK cells and ALT-803 treatment is better but the 
effect seems to decrease at 28 days. Therefore, further improvement by longer 
duration of DAC treatment for 10 days in each cycle and/or more treatment cycles 
should be tested to maximize the combined NK/DAC/ALT-803 effect. Opportunities 
could also be considered in the post-transplant setting, where low dose maintenance 
therapy with HMA has shown to be feasible.13 In this situation, using HSPC-NK cells 
generated from the donor stem cell graft would be beneficial to allow longer 
persistence of adoptively transferred NK cells.23 Furthermore, influence of DAC on 
inflammation and immune cell trafficking to the tumor site as well as further 
stimulation of NK and dendritic cell cross-talk could boost also anti-leukemic T cell 
responses.38-40 Therefore, our study showing that HSPC-NK cells and DAC can 
potently cooperate to eradicate AML provides a strong rationale to explore this 
combination strategy in AML treatment.
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Supplementary Information
Supplementary materials and methods
Antibodies
The following conjugated monoclonal antibodies were used for HSPC-NK cell 
phenotyping: CD56 (HCD56, Biolegend), NKG2A (Z199, Beckman Coulter), CD158a/h, 
b and e (clones HP-MA4, DX27, and DX9 respectively, used as a combined staining 
for KIRs), CD16 (3G8), NKG2D (1D11), NKp46 (9E2), NKp44 (P44-8), CD69 (FN50), TRAIL 
(RIK-2), FasL (NOK-1), CD11a (HI111),  CXCR3 (G025H7, all Biolegend), and DNAM-1 
(DX11; BD Bioscience). The panel for AML cell analysis included MIC-A/B (6D4, 
Biolegend), ULBP-1 (170818), ULBP-2 (165903), CD155 (300907), CD112 (610603, all 
R&D), TRAIL-R1 (DJR2-4), TRAIL-R2 (DJR2-1), and Fas (DX2, all Biolegend). IgG1 
(MOPC21) and IgG2a (MOPC173, Biolegend) isotype controls were included for 
calculation of specific fluorescence intensities. For ex vivo FCM analysis, HSPC-NK 
cells and THP-1.LucGFP cells were identified based on CD56 and GFP expression, 
respectively, in combination with human CD45 (J.33, Beckman Coulter) and mouse 
CD45 (30-F11, BD Biosciences) antibodies. Non-viable cells were excluded using 
SYTOX Blue (Life Technologies) or eFluor780 (eBiosciences) viability dye. Phenotypical 
analyses were performed using the Gallios flowcytometer and Kaluza analysis 
software (both Beckman Coulter).
Flow cytometry (FCM)-based cellular assays
The K562, THP-1, and KG1a cell lines (ATCC) were cultured in Iscove’s modified 
Dulbecco’s medium (Invitrogen) supplemented with 10% fetal calf serum (Integro). 
Patient-derived primary AML cells were obtained from diagnostic left-over material 
in accordance with the Declaration of Helsinki and institutional guidelines and 
regulations (CMO 2013/064). All samples employed in this study were from bone 
marrow origin and contained >90% blasts based on flow cytometric determination 
of CD45, CD33 and CD34 expression. NK cell co-cultures with primary AML cells were 
supplemented with SCF and Flt3L (both 20 ng/ml), IL-3 (50 ng/ml, Immunotools), 
G-CSF (20 ng/ml; Amgen) and IL-15 (5 ng/ml). Cytotoxicity assays were performed as 
previously described(2) using CFSE-labeled target cells. In experiments where AML 
or NK cells were pre-treated with HMA, cells were harvested, counted, and equal 
numbers of viable cells were plated in all experimental conditions. After overnight 
co-culture, the numbers of viable target cells were determined using the FC500 
cytometer (Beckman Coulter) by gating on CFSE+ cells, exclusion of the live/dead 
marker 7AAD (Sigma Aldrich) and back-gating on forward/side scatter. Target cells 
were plated alone as controls without killing. Proliferation of AML and NK cells was 
examined after labeling with CFSE, culture in the presence or absence of HMA, and 
subsequent FCM analysis. Analysis of NK cell reactivity at the single cell level was 
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determined following 4 hours stimulation with K562 cells in the presence of 
anti-CD107a (H4A3; BD Biosciences) and Brefeldin A (BD Biosciences) and subsequent 
intracellular staining for perforin (dG9, Biolegend) and IFN-γ (B27; BD Biosciences). 
FCM analysis was performed with exclusion of dead cells using the Fixable Viability 
Dye eFluor780 (eBiosciences), gating on CD56+Perforin+ NK cells, and using 
unstimulated cells as control.
Gene expression analysis
Total RNA was isolated using PureLink RNA mini-kit (Life Technologies) according to 
manufacturer’s instructions. Next, cDNA was synthesized using M-MLV-reverse 
transcriptase (Invitrogen) in a standard reaction after which real-time PCR was 
performed using the following Taqman Gene expression assays (Life Technologies): 
IFNG (Hs00989291_m1), TNF (Hs01113624_g1), PRF1 (Hs00169473_m1), GZMB 
(Hs00188051_m1), TNFSF10 (Hs00921974_m1), and FASLG (Hs00181225_m1). Expression 
levels were normalized to β-Actin (ACTB, NM_001101.2) using the ΔCt method. 
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Figure S1   HMA have a direct and dose-dependent effect on AML cell viability  
and proliferation
THP-1 and KG-1a cells were stained with CFSE and cultured in the presence of Azacitidine (AZA) or 
Decitabine (DAC) using the indicated concentrations. Treatment was applied for 5 consecutive 
days and both HMA were refreshed daily. Cell number, viability and proliferation were analyzed by 
flow cytometry after 1, 3, and 5 days of culture. Cell viability was determined on forward/side 
scatter and exclusion of 7AAD, and the proliferation index was determined using the mean 
fluorescence intensity (MFI) of CFSE and calculated as the ratio between untreated (No HMA) 
and treated cells. Representative data from one experiment are shown (mean ± SD).
Cell numbers Viability Proliferation 
THP-1 
KG-1a 
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Figure S2   Effect of HMA on primary AML cell viability and proliferation
Patient-derived primary AML cells were stained with CFSE and cultured in the presence of 
Azacitidine (AZA) or Decitabine (DAC) using the indicated concentrations. Treatment was 
applied for 5 consecutive days and both HMA were refreshed daily. Cell number, viability and 
proliferation were analyzed by flow cytometry after 1, 3, and 5 days of culture. Cell viability 
was determined on forward/side scatter and exclusion of 7AAD, and the proliferation index was 
determined using the mean fluorescence intensity (MFI) of CFSE and calculated as the ratio 
between untreated (No HMA) and treated cells. Combined data obtained with 5 different 
AML samples and analyzed at day+5 are shown (mean ± SEM). Data were analyzed using 
one-way ANOVA with comparison of each treatment condition to the control No HMA. 
*p<0.05, **p<0.01, ***p<0.001.
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Figure S3   Phenotypical analysis of HSPC-NK cells following exposure to HMA in vitro
HSPC-NK cells cultured under steady state (5 ng/ml IL-15) or proliferative (20 ng/ml IL-15 and 
103 U/ml IL-2) conditions and in the presence of Azacitidine (AZA) and Decitabine (DAC) were 
harvested at day+6 and analyzed by flow cytometry for their expression levels of maturation 
and activation markers, as well as adhesion molecules and homing receptor. Data obtained 
with one representative donor are shown.
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Figure S4   Tolerability and anti-leukemic activity of Azacitidine and Decitabine in mice
Adult NSG mice were injected IF with THP-1.LucGFP cells. One week later, treatments with 
deescalating doses of HMA were initiated as indicated. Drugs were prepared and administered 
daily. Azacitidine (AZA) was injected subcutaneously and Decitabine (DAC) intravenously, 
based on current clinical practice. (A) Weight follow-up (n=6 per group). Mice were monitored 
for weight and condition, and sacrificed when weight loss exceeded 20%. (B) Tumor load 
monitoring was performed weekly by bioluminescence imaging till day 28 (higher dosages) 
or 42 (for lower and tolerated dosages only). Dotted lines indicate upper detection limit 
for tumor load monitoring (signal saturation). Data are depicted as mean ± SD and include 
3-6 mice per group per time-point.
Dose translation: 
Dose in mg/kg =
Dose in mg/m2 
Km 
In mice: Km = 3 
In humans: Km = 37 
† † †
† †
A
B
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5Figure S5   Effect of HMA therapy on mouse CD45+ cells vs. HSPC-NK cells in vivo
Adult NSG mice were infused with 5x106 HSPC-NK cells and treated for 5 consecutive days 
with 12.5 mg/m2 Azacitidine (AZA) or 1.25 mg/m2 Decitabine (DAC). Survival of NK cells in vivo 
was supported by subcutaneous administration of IL-15 (1 µg/injection) every 2-3 days. 
Mice were sacrificed one week after cell infusion and percentages of HSPC-NK cells within 
total human and mouse CD45+ cells (A) as well as absolute numbers (B) were determined 
in peripheral blood and spleen. Data were analyzed using one-way ANOVA. **p<0.01, 
***p<0.001, n.s. not significant.
A
B
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Figure S6   Head-to-head comparison of recombinant human IL-15 and ALT-803  
to support survival and proliferation of HSPC-NK cells
HSPC-NK cells were stained with eFluor450 proliferation dye and cultured in basal medium 
only, or supplemented with equimolar concentrations of rhIL-15 vs. ALT-803. Cytokines were 
refreshed after 3 days, and NK cell proliferation (A), viability (using 7AAD live/dead marker, 
(B), and absolute numbers (C) were determined at day+6 by flow cytometry. Combined data 
(mean ± SEM) obtained with 3 HSPC-NK products are shown. Statistical analyses were 
performed using one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001.
A
B C
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Figure S7   Impact of Azacitidine on THP-1 cells and HSPC-NK cells in vivo
Adult NSG mice were injected with THP-1 or HSPC-NK cells, treated with 12.5 mg/m2 
Azacitidine (AZA) or 1.25 mg/m2 Decitabine (DAC), and sacrificed one week after the start of 
treatment for organ collection and detailed ex vivo analysis. (A-B) Phenotype of THP-1 cells 
(A) and HSPC-NK cells (B, n=5) isolated from bone marrow and spleen respectively, and 
analyzed by flow cytometry.  (C) Gene expression profiling for the cytolytic machinery of NK 
cells, analyzed by RT-qPCR on cells isolated from liver. Data were normalized to human 
β-Actin. (D) Absolute numbers of HSPC-NK cells determined in mouse bone marrow (2 femurs 
combined per mouse). Data were analyzed using two-way (B) and one-way (C and D) ANOVA. 
*p<0.05, ***p<0.001, n.s. not significant.
A
C
D
B
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hematopoietic stem and progenitor cells
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Abstract 
Early natural killer (NK) cell repopulation after allogeneic stem cell transplantation 
(allo-SCT) has been associated with reduced relapse rates without an increased risk 
of graft-versus-host disease (GVHD), indicating that donor NK cells have specific 
anti-leukemic activity. Therefore, adoptive transfer of donor NK cells is an attractive 
strategy to reduce relapse rates after allo-SCT. Since NK cells of donor origin will not 
be rejected, multiple NK cell infusions could be administered in this setting. However, 
isolation of high numbers of functional NK cells from transplant donors is challenging. 
Hence, we developed a cytokine-based ex vivo culture protocol to generate high 
numbers of functional NK cells from G-CSF mobilized CD34+ stem and progenitor 
cells (HSPCs). In this study, we demonstrate that addition of aryl hydrocarbon 
receptor (AhR) antagonist SR1 to our culture protocol potently enhances expansion 
of CD34+ HSPCs, and induces expression of NK cell associated transcription factors 
promoting NK cell differentiation. As a result, high numbers of NK cells with an active 
phenotype can be generated using this culture protocol. These SR1-generated NK 
cells exert efficient cytolytic activity and IFN-γ production towards acute myeloid 
leukemia (AML) and multiple myeloma (MM) cells. Importantly, we observed that NK 
cell proliferation and function is not inhibited by cyclosporin A (CsA), an immuno-
suppressive drug often used after allo-SCT. These findings demonstrate that SR1 can 
be exploited to generate high numbers of functional NK cells from G-CSF mobilized 
CD34+ HSPCs, providing great promise for effective NK cell based immunotherapy 
after allo-SCT.
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Introduction
Natural killer cells (NK cells) are CD3-CD56+ lymphocytes, which are part of the innate 
immune system and play an important role in the defense against virus-infected 
and transformed cells. NK cell activation and subsequent killing of target cells is 
regulated by a balance in their expression levels of inhibitory receptors, including 
the killer-immunoglobulin like receptors (KIRs) and CD94/NKG2A heterodimer, 
versus activating receptors, such as DNAX accessory molecule-1 (DNAM-1), natural 
cytotoxicity receptors (NCRs) and NKG2D. In homeostasis, NK cells are inhibited by 
their inhibitory receptors recognizing self human leukocyte antigen (HLA) class I 
molecules and/or HLA-E molecules presenting conserved HLA class I leader 
sequences. However, an NK cell-mediated anti-tumor effect can be induced by 
up-regulation of activating ligands or down-regulation of HLA class I molecules on 
tumor cells. In addition, in the setting of haploidentical allogeneic stem cell trans-
plantation (allo-SCT), donor NK cells may lack expression of inhibitory KIRs for 
recipient HLA class I molecules and hence be activated. This phenomenon is called 
missing-self recognition and can contribute to the curative graft-versus-tumor (GVT) 
effect.1
 Because of their ability to kill tumor cells, NK cells are considered potent effectors 
for adoptive immunotherapy against cancer. So far, promising results have been 
obtained by infusion of haploidentical NK cells after immunosuppressive 
chemotherapy in adult and childhood acute myeloid leukemia (AML).2-4 However, a 
limitation in these studies is the relatively low NK cell numbers that can be enriched 
from aphaeresis products for multiple infusions. Furthermore, contaminating 
alloreactive T cells risk the induction of graft-versus-host disease (GVHD), especially 
when IL-2 or IL-15 are co-administrated to boost NK cell survival and expansion. In 
order to generate high numbers of allogeneic NK cells completely devoid of T cell 
contamination, a Good Manufacturing Practice (GMP)-compliant, cytokine-based ex 
vivo culture protocol has been developed by our group.5,6 Using this procedure, 
CD34+ hematopoietic stem and progenitor cells (HSPCs) isolated from umbilical 
cord blood (UCB) can be expanded over 2000-fold in large-scale bioreactors into a 
mixture of immature and mature NK cells with a purity > 80%. Pre-clinical studies 
conducted in NOD/SCID-IL2Rγnull mice demonstrated that these HSPC-NK cells 
have BM homing capacity, display IL-15-driven in vivo expansion, and prolong 
survival of leukemia-bearing mice.7 Currently, administration of this HSPC-NK cell 
product following immunosuppressive chemotherapy is being investigated in a 
phase I clinical trial in older AML patients who are not eligible for allo-SCT (see www.
trialregister.nl and search for 2818).
 In HLA-matched non-myeloablative and T cell-depleted allo-SCT, early NK cell 
repopulation has been associated with decreased relapse rates, without increasing 
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GVHD incidence.8,9 Moreover, high NK cell numbers in stem cell grafts have been 
associated with a decreased incidence of GVHD.10 In addition, transplants from 
donors with KIR-B haplotypes, containing several activating KIRs, led to lower rates 
of relapse and improved survival.11-13 For these reasons, it would be highly valuable 
to exploit HSPC-NK cell products for adoptive immunotherapy after allo-SCT. 
Since NK cells of donor origin will not be rejected, multiple NK cell infusions without 
the need for immunosuppressive chemotherapy to prevent rejection, could be 
administered after allo-SCT. Consequently, these cells may potentially induce long- 
term GVT effects. However, to obtain large numbers of NK cells from donor origin, 
peripheral blood (PB) or bone marrow (BM)-derived CD34+ HSPCs, which have a lower 
expansion potential compared to UCB-derived CD34+ HSPCs, should be expanded 
and differentiated into NK cells. 
 Recently, it was described that expansion of CD34+ HSPCs can be enhanced by 
inhibition of the aryl hydrocarbon receptor (AhR) using the antagonist StemReginin1 
(SR1).14 AhR is a ligand-inducible transcription factor, which plays an important role 
in biological responses towards xenobiotic agents such as digoxin.15,16 Yet, it has 
become clear that AhR also has multiple naturally occurring ligands, like tryptophan 
metabolites and dietary compounds.15 Furthermore, AhR turned out to regulate 
 differentiation of multiple immune cells including dendritic cells,17,18 regulatory T 
cells,19,20 γδ T cells,21 Th17 cells22 and notably NK cells.23 Based on these findings, we 
hypothesized that addition of SR1 to our culture system might improve expansion 
of CD34+ HSPCs, and differentiation of these cells into NK cells. We found that SR1 
not only enhances expansion of CD34+ HSPCs, but also up-regulates the expression 
of early and late NK cell specific transcription factors, thereby potentiating differen-
tiation of SR1-expanded CD34+ cells into NK cells. These SR1-induced NK cells have a 
high purity, express high levels of activating receptors and efficiently target AML 
and multiple myeloma (MM) cells. Importantly, proliferation and cytolytic functions 
of SR1-induced HSPC-NK cells are not inhibited by cyclosporin A (CsA), in contrast to 
mycophenolic acid (MPA), which is used only shortly after allo-SCT, facilitating 
multiple infusions relatively shortly after allo-SCT. Therefore, our SR1 culture system 
holds great promise for future donor HSPC-NK cell adoptive immunotherapy after 
allo-SCT to boost anti-tumor and anti-viral immunity, leading to prolonged 
relapse-free survival.
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Materials and Methods
Cell lines
Cell lines (K562, THP1, HL-60, U266, UM9, RPMI8226) were cultured in Iscove’s 
modified Dulbecco’s medium (IMDM; Invitrogen, Carlsbad, CA, USA) containing 50 
U/mL penicillin, 50 µg/mL streptomycin and 10% fetal calf serum (FCS; Integro, 
Zaandam, The Netherlands).
Isolation of CD34+ stem and progenitor cells
Bone marrow samples were collected from healthy donors after written informed 
consent. Bone marrow-derived mononuclear cells (BM-MNCs) were isolated by 
Ficoll-hypaque (1.077 g/mL; GE Healthcare, Uppsala, Sweden) density gradient 
centrifugation. Peripheral blood-derived mononuclear cells (PB-MNCs) were 
obtained from aphaeresis material from stem cell donors who were treated with 
G-CSF (Neupogen®) 10 µg/kg/day subcutaneously for 5 to 6 days, after written 
informed consent. CD34+  HSPCs were isolated using anti-CD34 immunomagnetic 
beads (Miltenyi Biotech, Bergisch Gladbach, Germany) according to manufacturer’s 
instructions. CD34+ HSPCs were directly used for NK cell generation.
Ex vivo expansion of CD34+HSPCs, and differentiation into NK cells
CD34+ HSPCs were plated into 24-well or 6-well tissue culture plates (Corning 
Incorporated, Corning, NY, USA). Cells were expanded during 9 or 10 days with a 
high-dose cytokine cocktail (Expansion cocktail I) consisting of 25 ng/mL IL-7 
(Immunotools), 25 ng/mL SCF (Immunotools), 25 ng/mL TPO (Cellgenix) and 25 ng/
mL Flt3L (Immunotools). From day 9 or 10 until day 14 or 15, TPO was replaced by 20 
ng/mL IL-15 (Miltenyi). After day 14 or 15, cell differentiation was initiated by replacing 
Expansion cocktail I by a new high-dose cytokine cocktail (Differentiation cocktail) 
consisting of 20 ng/mL IL-7, 20 ng/mL SCF, 20 ng/mL IL-15 and 1000 U/mL IL-2 
(Proleukin®; Chiron, München, Germany). Where mentioned, 2 µM StemReginin1 
(SR1; Cellagen Technology, San Diego, CA, USA) was added to the culture medium 
(see Figure 1A). Cells were cultured in Cellgro GMP DC medium (Cellgenix, Freiburg, 
Germany) supplemented with 10% human serum (HS; Sanquin Bloodbank, 
Nijmegen, The Netherlands) and a low dose cytokine cocktail consisting of 250 pg/
mL G-CSF (Filgrastim, “Neupogen” - Amgen Corp. USA), 10 pg/mL GM-CSF and 50 
pg/mL IL-6 (both Immunotools, Friesoythe, Germany). During the first 14 or 15 days 
of culture, low molecular weight heparin (Clivarin®; Abbott, Wiesbaden, Germany) 
was added to the medium in a final concentration of 20 µg/mL. Freshly isolated 
CD34+ cells were plated at a concentration of 1 – 4 x 105/mL. After 3 days of culture, 
cells were transferred to a new plate in order to deplete for stromal cells. From day 
14 or 15 onward, cell counts were kept above 2 x 106 cells/mL. Cell cultures were 
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Figure 1   SR1 enhances expansion of peripheral blood-derived CD34+ HSPCs and 
improves NK cell differentiation
(A) Representation of the ex vivo cytokine-based culture protocol used for the generation of 
NK cells. (B-D) Kinetics of differentiation (B) and expansion (C) of CD34+ HSPCs in our ex vivo 
culture protocol in the presence or absence of 2 µM SR1 in one representative donor, 
determined by FCM. (C) Summary of total expansion, NK cell yield (calculated by [total 
expansion x percentage of CD56+ cells]/100), and NK cell differentiation after 5 weeks of 
culture in our ex vivo culture protocol in the presence or absence of 2 µM SR1 in 12 donors, 
determined by FCM. ** p<0.01, *** p<0.001, Wilcoxon matched-pairs signed rank test, Paired 
one-tailed student’s t-test.
D y 0a Day 9 Day 14 Week 5
HSPC expansion HSPC - NK cell dierentiation and expansion
IL-15 + Flt3L IL-15 + IL-2
IL-7 + SCF
D y 3 - New wella
TPO + Flt3L
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D
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refreshed with at least 30% new medium every 2 to 3 days. Cultures were maintained 
at 37˚C, in 95% humidity, and 5% CO2. NK cells were used in experiments after 
5 weeks of culture.
RNA isolation and real-time quantitative RT-PCR (qRT-PCR)
Total RNA from 0.5 - 2 x 105 cells, collected weekly from HSPC-NK cell cultures, was 
isolated using the Quick-RNATM MicroPrep Kit (Zymo Research, CA, USA). Next, cDNA 
was synthesized using M-MLV-reverse transcriptase (Invitrogen) in a standard 
reaction as described before 24, after which real-time PCR was performed using the 
following Taqman Gene expression assays (Applied Biosystems, Forster City, CA, 
USA): AhRR (Hs01005075_m1); TOX (Hs01055573_m1); ID2 (Hs04187239_m1); EOMES 
(Hs00172872_m1); GATA3 (Hs00231122_m1); SH2D1B (Hs01592483_m1); IFNG 
(Hs00989291_m1); GZMB (Hs01554355_m1); PRF1 (Hs99999108_m1).  For all genes, Ct 
values were normalized to GAPDH (Hs02758991_g1) by calculating ΔCt = Cttarget gene 
– CtGAPDH per sample. Finally, gene expression levels were quantified relative to 
GAPDH as follows: 2^(-[ΔCt]). 
Flow cytometry (FCM)
Cell numbers and expression of cell-surface markers were determined by FCM. 
Anti-human CD45-ECD (J.33, Beckman Coulter, Woerden, The Netherlands) and 
anti-CD56-PC7 (HCD56, Biolegend, San Diego, CA, USA) antibodies were used to 
follow cell number and NK cell differentiation during culture using the Coulter FC500 
flow cytometer (Beckman Coulter). The population of viable CD45+ cells was 
determined by exclusion of 7-AAD (Sigma, St Louis, MO, USA) positive cells. For 
phenotypical analysis, cells were incubated with antibodies in FCM buffer (PBS/0.5% 
bovine serum albumin (BSA; Sigma) for 30 minutes at 4°C. After washing, cells were 
resuspended in FCM buffer and analyzed. The following conjugated monoclonal 
antibodies were used for NK cell phenotyping: anti-NKG2A-PE (Z199; Beckman 
Coulter), anti-DNAM-1-FITC (DX11; BD Biosciences Pharmingen, Breda, The 
Netherlands), anti-CD16-FITC (3G8), anti-CD3-FITC (UCHT1), anti-NKG2D-PE (1D11), 
anti-NKp30-PE (P30-15), anti-NKp44-PE (P44-8),  anti-NKp46-PD (9E5), anti-CD158b-PE 
(Dx27), anti-CD158e-PE (Dx9), anti-CD158a/h-PE (HP-MA4), anti-CD62L-PE (DREG56), 
anti-CD253-PE (RIK-2), anti-CXCR3-PE (G025H7), anti-CXCR4-PE (12G5), anti-IgG1-PE 
(MOPC-21), anti-IgG2a-PE (MOPC-173), anti-IgG2b-PE (MCP-11), anti-IgG1-FITC 
(MOPC-21; all from Biolegend).
Fluorescence-activated cell sorting (FACS) of HSCP-NK cells
After 5 weeks of culture, CD56+ cells were isolated from the total cultured cells. 
For this purpose cells were stained for 15 minutes at 4°C using the appropriate 
concentration of anti-CD56-PEcy7 (CD56-PC7 (HCD56, Biolegend). Cells were 
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washed and resuspended in FACS buffer at a concentration of 1.5 x 106/mL, and 
subsequently sorted at the FACSAria Cell Sorter (BD Biosciences).
FCM-based cytotoxicity assays 
Cell lines were labeled with 1 µM carboxyfluorescein diacetate succinimidyl ester 
(CFSE; Molecular Probes Invitrogen, Eugene, OR, USA) and primary AML blasts were 
labeled with 1.5 µM CFSE, both in a concentration of 1 x 107/mL for 10 minutes at 
37°C. The reaction was terminated by adding an equal volume of FCS. After washing, 
cells were resuspended in IMDM/10% FCS to a final concentration of 3 x 105/mL. 
Target cells (3 x 104) were co-cultured in triplicate with effector cells at different ef-
fector:target (E:T) ratios in a total volume of 200 µL IMDM/10% FCS in 96-wells 
round-bottom plates (Corning Incorporated). Effector cells and target cells alone 
were plated out in triplicate as controls. In experiments with primary AML blasts, 
AML blasts were derived from bone marrow samples from 5 patients at the time of 
diagnosis and were supplemented with IL-3 (50 ng/mL; Cellgenix), SCF (25 ng/mL), 
Flt3L (20 ng/mL), GM-CSF (100 ng/mL), G-CSF (100 ng/mL) and IL-15 (5 ng/mL). To 
measure degranulation of NK cells, anti-CD107a-PC7 (H4A3, Biolegend) was added 
to the co-culture. After overnight co-culture at 37°C, 50 µL supernatant was discarded 
and 50 µL Coulter® Isoton® II Dilutent containing 0.2 µL 7-AAD was added instead. 
Cells were harvested and the number of viable target cells was quantified by FCM 
by gating on forward scatter and side scatter and exclusion of 7-AAD positive cells. 
Target cell survival was calculated as follows: % survival = ([absolute number of 
viable CFSE+ target cells co-cultured with NK cells]/[absolute number of viable CFSE+ 
target cells cultured in medium]) x 100%. The percentage specific lysis was calculated 
as follows: % lysis = (100-[% survival]), as described earlier by Jedema et al. 25,26 
Degranulation of NK cells during overnight co-culture was determined as the 
percentage of CD107a expressing cells measured by FCM.
Cytokine assays
The production capacity of IFN-γ and Granzyme B by NK cells were evaluated by 
enzyme-linked immunorbent assays (ELISA) according to manufacturer instructions 
(IFN-γ: Pierce Endogen, Rockfore, IL, USA; Granzyme B; Mabtech, Sweden). To this 
end, NK cells (1 x 105) were co-cultured in triplicate with target cells (1 x 105) in a total 
volume of 200 µL IMDM/10% FCS in 96-wells round-bottom plates (Corning 
Incorporated). NK cells alone were plated out in triplicate as controls. After incubation 
overnight at 37°C, 150 µL supernatant was collected and stored at -20°C until use.
Proliferation assays
HSPC-NK cells were cultured according to our culture protocol for 35 days. After 35 
days, NK cells were labeled with 1 µM CFSE as described previously. After staining, 
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cells were resuspended in differentiation medium at a concentration of 2 x 106/mL 
and plated in duplicate in a 96-well plate. CsA (Biovision Incorporated, Milpitas, CA, 
USA) or MPA (Sigma-Aldrich, Zwijndrecht, The Netherlands) were added to final 
concentrations of 0.01 to 1 µg/mL (CsA) or 0.1 to 10 µg/mL (MPA). Half of the medium 
containing MPA or CsA in the final concentration was refreshed every 2-3 days. After 
7 days, cells were harvested. The number of viable target cells was quantified by 
FCM by gating on forward scatter and side scatter and exclusion of 7-AAD positive 
cells. Proliferation was analyzed by determining the CFSE dilution within CD56+ cells.
Statistical analysis
Results from different experiments are described as mean ± standard error of the 
mean (SEM). Statistical analysis was performed using a one-tailed paired student’s 
t-test, a two-tailed unpaired student’s t-test or one-way ANOVA if values had a 
normal distribution (normality was determined using the Kolmogorov-Smirnov 
test). For values without normal distribution we used the Wilcoxon matched-pairs 
signed rank test. Differences were considered to be significant for p values <0.05.
Results
SR1 enhances expansion of PB and BM-derived CD34+ HSPCs  
and improves NK cell differentiation
In this study, we investigated whether NK cells could be generated in vitro from PB or 
BM-derived CD34+ HSPCs. We used the feeder-free culture protocol described in 
Figure 1A, which was reported previously to generate high numbers of functional 
NK cells from UCB-derived CD34+ HSPCs.5,6 However, in our initial cultures using PB 
or BM derived HSPCs, expansion and differentiation were low, which was associated 
with high numbers of stroma-like cells observed in culture plates (data not shown). 
Therefore, we investigated transfer of non-adherent cells to a new culture plate after 
3 days of culture. Although this resulted in much lower outgrowth of stromal cell 
layers in the culture plates, expansion and NK cell differentiation were still low. For 
that reason, we investigated whether addition of the AhR antagonist SR1 (2 µM), 
which is known to improve expansion of CD34+ HSPCs and to influence NK cell dif-
ferentiation, could improve NK cell generation from HSPCs. Importantly, addition of 
SR1 strongly enhanced expansion of CD34+ cells from both PB-derived HSPCs 
(Figure 1), as well as BM-derived HSPCs (Supplementary Figure 1 A-B). Mean NK cell 
yield after 5 weeks of culture was 235 fold (range 115 – 904 fold; n = 10, Figure 1D) 
for G-CSF mobilized CD34+ cells, and 129 fold (range 33 – 301; n=4, Supplementary 
Figure S1B) for BM-derived CD34+ HSPCs. Interestingly, differentiation also improved 
by addition of SR1 to our cultures, resulting in a purity of 83% ± 9% for G-CSF 
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mobilized CD34+ HSPCs, and 84% ± 18% for BM-derived CD34+ cells. The remaining 
non-NK cells in the cultures represented mainly CD14+ and/or CD15+ mature 
monocytic and myelocytic cells (11% ± 6%). A small frequency of CD34+ cells could 
also be detected at the end of the culture process (0.7% ± 0.4%). Most importantly, 
the amount of CD3+ T cells in the SR1-based NK cell cultures investigated was very 
low (0.1% ± 0.1%). Altogether, these data demonstrate that the AhR pathway 
negatively influences NK cell development, and that by combining SR1 with cytokine 
mixtures, high numbers of CD56+ NK cells can be generated from G-CSF-mobilized 
and BM-derived CD34+ HSPCs ex vivo. Since G-CSF-mobilized CD34+ HSPCs are the 
main stem cell source for allo-SCT, we concentrated on these HSPC-NK cells for 
further investigations.
SR1 influences expression of transcription factors important for  
NK cell differentiation and maturation
To gain insight into the molecular processes behind the SR1-enhanced differentiation 
of CD34+ HSPCs into NK cells, we analyzed the gene expression profile of several 
transcription factors that are described to be important for NK cell differentiation 
and maturation.27-31 To analyze the culture composition, we concomitantly determined 
the percentage of CD56+ cells in our cultures at different time points (Figure 2A). 
Next, we compared expression levels of several transcription factors in the presence 
or absence of SR1 in total cells at these time points in our ex vivo culture system 
(Figure 2B). We observed efficient down regulation of AhRR (i.e. direct target gene of 
AhR signaling14) in the presence of SR1, indicating that a concentration of 
2 µM SR1 is sufficient for AhR inhibition. Interestingly, we observed higher expression 
of thymocyte selection-associated HMG box factor (TOX), which is important in 
early NK cell differentiation,27 from day 7 onward (Figure 2B-C). This suggests that 
SR1 increased the number of NK cell precursors, even before the induction of NK cell 
differentiation was initiated by addition to IL-15 to the culture, and before CD56 
acquisition. Expression of ID2, which is important for NK cell maturation,28,29 was 
increased from day 14 onwards, after addition of IL-15 to the culture (Figure 2B). 
Eomesodermin (EOMES), another factor important for NK cell maturation, was 
upregulated from week three onward. Finally, expression of GATA-3 and Ewing’s 
 sarcoma-associated transcript 2 (EAT-2; SH2D1B), required to develop cytotoxic 
functions,30,31 was increased in cells cultured in the presence of SR1 (Figure 2B). 
 To investigate whether the increased expression levels of these transcription 
factors reflected a difference between NK cells generated in the presence or absence 
of SR1, or resulted from the different composition of the cultures, CD56+ NK cells, 
generated in the presence or absence of SR1, were sorted by FACS from HSPC-NK 
cultures after 5 weeks. Subsequently, gene expression levels of the previously 
mentioned transcription factors were determined. We did not observe increased 
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Figure 2   SR1 reduces expression of AhRR and increases expression of several 
transcription factors important for NK cell differentiation and NK cell 
effector functions
Cells generated from CD34+ HSPCs in the presence or absence of SR1 were collected at 
different time points. (A) Kinetics of CD56 expression in the cultures used for weekly mRNA 
isolation were determined using FCM. Means ± SEM of 4 - 6 different donors. (B) Expression 
levels of AhRR and transcription factors relative to GAPDH at different time points during 
culture were determined using qRT-PCR. Means ± SEM of 4 – 6 different donors. (C)  Expression 
levels of AhRR and TOX relative to GAPDH after 7 days of culture were determined using 
qRT-PCR. Means ± SEM of 6 different donors. (D) Expression levels of AhRR and transcription 
factors in CD56+ cells which were FACS sorted from cultures after 5 weeks of culture were 
determined using qRT-PCR. Means ± SEM of 4 different donors. *p<0.05. Paired one-tailed 
student’s t-test.
CD56 AhRR TOX
EOMESID2 GATA3
EAT2
A B
C D
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expression of the NK cell differentiation factors TOX, ID2 and EOMES suggesting that 
SR1 increases the number of NK cell progenitors resulting in more NK cells, but it 
does not intrinsically change HSPC-NK cells (Figure 2D). In addition, expression levels 
of GATA-3 and EAT-2 were similar in CD56+ NK cells cultured in the presence of SR1. 
Expression of GZMB and PERF was slightly higher, but not significantly increased. 
Furthermore, IFN-γ was not increased in NK cells cultured in the presence of SR1, but 
these cells were not exposed to target cells prior to mRNA analysis.
 Collectively, these data demonstrate that addition of SR1 to our ex vivo culture 
system blocks function of AhR, resulting in the upregulation of several transcription 
factors that are required for NK cell differentiation and maturation.
SR1-generated HSPC-NK cells have an activated and mature phenotype
To further elucidate the effect of SR1 on NK cell activation status and function, we 
investigated the influence of SR1 on the phenotype of our ex vivo-generated CD56+ 
NK cells. After 35 days of culture in the presence of SR1, NK cell phenotype was 
analyzed using FCM (Figure 3A-D, Supplementary Figure S1C). SR1-generated NK 
cells expressed high levels of NKG2A, which indicates transition between stage 3 
and stage 4 NK cell progenitors.32,33 CD16, important for antibody-dependent cell 
mediated cytotoxicity (ADCC), was expressed on 22.7 ± 2.6% of the CD56+ cells. 
Furthermore, we found high expression levels of the activating markers DNAM-1, 
NKG2D, NCRs, and TRAIL. Expression of KIRs was observed in a low percentage of 
CD56+ cells. However, expression levels were similar as observed for UCB-NK cells 
generated in our culture system.5,6,32 Importantly, our NK cells also expressed high 
levels of CD62L and chemokine (C-X-C motif) receptor 3 (CXCR3), which are involved 
in homing to the lymphoid organs and trafficking of NK cells towards inflammation 
in vivo.7,34,35 Interestingly, presence of CD62L, CXCR3, DNAM-1 and TRAIL were 
significantly higher in CD56+ cells generated in the presence of SR1 (Figure 3C-D). 
Increased expression of DNAM-1 and TRAIL suggests that NK cells generated in the 
presence of SR1 are more active as compared to NK cells generated in the absence 
of SR1. We did not find significant differences in expression of the other molecules in 
the cultures with SR1 compared to the cultures without SR1 (data not shown). 
Altogether, these results indicate that SR1-generated HSPC-NK cells consist of a 
mixture of immature and mature NK cells expressing various activating receptors, 
similarly to our previously described UCB-derived NK cells.6
SR1-generated HSPC-NK cells have efficient IFN-γ production capacity 
and cytolytic activity against AML and MM cells
Next, we investigated the functional activity of SR1-generated NK cells, and 
compared them with NK cells generated in the absence of SR1. After 5 weeks of 
culture, NK cell products were harvested and co-cultured overnight with AML or 
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MM tumor cell lines. Target cell induced IFN-γ production was determined. We 
found that our SR1-generated HSPC-NK cells have a good IFN-γ producing capacity, 
which is improved in cells generated in the presence of SR1 (Figure 4A). Subsequently, 
we compared the killing capacity of NK cells generated in the presence of absence 
of SR1. Therefore, 1 x 104 CD56+ NK cells were co-cultured overnight with different 
AML cell lines. We observed significantly improved killing of K562 and HL-60 cells, 
and also a trend towards improved killing of THP-1 cells by SR1-generated NK cells 
(Figure 4B). To rule out an effect of non-NK cells in the cultures, we repeated the 
Figure 3   NK cells generated in the presence of SR1 have an active and mature 
phenotype
NK cells were generated from CD34+ progenitor cells in the presence or absence of SR1. After 
5 weeks a phenotypical analysis was performed by  FCM. (A) Phenotype of a representative 
NK cell product. Density plot of live cells gated on forward scatter/ side scatter. (B) Expression 
level of several NK cell specific surface antigens on live CD56+ NK cells from 3 – 8 different 
donors (Mean ± SEM) are shown (C) Expression levels of NK cell-specific antigens on CD56+ 
NK cells generated in the presence (grey histograms) or absence (black histogram) of SR1 
from one representative donor as compared to isotype controls (white histogram). Numbers 
represent % positive cells. (D) Expression levels of NK cell-specific antigens on CD56+ NK cells 
generated in the presence or absence of SR1 from 3 - 7 different donors (Mean ± SEM) are 
shown. *p<0.05,  **p<0.01, Paired one-tailed student’s t-test.
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killing experiments using sorted NK cells. Therefore, CD56+ NK cells were sorted 
from the NK cell products after 5 weeks of culture. Next, NK cells were co-cultured 
overnight with AML or MM tumor cell lines as described earlier. Importantly, we also 
observed higher killing of K562, HL-60 and RPMI8226 cells by sorted SR1-generated 
NK cells (Figure 4C). In addition, granzyme B production was enhanced in SR1- 
generated HSPC-NK cells as compared to NK cells generated in the absence of SR1 
(Figure 4D). These results indicate that addition of SR1 to our culture system not only 
increases the number of CD56+ cells we can generate, but also enhances the 
functional activity of the CD56+ NK cells.
 To further confirm the functional activity of SR1-generated NK cells, we 
investigated degranulation of these cells after overnight co-culture with AML or MM 
tumor cell lines. We found marked degranulation of our SR1-generated NK cells 
upon co-culture with the different cell lines (Figure 4E-F). Most efficient degranulation 
was observed against MHCneg K562 cells as well as the MHC-expressing AML cell line 
HL-60. We also observed marked degranulation upon co-culture with the MM cell 
lines U266 and RPMI8226. The MM cell line UM9 was the least potent cell line to 
induce degranulation. 
Figure 3   Continued
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Figure 4   NK cells generated in the presence of SR1 are functionally active
NK cells were generated from CD34+ HSPCs in the presence or absence of SR1. After 5 weeks 
the functional activity of the cells was investigated. (A-F) NK cells were co-cultured overnight 
with the leukemia cell lines K562, HL-60 or THP-1, or the MM cell lines RPMI8226, U266 or UM9 
at an E:T ratio 0.3:1, 1:1 or 3:1. (A) IFN-γ levels were determined by ELISA in the co-culture 
supernatants of 1 x 105 CD56+ NK cells and 1 x 105 target cells. Means ± SEM of 3 – 4 donors 
generated in the presence or absences of SR1 are shown. (B) Specific killing of leukemia cell 
lines at an E:T ratio 0.3:1 was determined in a FCM-based cytotoxicity assay. Means ± SEM of 
3 donors generated in the presence or absence of SR1 are shown. (C-D) After 5 weeks of 
culture, CD56+ NK cells were FACS sorted from the cultures, and co-cultured with leukemia 
cell lines or the MM cell line RPMI8226 at an E:T ratio 1:1. Cultures were supplemented with 
IL-15 (5 ng/ml). (C) Specific killing of the cell lines was determined in a FCM-based cytotoxicity 
assay. Data are depicted as mean ± SD. (D) Granzyme B production by the CD56+ NK cells 
was measured by ELISA. Data are depicted as mean ± SD. (E-F) Degranulation of SR1-generated 
CD56+ cells after co-culture at an E:T ratio 1:1, determined by FCM as the percentage of 
CD107a expressing cells. One representative donor (E) and means ± SEM of 4 - 7 donors (F) 
are shown. (G) Specific killing of leukemia or MM cell lines by SR1-generated NK cells at 
different E:T ratios was determined in a FCM-based cytotoxicity assay. Means ± SEM of 3 – 7 
donors are shown. (H) Specific killing of primary AML cells by SR1-generated NK cells from 5 
different patients (#1 AML-M2, #2 AML-M2, #3 AML-M4, #4 AML-M5, #5 AML-M0) was 
determined for 5 different HSPC donors. Specific killing was determined after 1, 2 and 3 days 
of co-culture in a FCM-based cytotoxicity assay at an E:T ratio of 3:1. Data are displayed as 
mean ± SD of triplicate samples. *p<0.05, ** p<0.01, *** p<0.001. Paired one-tailed (A, B, F) or 
an unpaired two-tailed (C-D) student’s t-test.
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Next, we performed cytotoxicity experiments using SR1-generated HSPC-NK cells 
harvested after 5 weeks of culture. For this, NK cells were co-cultured overnight with 
different CFSE-labeled AML (K562, HL-60 and THP-1) and MM (UM9, U266 and 
RPMI8226) cell lines. The next day, specific killing was determined by FCM. We 
observed very efficient killing of most AML and MM cell lines, even at an E:T ratio of 
1:1 (Figure 4G). Subsequently, we investigated whether patient-derived primary AML 
blasts were susceptible to killing by SR1-induced NK cells. Therefore, we performed 
cytotoxicity assays with AML blasts from 5 different patients. Importantly, AML blasts 
could be potently killed within 3 days of co-culture (Figure 4H). We observed some 
variance in susceptibility between the different patients, but variance between 
HSPC-NK cell donors was small, indicating that the quality of the SR1-induced NK cell 
products is consistent. 
Figure 4   Continued
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Taken together, these data demonstrate that SR1-induced HSPC-NK cells, generated from 
G-CSF-mobilized CD34+ cells, mediate efficient IFN-γ production, degranulation and 
cytolytic activity against hematological tumor cells. Furthermore, as expected by 
increased expression of activating markers, SR1 augments IFN-γ production and 
cytotoxic activity of ex vivo-generated HSPC-NK cells.
HSPC-NK cell proliferation, viability and function is inhibited by 
mycophenolic acid (MPA) but not by cyclosporin A (CsA)
Increased NK cell numbers after non-myeloablative allo-SCT have been associated 
with decreased relapse rates, without an increased risk for GVHD.8,9 Hence, adoptive 
transfer of ex vivo-generated NK cells shortly after allo-SCT is an attractive approach 
to improve patient outcome. Our therapeutic strategy is to apply HSPC-NK cell 
adoptive transfer for high-risk patients treated with non-myeloablative allo-SCT 
(Figure 5A). For this purpose, we want to exploit 15-30 x 106 CD34+ cells from the 
G-CSF-mobilized donor stem cell graft, which represents approximately 5-10% of 
the total graft, for ex vivo NK cell generation. These HSPC-NK cells can be infused as 
a single infusion, or multiple infusions after allo-SCT, to improve the GVT effect. 
However, these allo-SCT patients are treated with immunosuppressive drugs to 
prevent GVHD, so the effect of these drugs on HSPC-NK cell proliferation and viability 
should be known. For that reason, we investigated the effect of CsA and MPA, which 
are often used after non-myeloablative allo-SCT, on SR1-induced NK cells. For this, 
week 5 HSPC-NK cells were cultured for 7 additional days in the presence of absence 
of therapeutic concentrations of MPA or CsA (Figure 5 B-F). After 7 days, we analyzed 
NK cell proliferation and viability using FCM (Figure 5 B-D). We found that proliferation 
of HSPC-NK cells was already inhibited by MPA in a therapeutic concentration of 0.1 
µg/ml. In contrast, CsA, even at a concentration of 1 µg/ml, did not inhibit HSPC-NK 
cell proliferation (Figure 5B-C). In addition, NK cell viability was not affected by CsA, 
while MPA induced dose-dependent cell death (Figure 5D). Next, we investigated 
the effect of MPA and CsA on HSPC-NK cell function. For this, CD56+ NK cells cultured 
in the presence of MPA or CsA were co-cultured overnight with K562 cells at an E:T 
ratio of 1:1. As a control, week 6 CD56+ NK cells were used. We observed impaired 
killing by NK cells cultured in the presence of MPA; however, CsA did not inhibit NK 
cell-mediated killing (Figure 5E). In addition, we observed impaired IFN-γ production 
after incubation with MPA, while incubation with CsA even enhanced IFN-γ 
production (Figure 5F). These data indicate that adoptive transfer of SR1-generated 
HSPC-NK cells can be applied in patients treated with CsA, but infusion should be 
postponed until cessation of MPA therapy. 
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Figure 5   NK cell viability, proliferation and function is inhibited by mycophenolic 
acid (MPA) but not by cyclosporin A (CsA)
(A) Suggested strategy for adoptive transfer of ex vivo generated SR1-NK cells after non-myelo-
ablative allo-SCT. A patient is conditioned with non-myeloablative conditioning; subsequently, 
the patient receives a T cell replete stem cell graft. Ten percent of CD34+ cells of the donor graft 
are used for NK cell generation. To prevent GVHD, patients are treated with MPA and CsA. After 
cessation of MPA (around day 28 after transplantation), NK cells can be infused as a single 
infusion or multiple infusions. (B-F) The effect of immunosuppressive drugs used after non-my-
eloablative allo-SCT was investigated. NK cells were generated from CD34+ HSPCs in the 
presence of SR1. After 5 weeks, NK cells were cultured for 7 more days in the presence or 
absence of different dosages of MPA or CsA. (B) Proliferation of CFSE-labelled NK cells cultured 
in the presence of absence of drugs measured by CFSE dilution in a representative donor. 
(C) Proliferation of NK cells in the presence or absence of drugs measured as CFSE dilution. 
Mean MFI relative to MFI of control cells ± SEM of 4 different donors is shown. (D) The number 
of living cells determined by forward scatter/side scatter and exclusion of 7-AAD positive cells. 
Percentage of living NK cells cultured for 7 days in the presence or absence of drugs. Mean 
viability relative to control cells ± SEM of 4 different donors is shown. (E-F) 1 x 105 CD56+ NK cells 
cultured in the presence or absence of MPA or CsA were co-cultured overnight with K562 cells 
in the presence of IL-15 (5 ng/ml), at an E:T ratio of 1:1. (E) Specific killing of K562 cells was 
determined in a FCM-based cytotoxicity assay. Data are depicted as mean ± SD and are 
representative of 2 different donors. (F) IFN-γ levels were measured in the supernatant after 
overnight co-culture using ELISA. Data are depicted as mean ± SD and are representative of 
2 different donors. ** p<0.01, *** p<0.001, One-way ANOVA.
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NK cells are the first lymphocyte population recovering after allo-SCT, and have 
several important functions shortly after allo-SCT.36 First of all, they are involved in 
defence against viral infections such as cytomegalovirus (CMV) infections,37,38 which 
can cause high morbidity shortly after allo-SCT. Furthermore, high NK cell numbers 
shortly after non-myeloablative and T cell-depleted allo-SCT have been associated 
with reduced relapse rates without an increased risk of GVHD,8,9 indicating that 
allogeneic donor NK cells have specific antitumor activity. Nevertheless, it was 
shown that early engrafting NK cells have decreased cytokine producing capacity.39 
So, in order to further exploit the beneficial effects of NK cells after allo-SCT, 
adoptive transfer of functional and rapidly maturating NK cells would be an attractive 
immuno therapeutic strategy. Since donor-derived NK cells will not be rejected 
post-transplant, multiple NK cells infusions without the need for immunosuppres-
sive chemotherapy to prevent rejection, will be feasible in this setting. However, 
high numbers of functional NK cells of donor origin are needed to apply this strategy. 
Since isolation of sufficient numbers of NK cells from donors, without contaminating 
alloreactive T cells, is challenging; we investigated if high numbers of functional NK 
Figure 5   Continued
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cells could be generated from G-CSF mobilized CD34+ HSPCs, using an ex vivo 
cytokine-based culture protocol. This protocol was developed by our group earlier, 
and high numbers of pure and functional NK cells with in vivo maturation capacity, 
can be generated from UCB-derived CD34+ HSPCs using this GMP-compliant 
protocol.5-7
 We found that NK cell expansion and differentiation from G-CSF-mobilized and 
BM-derived CD34+ cells in the absence of SR1 was very limited, as compared to NK 
cell expansion and differentiation of UCB-derived CD34+ HSPCs observed in our 
previously developed culture protocol. Interestingly, we found that addition of the 
AhR antagonist SR1 to our cultures greatly enhanced NK cell expansion and differen-
tiation. As a result, we can expand G-CSF-mobilized CD34+ cells on average 268-fold 
using our newly developed SR1-based protocol. In addition, SR1-generated NK cell 
products are 83% ± 9% pure. The remaining non-NK cells in the cultures represented 
mainly CD14+ and/or CD15+ mature monocytic and myelocytic cells.  Probably due 
to SR1 addition still some remaining low amount CD34+ cells could be detected. 
However, contaminating CD3+ T cells were either not detectable or at very low 
frequency (0.1% ± 0.1%). Furthermore, we found that SR1-NK cells have a similar 
phenotype as our NK cells previously generated from UCB-derived CD34+ HSPCs, 
which is a highly active phenotype, characterized by expression of high levels of 
activating NK cell receptors.5-7 Interestingly, expression levels of CD62L, CXCR3, 
DNAM-1 and TRAIL were even higher on NK cells generated in the presence of SR1. 
CD62L and CXCR3 are involved in homing to lymphoid organs and trafficking 
towards inflammation in vivo, so high expression of these markers can contribute to 
trafficking of NK cells toward hematological tumor cells in the lymphoid organs.7,34,35 
In addition, it was described that CD62L indicates an unique subset of polyfunctional 
NK cells combining the ability to produce IFN-γ with cytotoxic properties.40 DNAM-1 
and TRAIL are activation markers, increased expression levels of these markers 
suggests that SR1-generated NK cells are more active as compared to NK cells 
generated in the absence of SR1. This was indeed confirmed in functional studies 
showing that SR1-induced NK cells have increased INF-γ production capacity and an 
increased capability to kill AML cell lines, as compared to NK cells generated in the 
absence of SR1. Furthermore, SR1-generated NK cells show efficient degranulation 
against AML and MM cell lines. Besides, even at low E:T ratios, these cells efficiently 
kill hematological tumor cell lines, and most importantly, patient-derived primary 
AML blasts. To further investigate the applicability of our SR1-NK cell product after 
allo-SCT, we investigated the effect of the immunosuppressive drugs MPA en CsA, 
which are commonly used after non-myeloablative allo-SCT, on our SR1-NK cell 
product. Importantly, we found that therapeutic CsA concentrations do not affect 
HSPC-NK cell viability, proliferation or function, while exposure to therapeutic levels 
of MPA did have a negative effect. Exposure to CsA did even enhance IFN-γ 
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production by the HSPC-NK cells. This is in accordance with the effect of CsA and 
MPA on naturally occurring NK cells described in literature.41,42 These results provide 
strong rational to infuse SR1-generated HSPC-NK cells relatively short after allo-SCT, 
since MPA treatment is generally stopped at day 28 after allo-SCT. CsA, which is 
usually prescribed for at least six months, will most likely not affect NK cell viability, 
proliferation or function in vivo upon transfer.
 Several methods to generate NK cell products from donor origin for 
immunotherapy have been reported.43-48 In most studies, NK cells are isolated from 
aphaeresis products using magnetic cell sorting systems. However, poor recovery 
and viability is a common problem in these procedures, therefore NK cells require 
cytokine stimulation and expansion before infusion.2,46-50 NK cell numbers up to 7.6 
x 108 have been reported using this method.49 Nevertheless, large-scale aphaeresis 
procedures are necessary to obtain this amount of NK cells, and contaminating T 
cells can potentially cause GVHD. To circumvent these problems, NK cell generation 
from CD34+ HSPCs is an attractive option. Yoon et al. recently reported safe infusion 
of NK cells generated using a feeder-free 6-week culture procedure after 
HLA-mismatched allo-SCT. Using this procedure, an average number of 9.28 x 106 NK 
cells/kg was generated from 2.22 x 106 donor CD34+ HSPCs/kg.45 In our system, the 
average NK cell expansion from CD34+ HSPCs was 235 fold (range 115 – 904 fold). 
Therefore, if we use 10% of the G-CSF-mobilized CD34+ HSPCs isolated from donors 
for allo-SCT, we will have on average 0.5 x 106 CD34+ cells/kg. In case of a 70 kg 
donor and patient, we will get on average 8 x 109 NK cells (> 1 x 108 NK cells/kg). 
So we will be able to infuse large numbers of NK cells from donor origin using our 
SR1 based NK cell generation protocol.
 In the present study, we showed that the AhR antagonist SR1 greatly enhances 
NK cell expansion and differentiation. AhR is a ligand-inducible transcription factor 
which has extensively been studied in the context of its activation by environmental 
pollutants, such as dioxins and polycyclic aromatic hydrocarbons.51,52 Until recently, 
little was known about the physiological role of AhR, but a growing body of evidence 
shows that AhR has multiple endogenous activators,15 and is involved in several 
physiological processes.22,53,54 Examples of endogenous ligands are metabolites of 
dietary substances15,55 and tryptophan metabolites like cinnabarinic acid,56 
6-formylindolo[3,2-b]carbazole (FICZ), which can be produces in the skin upon light 
exposure,57 and the indoleamine 2,3-dioxygenase 1 (IDO1)-metabolite kynurenin.58 
AhR also regulates differentiation of various immune cells like T helper 17 (TH17) 
cells,22 dendritic cells,17,18 regulatory T cells19,20 and γδ T cells.21 Recently, Hughes et 
al. reported that antagonism of AhR promotes differentiation of immature innate 
lymphoid cells into NK cells expressing EOMES and TBET.23 In our SR1-based 
HSPC-derived NK cell culture, we also observed up-regulation of EOMES, which is 
involved in NK cell maturation,29 and additionally we found upregulated expression 
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of TOX, ID2, GATA-3 and EAT-2 after AhR inhibition. TOX is important for early NK cell 
development,27 ID2 is involved in NK cell maturation28 and GATA-3 and EAT-2 are 
important for NK cell effector functions.30,31 Interestingly, expression of TOX 
markedly decreased in the first week of culture in our culture system in the absence 
of SR1. In the presence of SR1, TOX expression is more preserved, resulting is 
significantly higher TOX expression after one week. This suggests that before 
induction of differentiation by addition of IL-15, early NK cell progenitors are 
expanded in the presence of SR1, explaining increased NK cell numbers generated 
in the presence of SR1, IL-15 and IL-2. To our knowledge, this is the first report of an 
applying AhR blocking in an in vitro system to generate high numbers of functional 
NK cells. 
 In conclusion, we developed a cytokine-based ex vivo culture system, which 
enables us to generate high numbers of very potent NK cells from G-CSF mobilized 
CD34+  HSPCs. Addition of SR1 to the culture system induced up-regulation of 
multiple NK cell-related transcription factors, and resulted in generation of  NK cell 
products with very high cell numbers and purity. These NK cells have an active 
phenotype and are highly functional in vitro, therefore they hold great promise for 
future adoptive HSPC-NK cell therapy after allo-SCT.
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Figure S1   SR1 enhances expansion and NK cell differentiation of bone 
marrow-derived CD34+ HSPCs, thereby NK cells with a mature and 
active phenotype can be generated
CD34+ HSPCs were isolated from bone marrow samples. The cells were cultured for 5 weeks 
in the ex vivo cytokine-based culture protocol described in the Materials and Method section 
and Figure 1A. (A) Kinetics of differentiation and expansion of CD56+ cells in the presence or 
absence of 2 µM SR1 from one representative donor. (B) Summary of total expansion, NK cell 
yield (calculated by [total expansion x percentage of CD56+ cells]/100), and NK cell differentiation 
after 5 weeks of culture in our ex vivo culture protocol in the presence or absence of 2 µM SR1 
in 4 donors. (C) After 5 weeks of culture, expression of NK cell markers was analyzed using 
FCM. Expression levels and MFI of several NK cell specific surface antigens on living cells. 
Mean ± SEM of 2 – 3 different donors are shown. Paired one-tailed student’s t-test.
A
B
C
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Abstract
Cellular immunotherapy can be an effective adjuvant treatment for multiple 
myeloma (MM), as demonstrated by induction of durable remissions after allogeneic 
stem cell transplantation. However, anti-myeloma immunity is often hampered by 
suppressive mechanisms in the tumor micro-environment resulting in relapse or 
disease progression. To overcome this immunosuppression, new cellular immuno-
therapies have been developed, based on the important effector cells in 
anti-myeloma immunity, namely T cells and natural killer cells. These effectors can 
be modulated to improve their functionality, activated by dendritic cell vaccines, or 
combined with immune stimulating antibodies or immunomodulatory drugs to 
enhance their efficacy. In this review, we discuss promising pre-clinical and clinical 
data in the field of cellular immunotherapy in MM. In addition, we address the 
potential of combining these strategies with other therapies to maximize clinical 
effects without increasing toxicity. The reviewed therapies might pave the way to 
effective personalized treatments for MM patients.
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Introduction
Multiple myeloma (MM) is an aggressive plasma cell disease, which accounts for 
approximately 10% of all hematologic neoplasms.1 In Western countries, the annual 
incidence is 5.4 cases per 100,000 persons.2 MM is characterized by clonal 
proliferation and accumulation of malignant plasma cells in the bone marrow (BM) 
and a high concentration of monoclonal immunoglobulin light and/or heavy chains 
in the blood or urine. This results in organ damage and clinical symptoms including 
anemia, bone pain, renal insufficiency, hypercalcemia and infections.3 Over the past 
decade overall survival (OS) has improved significantly, especially in younger 
patients, because of the introduction of novel therapies like immunomodulatory 
drugs and proteasome inhibitors before and after autologous hematopoietic stem 
cell transplantation (SCT). Currently, the average 10-year OS is approximately 17% for 
all ages, and in patients younger than 60 years the 10-year OS is about 30%.4 
 Current treatment of young patients, generally defined as 65 years of age or 
younger, consists of induction therapy followed by autologous SCT. The induction 
therapy can reduce tumor mass and create a state of minimal residual disease (MRD). 
Initially, it consisted of conventional chemotherapy, however, nowadays immuno-
modulatory derivates (IMiDs), like thalidomide and lenalidomide and the proteasome 
inhibitors like bortezomib are combined with chemotherapy. These new combination 
therapies improved the complete response (CR) rates, which are correlated with 
improved progression-free survival.5 After induction therapy, patients are treated 
with high dose melphalan in order to destroy residual tumor cells, followed by 
autologous stem cell rescue6
 Older patients more often have a poor performance status and suffer from co-
morbidities. Although it has been shown that autologous SCT is feasible in patients 
up to 75 years of age with good performance status,7 benefits for older patients 
have not been demonstrated in clinical trials as these patients are often excluded.8 
Therefore, patients above 65 years of age are generally excluded from autologous 
SCT.7 Traditionally, older patients were treated with melphalan and prednisone (MP). 
In recent years, phase III randomized trials in patients not eligible for SCT have 
investigated the combination of MP plus thalidomide or lenalidomide, or proteasome 
inhibitors, like bortezomib and recently carfilzomib, on outcome. These studies, 
demonstrated improved progression-free survival (PFS) in patients with combined 
therapy.9 MP was compared with the combination of MP and thalidomide (MPT) in 
a meta-analysis using pooled data of 1682 patients treated in 6 different trials. 
Median OS was 32.7 (95% CI 30.4-36.5) months in the MP arm and 39.3 (95% CI 35.6 
– 39) months in the MPT arm. Median PFS was 14.9 (14.0 – 16.6) in the MP arm and 
20.4 (18.8-21.6) months in the MPT arm.10 The largest MP-based phase III study so far, 
the VISTA (Velcade as Initial Standard Therapy) trial, investigated combination of MP 
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with bortezomib (VMP) in 682 patients. Time to progression in the VMP group was 
24.0 months, as compared to 16.6 months in the MP group (P<0.001). Furthermore 
CR rates were 30% and 4%, respectively (P<0.001).11 After 3 years, OS rates were 
68.5% in the VMP group versus 54.0% in the MP group.12 However, despite these 
improvements in MM treatment, OS is still poor and most patients eventually 
experience relapse of the disease. Therefore, additional potent therapeutic strategies 
are urgently needed. 
 In this review, we will discuss promising novel cellular immunotherapeutic 
therapies, which could improve outcome in MM patients with reduced side effects. 
We will first describe how allogeneic SCT, which is the oldest immunotherapeutic 
strategy in MM, indicated the importance of the immune system in targeting MM. 
Secondly, we will explain how MM can progress or relapse by evasion of the immune 
system. Finally, we will address how different cellular immunotherapeutic strategies, 
alone or in combination with other therapies, can circumvent immune evasion and 
thereby improve anti-myeloma immune responses.
Lessons from Allogeneic SCT 
Hematopoietic SCT is a well-established treatment for MM patients. In autologous 
SCT, stem cells are isolated from the patients themselves and may contain residual 
tumor cells, which can cause relapse of the disease. Additionally, malignant plasma 
cells that survive the high dose melphalan may cause relapse of the original disease. 
In allogeneic SCT, stem cells are derived from a Human Leukocyte Antigen 
(HLA)-matched healthy donor and a potent graft-versus-myeloma (GVM) response 
can be induced. This response can eliminate residual tumor cells in the patient, 
thereby resulting in long-term remission and potentially even cure of the disease. 
However, allogeneic SCT is curative only in a minority of MM patients, and treat-
ment-related mortality (TRM) is generally high.
 Important immune effectors involved in the GVM response are T cells and 
Natural Killer (NK) cells. T cells can recognize specific antigens presented by HLA 
molecules via their T cell receptor (TCR). When T cells encounter their cognate 
antigens and receive appropriate co-stimulation, they become activated and acquire 
effector functions. In MM, T cell responses can be induced towards the tumor 
specific immunoglobulin idiotype (Id) protein and/or tumor-associated antigens 
(TAAs). These latter are antigens expressed at high levels by the tumor cells, but 
generally also at low levels by normal cells which limits their immunogenicity.13 
Important TAAs in MM are cancer germline antigens (CGAGs), like Mage, Gage, Lage 
and NY-ESO-1,14 Survivin,15 BCMA16 and MUC1.17 Moreover, in the allogeneic SCT 
setting potent immune responses can be generated against recipient-specific 
514292-L-bw-Roeven
Processed on: 6-10-2017 PDF page: 177
177
Immunotherapeutic approaches in multiple myeloma
7
allo-antigens, known as minor histocompatibility antigens (MiHAs). MiHAs are 
polymorphic peptides derived from intracellular proteins that are presented by HLA 
molecules, and differ between donors and recipients. Numerous MiHAs have been 
identified in the past decades and T cell responses against these MiHAs have been 
associated with improved relapse-free survival. While in some studies the induction 
of MiHA-specific T cell responses was associated with an increase in the incidence of 
GVHD and improved relapse-free survival,18-21 other studies could not confirm these 
results.22,23 Importantly, boosting of T cell responses against MiHAs with a hemato-
poietic-restricted expression pattern, e.g. HA1,24 LRH1,25 ARHGDIB26 and UTA2-127 
has the potential to induce a selective GVM effect with only limited risk of eliciting 
GVHD. Therefore, these MiHAs are interesting candidates for targeted immunotherapy.
 The other important immune effectors are NK cells, which are part of the innate 
immune system. Their activation is regulated by the balance in expression levels of 
numerous inhibitory and activating receptors. The most well characterized inhibitory 
receptors are the killer immunoglobulin-like receptors (KIR) and NKG2A. KIR receptors 
can bind to HLA-A, -B and -C molecules, while NKG2A binds to HLA-E. Examples of 
activating receptors are CD16, which is involved in antibody-dependent cytotoxicity 
(ADCC), activating KIRs (e.g. KIR2DS, KIR3DS), NKG2D, DNAX accessory molecule-1 
(DNAM-1) and the natural cytotoxicity receptors (NCRs). These latter receptors can 
interact with ligands, like UL16-binding protein (ULBP)1-4, MHC class I chain-related 
protein A (MIC-A) and Nectin-2, that are expressed during infections or stress. In 
homeostasis, NK cells are inhibited by their inhibitory receptors recognizing self HLA 
class I molecules. On the other hand, GVM effect can be induced by up-regulation 
of activating ligands or down-regulation of MHC Class I molecules. In addition, in the 
setting of allogeneic SCT, donor NK cells may lack expression of inhibitory KIRs for 
recipient MHC Class I molecules and hence be activated. This phenomenon is called 
missing-self recognition and can contribute to the GVM effect.28,29 Nevertheless, 
this effect is usually limited because in allogeneic SCT donor and recipient are 
matched for their HLA molecules. This is essential to prevent induction of severe 
alloreactive T cell responses against healthy tissues expressing foreign HLA molecules 
causing graft-versus-host disease (GVHD).30 
 Despite the immune susceptibility of MM, the OS after allogeneic SCT was not 
improved compared to autologous SCT. This was mainly due to high TRM after 
allogeneic SCT consisting of conditioning-related toxicity, infections and GVHD.31,32 
Furthermore, relapse rates were still high. In recent years, transplant-related toxicity 
decreased significantly due to the introduction of reduced intensity conditioning 
(RIC) chemotherapy regimens, but unfortunately OS did not improve due to higher 
relapse rates.33 In order to reduce the incidence and severity of GVHD, complete and 
partial T cell-depleted allogeneic SCT programs have been developed. After six 
months, when the treatment-related inflammation has resolved, GVM responses 
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can be boosted by giving donor lymphocyte infusions (DLI).34 Furthermore, DLI can 
also be an effective therapy in relapsed MM.35
 RIC allogeneic SCT has been compared to autologous SCT in six large trials.36-41 
Two trials reported a survival benefit for patients receiving allogeneic SCT. The first 
was performed by the Italian GIMEMA group and found a median OS of 80 months 
in 80 patients in the allogeneic SCT group compared to 54 months in 82 patients in 
the autologous SCT group.37 In addition the EBMT observed improved OS after 6 
years in 108 patients who underwent autologous/allogeneic SCT (auto/alloSCT) 
compared to 249 patients receiving only autologous SCT (49% vs. 36%, P=0.030).40 
Four trials did not show improved OS after allogeneic SCT. The first study was 
performed by Garban et al.36 who observed a trend towards better OS in the 
autologous group at 56 months (OS 48 vs. 34 months, P=0.07),42 however high dose 
anti-thymocyte globulin (ATG) was part of the conditioning regimen. The PETHEMA 
study included patients not achieving a CR after a first autologous SCT and found no 
difference in OS after 5 years (autologous vs. allogeneic = 60% [95% CI 48.3%-73%] 
vs. 61.8% [95% CI 40.6%-82%].38 The BMT CTN study compared auto/alloSCT in 226 
patients with double autologous SCT in 484 patients. OS survival was 77% in the 
auto/alloSCT-group and 80% in the double autologous SCT-group after three years, 
however this follow-up period is still relatively short, as the EBMT trial only observed 
improved OS after six years.41 In a study by the Dutch HOVON Group 115 patients 
who underwent a single autologous SCT followed by maintenance therapy 
consisting of α-interferon or thalidomide were compared to 99 patients with an 
auto/alloSCT with a follow-up of 6 years. After 6 years, PFS was prolonged in patients 
who underwent allogeneic SCT compared to autologous SCT (HR 0.75, 95% CI = 
0.55-1.03, P=0.07), however OS was not different.39 Remarkably, survival rates of the 
autologous SCT-group in this study were better than those in other studies. An 
explanation for this could be that one of the novel agents, thalidomide, bortezomib 
or lenalidomide could have been given to patients with relapsed disease. These 
compounds can significantly prolong survival of relapsed patients, therefore the 
survival benefit for allogeneic SCT will only become clear very long time after trans-
plantation. Therefore, allogeneic SCT is currently not considered first line treatment 
for MM patients.43
Immune escape in multiple myeloma
Despite the high immunogenicity of MM, as demonstrated with allogeneic SCT, still 
too many patients relapse after initial therapy. This might be the result of immune 
evasion mechanisms exploited by the tumor cells, including intrinsic alterations and 
the establishment of an immunosuppressive milieu thereby limiting the efficacy of 
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immune effector cells.44 Here, we will discuss which mechanisms can be involved in 
immune escape of MM (Figure 1).
Defects in antigen processing and presentation
Presentation of the tumor antigen is essential for the induction of tumor-reactive T 
cell responses. In order to activate T cells, the TCR:CD3 complex should interact with 
the HLA-antigen complex presented on antigen presenting cells (APCs).44 It has 
been described that antigen expression can be down-regulated by tumor cells. 
Figure 1   Mechanisms involved in immune escape in Multiple Myeloma
Multiple myeloma can inhibit efficient immune recognition and destruction via multiple 
direct and indirect mechanisms. These include impaired antigen presentation, signaling via 
co-inhibitory molecules, secretion of immunosuppressive factors and recruitment of 
suppressive immune cells. HLA, human leukocyte antigen; Th2 cell, T helper 2 cell; IDO, 
indoleamine 2,3-dioxygenase; TGF-β, transforming growth factor-β; sMIC-a, soluble major 
histocompatibility antigen class I polypeptide-related sequence A; IL-6, Interleukin-6; NK cell, 
natural killer cell; CTLA-4, cytotoxic T lymphocyte associated antigen-4; PD-1, programmed 
death-1; BTLA, B and T lymphocyte attenuator.
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Furthermore, defects in components of the antigen presentation machinery can 
occur, including the transporter associated with antigen processing-1 (TAP-1) and 
subunits of the immunoproteasome (LMP-2, LMP-7).45 In addition, tumor cells can 
down-regulate or even lose expression of HLA class I proteins, due to deletions in 
chromosome 6, where HLA alleles are located, or due to mutations in the β2-micro-
globulin, an essential molecule for stable HLA expression on the cell surface.46 All 
these modifications contribute to invisibility of the tumor cells, thereby hampering 
efficient recognition by tumor-reactive T cells. 
Signaling via co-inhibitory molecules
In addition to presentation of the antigen by an APC, T cells need a second signal 
provided by co-stimulatory molecules of the B7/CD28 family in order to become 
activated. Together, these two signals trigger expansion and differentiation of the T 
cells, and induce acquisition of effector functions. Following T cell activation, 
expression levels of co-inhibitory molecules like Cytotoxic T lymphocyte associated 
antigen-4 (CTLA-4), B and T lymphocyte attenuator (BTLA) and Programmed death-1 
(PD-1) are up-regulated. Ligation of these receptors to their corresponding ligands 
on APCs results in functional inhibition of the T cells. Via this natural feedback loop 
sustained T cell activation is prevented and the effector T cell response is resolved.47 
However, tumor cells can up-regulate co-inhibitory molecules and down-regulate 
co-stimulatory molecules to acquire an immune inhibitory phenotype and thereby 
prevent productive tumor-reactive T cell responses. In MM increased expression 
levels of the co-inhibitory ligands of PD-1, BTLA and CD200R have been observed on 
MM cells.47-50 Moreover, interference with BTLA signaling using blocking antibodies 
can augment proliferation of tumor-reactive CD8+ T cells stimulated with peptide- 
loaded HVEM+ DCs49 and small interfering RNA (siRNA) mediated silencing of PD-L1 
and PD-L2 on DCs enhances their potential to stimulate T cell proliferation and 
cytokine production.51 In addition to the B7/CD28 family members, MM cells can 
also express other inhibitory molecules, like carcinoembryonic antigen-related cell 
adhesion molecule-6 (CEACAM-6), an immunoglobulin-like receptor. It has been 
shown that increased expression of CEACAM-6 in MM resulted in inhibition of 
anti-myeloma T cell responses.52 
Secretion of immunosuppressive factors
Another way to evade the immune system is creation of an immunosuppressive 
microenvironment by secretion of immune inhibitory factors like soluble MIC-A, 
interleukins (IL), transforming growth factor (TGF)-β and indoleamine 2,3-dioxy-
genase (IDO). Increased levels of these factors have been detected in serum of MM 
patients.53-56 Secretion of soluble MIC-A by MM cells can mediate inhibition of NK 
cells and CD8+ T cells by down-regulation of NKG2D, and is associated with poor 
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survival.54,55 Moreover, IL-6 producing tumors can directly impair NK cell cytotoxicity 
and can stimulate IL-10 production in MM cells.57,58 This IL-10 can suppress dendritic 
cell (DC) function and induce the development of Th2 T cells, which are less effective 
in supporting tumor-reactive cytotoxic T cell formation and function than the Th1 
counterparts.44 Furthermore, interferon (IFN)-γ production by NK cells, which is 
important for their killing capacity, is inhibited by IL-10.59 In addition, TGF-β can 
down-regulate expression of activating NK cell receptors, such as NCRs and NKG2D, 
and also inhibits IFN-γ production by NK cells, as well as T cells. Additionally, other 
effector molecules like perforin are down-regulated and DC activation can be 
blocked by TGF-β.60 Finally, IDO is an enzyme that catalyzes metabolization of the 
essential amino acid tryptophan resulting in tryptophan depletion in the tumor 
micro environment. This causes cell cycle arrest and apoptosis of effector T cells.61 
Recruitment of suppressive immune cells
Beside apoptosis of T cells, IDO and also IL-10 and TGF-β can recruit or induce 
suppressive immune cells like M2 macrophages, regulatory T cells (Tregs) and 
myeloid- derived suppressor cells (MDSCs). Tregs are characterized by expression of 
CD25 and transcription factor FOXP3 and are capable of inducing expression of 
co-inhibitory molecules on APCs and IDO production by APCs. In addition, they 
produce IL-10 and TGF-β themselves, and have the potential to kill APCs and 
cytotoxic T cells via perforin- and granzyme-dependent pathways.62,63 Increased 
levels of Treg subsets have been observed in blood of MM patients and were 
associated with increased disease burden and poor survival.56,64 Other suppressive 
cell types are MDSCs and M2 macrophages. MDSCs are a heterogeneous subset of 
immature myeloid progenitor cells, characterized by expression of CD33 and CD11b, 
and lack of CD14 and HLA-DR expression. M2 macrophages have an IL12loIL-10hiIL-1de-
coyRhiIL-1RAhi phenotype and express scavenger receptors such as the mannose 
receptor (CD206) and hemoglobin/haptoglobin scavenger receptor (CD163) on 
their cell surface65. MDSCs and M2 macrophages can suppress both T cell and NK 
cell mediated immune responses by arginine depletion due to catabolism by 
arginase-1, and nitric oxide production by inducible nitric oxygen synthase.66,67 
Increased numbers of MDSCs have been observed in the blood and BM of MM 
patients. Notably, it has been demonstrated that MM cells can induce development 
of MDSCs from healthy donor peripheral blood mononuclear cells (PBMCs).68,69 In 
one study in 68 patients, increased numbers of M2 macrophages, characterized by 
expression of CD163 and CD68, in the BM of MM patients, were associated with an 
unfavorable prognostic impact on 6-year OS.70 
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T cell based immunotherapy
To overcome immune escape, resulting in improved PFS and OS in MM patients, 
potent cellular immunotherapies boosting T or NK cell-mediated immunity can be 
exploited. These highly potent immune effectors can be given either as single 
therapy, or in combination with immune stimulating antibodies or immunomodula-
tory drugs (Figure 2). First, we will address promising T cell based therapies, and in 
the next part we will discuss interesting NK cell based therapies. An overview of the 
reported and ongoing clinical trials in MM patients is given in Table 1.
Chimeric Antigen Receptor (CAR)-Modified T cells 
The presence of circulating T cells specific for myeloma-associated antigens has 
been correlated with increased OS in MM patients, indicating the importance of 
exploiting myeloma-reactive T cells to further improve outcome.71 However, the 
isolation and expansion of these low frequent T cells for adoptive transfer is 
challenging. Therefore, genetic modification of T cells by induction of CARs is a 
promising alternative. These CARs consist of a single chain variable fragment, 
derived from a monoclonal antibody specific for a tumor specific protein, fused to 
native human T cell receptor CD3ζ signaling domains. The 2nd and 3rd generation 
CARs have one or more additional activating signaling domains derived from 
co-stimulatory molecules such as CD28, 4-1BB and OX40. Very promising results 
have been obtained in pilot studies using CD19-reactive CAR-T cells in CD19 
expressing B cell leukemias and lymphomas.72-74 Kochenderfer et al.74 infused 
8 patients with either advanced chronic lymphocytic leukemia or B cell lymphoma 
with 0.3 to 3x107 CAR-T cells/kg in combination with IL-2, after conditioning with 
cyclophosphamide and fludarabine. Importantly, six patients obtained remission 
showing the potent anti-tumor efficacy of this CAR-T cell therapy. However, 4/8 
patients showed long-term depletion of normal polyclonal CD19+ B-lineage cells. 
Furthermore, 4 patients had prominent elevations in serum levels of IFNγ and TNFα 
resulting in acute toxicity. Other studies also reported chronic hypogammaglobulin-
emia72,73 and delayed tumor lysis syndrome.72 In order to improve safety, new 
methods to ablate CAR-T cells are being developed, like the incorporation of a 
suicide gene that encodes human caspase-9 fused to a modified human FK-binding 
protein that confers sensitivity to a synthetic small molecule.75
 For the treatment of MM various CARs have been developed. For instance, T 
cells can be transfected with a chimeric NKG2D receptor. MM cells express the 
corresponding ligands, which enhance NK cell and CD8+ T cell mediated lysis. 
Infusion of these NKG2D-expressing CAR-T cells induced tumor reduction in a 
mouse model.76 Even though most healthy tissues do not express NKG2D ligands, 
low levels of NKG2D ligands could potentially induce toxicity in patients. Therefore, 
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more specific targets are probably warranted. In this regard, expression of the 
carbohydrate antigen Lewis(Y) has been detected on 52% of plasma cells in BM 
samples of MM patients, while it is expressed in very low levels on healthy tissues.77 
In a mouse model delayed growth of myeloma xenografts was observed in NOD/
Figure 2   Cellular immunotherapeutic approaches in multiple myeloma
To improve survival in multiple myeloma patients, several cellular immunotherapies boosting 
NK cell and T cell mediated immunity, can be exploited. NK cells can be isolated or generated 
ex vivo, and can subsequently be used for adoptive transfer. The efficacy of NK cell-based 
therapy can be enhanced by the introduction of tumor-targeting CARs.  Furthermore, 
combination with antibodies like anti-KIR or anti-CS1, or anti-myeloma drugs further boost 
anti-myeloma NK cell immunity. Adoptive T cell transfer after allogeneic stem cell transplan-
tation can induce complete remission in MM patients. In addition adoptive transfer 
CAR-modified T cells might be even more specific and effective. Tumor specific T cells can 
also be expanded in vivo following DC vaccination. Silencing of co-inhibitory molecules like 
PD-L by silencing RNA, can further increase efficacy of DC vaccination. Finally, interference 
with co-inhibitory pathways using blocking antibodies like anti-PD1 is a promising strategy 
to increase the therapeutic effect. NK cell, Natural Killer cell; CAR, Chimeric Antigen Receptor; 
HDAC, Histone Deacetylase; PD-L, Programmed Death-ligand; DC, Dendritic Cell; anti-PD-1, 
anti-Programmed Death-1; anti-KIR, anti-Killer Immunoglobulin-like Receptor.
T cell
Multiple Myeloma cell PD-L  silenced DC
ex vivo NK
Adoptive NK cell
transfer
CAR-NK
Antibody therapy
anti-KIR
anti-CS1
anti-PD-1
Adoptive T cell
transfer
CAR-T
DC/myeloma fusion
Dendritic cell
vaccination
Immunomodulatory
drugs
Proteasome 
inhibitors
IMiDs
HDAC
inhibitors
514292-L-bw-Roeven
Processed on: 6-10-2017 PDF page: 184
184
Chapter 7
Table 1  Clinical trials in the field of immunotherapy in MM
Therapy Patients Outcome Reference/Trial name
T cell based therapy
Id-pulsed DC vaccination After autologous SCT 2/12 Id-specific T cell proliferation ex vivo, and durable CR 81
Id-pulsed DC vaccination, followed by s.c. Id-KLH After autologous SCT 4/26 Id-specific T cell proliferation ex vivo, no increase in anti-Id titer 82
Id-pulsed DC vaccination Pretreated advanced MM 4/10 Id-specific T cell IFN-γ production, 3/10 increased anti-Id titer 83
Id-pulsed, CD40 ligand matured DC vaccination Smoldering or stable MM 5/9 Id-specific cytotoxic T cell proliferation ex vivo, 7/9 DTH reaction 84
Id-pulsed DC vaccination Stage-I MM, no treatment 5/9 Id-specific T cell proliferation ex vivo, 3/9 decreased M protein 85
TAA (MAGE3, BCMA, survivin) mRNA loaded DC vaccination Stage-II/III MM with CR, VGPR or PR 
after intensive chemotherapy
6/12 DTH reaction, 2/6 TAA-specific T cells from DTH 88
DC/MM cell fusion vaccination + GM-CSF Active MM, ≥ 20% plasma cells in 
bone marrow
11/15 increased number of tumor-reactive T cells, 11/16 stable disease 
after vaccination
90
DC/MM cell fusion vaccination Patients after autologous SCT and 
patients before and after autologous 
SCT
24% conversion from PR following transplantation to CR/near CR after 
vaccination
91
Anti-PD1 (nivolumab) Relapsed/refractory MM 63% stable disease, median duration 11.4 weeks 96
Anti-PD1 (CT-011) + DC/MM fusion vaccination After autologous SCT Ongoing NCT01067287
NK cell based therapy
Haplo-identical KIR matched NK cells + IL-2 Relapsed MM, melphalan/ fludarabin 
conditioning
RR 50% in treated patients vs. 40% in control patients 111
Anti-KIR (IPH2101) Relapsed/ refractory MM >90% KIR occupancy 119
Anti-KIR (IPH2101) + Lenalidomide Relapsed MM 2/15 VGPR, 3/15PR 120
Anti-KIR (IPH2101) Stable PR after first line therapy Ongoing NCT00999830
Anti-KIR (IPH2101) Smoldering MM No clinical responses 121
Elotuzumab Relapsed/ refractory MM 26.5% disease stabilization 125
Elotuzumab/ Lenalidomide/ Dexamethason Relapsed/ refractory MM 82% RR (23/28) 126
Elotuzumab/  Bortzomib Relapsed/ refractory MM 48% RR (13/27) 127
Elotuzumab/ Bortzomib/ Dexamethason Newly diagnosed, high risk MM Ongoing NCT01668719
Elotuzumab/ Bortzomib/ Dexamethason Relapsed/ refractory MM PFS E/B/D vs. B/D  9.7 vs. 6.9 months 128
Elotuzumab/ Lenalidomide/ Dexamethason Newly diagnosed, high risk MM Ongoing NCT018916430
Elotuzumab/ Lenalidomide/ Dexamethason Relapsed/ refractory MM PFS E/L/D vs. L/D  19.4 vs. 14.9 months 129
BCMA, B cell maturation antigen; CR, complete response; DC, dendritic cell; DTH, delayed type 
hypersensivity; Id, idiotype; GM-CSF, granulocyte macrophage colony-stimulating factor; KIR, killer im-
munoglobulin-like receptor; KLH, keyhole limpet hemocyanine; MM, multiple myeloma; PD-1, 
programmed death-1; PFS, progression-free survival; PR, partial response; RR, response rate; SCT, stem 
cell transplantation; TAA, tumor associated antigen; VGPR, very good partial response.
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SCID mice treated with CAR-T cells directed against Lewis(Y).78 Safety of the Lewis Y 
CAR is currently investigated in a phase I trial in AML, myelodysplastic syndrome 
(MDS) and MM patients (NCT01716364). The results of the first four patients have 
been published with some evidence of activity and homing of the T cells to sites of 
disease involvement.79 Notably, due to the relatively low expression levels of Lewis(Y) 
on MM cells there is a potential risk of immune escape. Hence, B cell maturation 
antigen (BCMA) might be a more suitable target, as it is uniformly and highly 
expressed on MM cells and expression is absent on normal tissues, except for normal 
plasma cells. Preclinical studies have shown that CAR-T cells specific for BCMA are 
able to eradicate human MM cell line tumors in immunodeficient mice. These data 
indicate that adoptive transfer of CAR-T cells directed against BCMA might be an 
interesting approach for the treatment of MM.80
Dendritic cell vaccination
Another strategy to boost anti-myeloma T cell immunity in MM patients is DC 
vaccination. DCs are the most potent professional APCs, and therefore they an 
attractive way to expand myeloma-reactive T cells in vivo. Reichardt et al. were the 
first to explore DC vaccination in MM patients.81 In this pioneering study, 12 patients 
were treated with blood-derived precursor DCs, cultured for 36-48 hours in the 
presence of the Id protein. Two out of twelve patients developed an Id-specific 
proliferative T cell response and remained in complete remission. Moreover, one 
patient developed a transient Id-specific cytotoxic T cell response. Following this 
first report, multiple clinical studies have investigated Id-pulsed DCs and showed 
that these DCs are capable of inducing humoral and cellular immune responses 
against the Id protein with limited toxicity.82-84 However, clinical efficacy was 
disappointing. A possible explanation could be that most of these studies were 
performed in patients with advanced disease. Nevertheless, one study in stage-I 
myeloma also showed a decrease in M-protein in only 3 out of 9 patients.85 
Furthermore, most studies have been performed using relatively immature DCs, 
while it has been shown that mature DCs are superior in the induction of anti-tumor 
immunity.86 Another explanation could be the lack of Id-specific T cell precursors in 
MM patients, due to tolerance and deletion as a result of high amounts of secreted 
free protein.87 Consequently, other TAAs can be targeted to improve DC vaccination. 
 Recently, we performed a phase 1 clinical trial in which we evaluated safety and 
immunological effects of mature DCs pulsed with TAA mRNA, specific for MAGE3, 
Survivin and BCMA, in twelve MM patients with a CR or partial response (PR) after 
high-dose chemotherapy and autologous SCT.88 Loading with TAA RNA results in 
processing of both class I and II epitopes, and hence has the potential to induce a 
broad TAA-reactive T cell repertoire.89 In all patients vaccination was well tolerated 
with limited toxicity. Importantly, in two patients vaccine-specific T cells were 
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detected, illustrating that TAA-mRNA-loaded mature DCs are capable of inducing 
TAA-reactive T cell responses in MM patients after autologous SCT. Another strategy 
to achieve presentation of a broad panel of MM antigens is the use of autologous 
DC/MM cell fusion vaccines. These vaccines expanded circulating CD4+ and CD8+ 
cells reactive to autologous MM cells, and were demonstrated to stabilize disease in 
11 out of 16 MM patients with advanced disease in a phase I study.90 In a phase II 
study, where patients were vaccinated with DC/MM cell fusion vaccines after 
autologous SCT, 24% of the patients who achieved a PR upon transplant converted 
to complete remission/near complete remission (CR/nCR) following vaccination.91 
In order to further augment the activation and expansion of anti-myeloma T cells, 
DC vaccination may be combined with strategies that interfere with immunosup-
pressive mechanisms exploited by MM cells. We recently showed that siRNA 
mediated silencing of programmed death ligand-1 (PD-L1) and PD-L2 on mono-
cyte-derived DCs resulted in generation of DCs with superior potential to stimulate 
tumor-reactive T cell responses ex vivo.51,92 
Anti-PD-1
Besides using PD-L siRNAs, DC vaccine efficacy can also be improved by combination 
with blocking antibodies targeting the PD-1/PD-L co-inhibition pathway. Incubation 
of DC/MM cell fusions with anti-PD-1 antibody (CT-011) and subsequent co-culture 
with autologous T cells, resulted in reduced numbers of regulatory T cells, increased 
levels of Th1 T cells and augmented tumor killing in ex vivo cytotoxicity assays.93 
Currently, the combination therapy of DC/MM cell fusions with CT-011 after 
autologous SCT is being investigated in MM patients (NCT01067287). Recently, a 
phase I clinical trial investigating CT-011 in patients with varying hematological 
malignancies, including one patient with MM, has been finished. CT-011 proved to 
be safe, and a clinical benefit was observed in 33% of 17 patients. Patients showed 
increased CD4+ T cell counts without further evidence of T cell activation.94 In 
addition to improved T cell immunity, Benson et al.95 showed that NK cell-mediated 
killing of MM cells can also be enhanced by CT-011, suggesting a role for CT-011 in 
NK cell-based therapies. Another potent anti-PD-1 antibody, nivolumab, has shown 
durable tumor regression in a phase 1 trial in patients with melanoma, renal-cell 
cancer and non-small-cell lung cancer, however in a phase I trial investigating 
nivolumab in heavily pretreated relapsed or refractory MM patients stable disease 
was the best response.96 Stable disease occurred in 63% of patients with a mean 
duration of 11.4 weeks. These results indicate that nivolumab monotherapy seems 
not effective in MM patients, probably due to the highly immunosuppressive nature 
of the MM tumor microenvironment.
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Natural killer cell based immunotherapy
NK cell based monotherapy
Besides T cells, NK cells are important effector cells involved in anti-myeloma 
immunity. They are activated upon increased expression of activating ligands or 
decreased expression of inhibitory ligands. In vitro studies indicated that cytokines, 
like IL-2 and IL-15 can enhance the killing capacity of NK cells.97 Therefore, the effect 
of in vivo administration of these cytokines on NK expansion and activation has 
been investigated in patients.98 It has been shown that IL-2 administration mediated 
expansion of the NK cells. In addition, IFN-α increased NK cell activity, however the 
therapy induced toxicity and clinical benefits in MM patients were limited.99-101 
 Importantly, various studies indicate an anti-tumor effect mediated by NK cells. 
For example, after allogeneic SCT early NK cell repopulation has been associated 
with decreased relapse rates, without increasing GVHD incidence.102 In haplo-iden-
tical SCT, where patient and donor are not fully matched for HLA-type, improved 
disease-free survival and lower relapse rates, without increased incidence of GVHD, 
have been observed if the patient and donor were mismatched for their KIR-ligands.29 
Those results have been confirmed in different studies,103,104 though other groups 
could not reproduce these findings.105,106 These differences can probably be 
attributed to variance in conditioning and transplantation regimens.98 The KIR 
gene-gene model, which uses KIR genotype, is another method used to predict NK 
reactivity and clinical outcome after allogeneic SCT. KIR genes are located apart 
from HLA genes on chromosome 16. Two KIR genotypes can be distinguished; 
genotype A, which contains mostly inhibitory KIR receptors, and group B, which 
comprises more activating receptors. Consequently, donors and recipients can be 
categorized as having one of two KIR genotypes: AA which is homozygous for 
group A KIR haplotypes, or Bx, which contains either one (AB) or two (BB) group B 
haplotypes.107 After non-myeloablative HLA-haploidentical SCT, it was observed 
that patients with KIR group A haplotypes showed improved overall survival, 
event-free survival and non-relapse mortality in case the donor had a KIR group B 
haplotype. For patients with KIR group B haplotypes no benefit was demonstrated. 
108 Furthermore, improved PFS and OS was observed in acute myeloid leukemia 
(AML) patients and relapsed MM patients after HLA-matched SCT when the donor 
had a group B haplotype. This was independent of the patients haplotype. In AML 
patients no effect on the incidence of GVHD was found, however in MM patients a 
donor with a group B haplotype was associated with an increased incidence of 
chronic GVHD, but not acute GVHD.109,110
 Nevertheless, allogeneic SCT is not standard treatment for MM, because of the 
high TRM.43 Therefore, novel strategies exploiting the anti-myeloma activity of NK 
cells in MM with less side effects are being explored. One approach is the adoptive 
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transfer of NK cells. This provides the opportunity to infuse alloreactive NK cells, that 
are optimally mismatched, without the toxicity associated with allogeneic SCT. 
Shi et al.111 investigated infusion of haplo-identical KIR mismatched NK cells in 
relapsed MM patients following conditioning with melphalan and fludarabine. 
Furthermore, patients were treated daily with IL-2 injections for 11 days, and received 
a delayed autograft at day 14. Although donor NK cells could be detected, they 
disappeared by day 9 – 14. Moreover, the response rate was 50% compared to 40% 
in the control group not receiving NK cells (P=0.32). An explanation for the quick 
disappearance of NK cells could be the early repopulation of T cells. Furthermore, 
the number of infused NK cells was low (1x106/kg). In a study by Miller et al.112 in poor 
risk AML patients a complete hematologic remission was induced in 5 out of 
19 patients by infusion of ex vivo expanded alloreactive NK cells combined with a 
high dose immunosuppressive regimen and low dose IL-2. However, in this study 
low levels of T cells in the graft could have contributed to the observed effect.112,113 
In order to infuse higher numbers of NK cells without T cell contamination a new 
current current Good Manufacturing Practice-grade culture protocol has been 
developed by our group. In this procedure CD34+ hematopoietic stem cells can be 
expanded ex vivo 2000-fold, and a NK cell product with a purity > 90% and without 
B or T cell-contamination can be generated.114 Currently, these NK cells are 
investigated in a phase I clinical trial in older AML patients who are not eligible for 
allogeneic SCT (NTR2818). In the future these NK cells, combined with autologous 
SCT, could also be a promising therapy in relapsed MM patients.
NK cell based combination therapy
Beside adoptive transfer of NK cells, several other therapies exist that aim to improve 
NK cell mediated anti-myeloma immunity. New anti-myeloma drugs introduced 
into the clinic have shown to influence NK cell mediated killing, therefore 
combination therapy with these drugs can be a rational therapeutic strategy. 
Furthermore, in the past decade increasing numbers of clinical grade antibodies 
have been developed for the treatment of cancer. These antibodies can mediate 
tumor clearance via various mechanisms.115 Upon binding to the target molecule, 
the Fc-tail of the antibody can be recognized by Fc-receptors on NK cells resulting in 
NK cell degranulation and lysis of the target cell. Besides this ADCC, cytolysis can be 
mediated by activation of the complement system upon binding of complement 
components to the Fc-tail of the antibody. In addition, the antibody itself may 
directly affect signal transduction of the targeted molecule, or induce apoptosis. 
Furthermore, cytotoxic drugs or radionuclides can be coupled to the antibodies, 
thereby the targeted cells are specifically damaged and patients will encounter less 
side effects than with regular treatment. At the moment, several monoclonal 
antibodies are being developed for MM.116 Some of these antibodies are promising 
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candidates for combination therapy, together with adoptive transfer of NK cells, 
to enhance NK cell mediated killing.
IPH2101 (Lirilumab)
One of these interesting antibodies, is the anti-KIR antibody IPH2101. NK cells initiate 
cytotoxicity against target cells through a positive balance of signals received via 
activating and inhibitory receptors. Binding of inhibitory KIRs to MHC class I 
molecules on target cells prevents NK cell activation.98 IPH2101 is a human IgG4 
monoclonal antibody against common inhibitory KIR2DL-1, KIR2DL-2 and KIR2DL-3, 
which blocks the KIR-ligand interaction and thereby augments killing of autologous 
tumor cells.117,118 In a phase I clinical trial in 32 relapsed/refractory MM patients, 
IPH2101 was well tolerated and no evidence of autoimmunity was observed. In the 
highest dose >90% KIR occupancy was achieved and enhanced ex vivo patient- 
derived NK cell cytoxicity against MM was observed.119 A phase I clinical trial 
combining IPH2101 with lenalidomide in patients with relapsed/refractory MM, 
showed objective responses in 5/15 patients.120 Three of these patients had been 
treated with lenalidomide before. Unfortunately, a phase 2 clinical trial investigating 
lirilumab monotherapy in smouldering myeloma did not reveal any clinical 
responses.121 
Elotuzumab
Another interesting antibody which can augment NK cell-mediated immunity 
against MM is elotuzumab. Elotuzomab (i.e.  HuLuc63) is a humanized antibody 
against CS1 (i.e. CD2 subset-1, CRACC, SLAMF7 or CD319), a cell surface glycoprotein 
that is highly expressed on MM cells and normal plasma cells.122 In addition to 
expression on MM cells, CS1 is also expressed on NK cells, NKT cells, CD8+ T cells, 
activated monocytes and DCs, but to a lesser extent. Notably, CS1 is not expressed 
by healthy hematopoietic stem cells, other hematological malignancies or non- 
lymphoid tissues. Although the function of CS1 is not fully known, on MM cells it 
seems to interact with cell adhesion molecules on BM stromal cells.122,123 On NK 
cells, CS1 appears to serve as an activator via the adapter protein Ewing’s sarcoma- 
activated transcript-2 (EAT-2).124 Elotuzumab performs its anti-MM effects mainly via 
induction of NK cell-mediated ADCC. 122 In ex vivo experiments, ADCC against 
primary MM cells, resistant to conventional or novel therapies like bortezomib, could 
be enhanced using elotuzumab.123 A phase I study in relapsed/refractory MM 
patients showed acceptable toxicity and disease stabilization in 26.5% of patients.125 
Furthermore, two phase I studies investigating elotuzumab, in combination with 
either lenalidomide and low-dose dexamethasone, or bortezomib, in relapsed or 
refractory MM patients showed objective response rates of 82% and 48% 
respectively, including a response in 2 out of 3 bortezomib resistant patients in the 
514292-L-bw-Roeven
Processed on: 6-10-2017 PDF page: 191
191
Immunotherapeutic approaches in multiple myeloma
7
study combining elotuzumab with bortezomib.126,127 Recently a randomized phase 
2 study investigating bortezomib/dexamethasone with or without elotuzumab in 
relapsed/refractory MM showed a progression free survival of 9.7 months in patients 
treated with elotuzumab as compared to 6.9 months without elotuzumb.128 
Additionally, a phase III trials investigating elotuzumab in combination with 
lenalidomide and dexamethasone in relapsed or refractory MM patients showed a 
median progression-free survival of 19.4 months in the elotuzumab group versus 
14.9 months in the control group.129 Clinical trials investigating elotuzumab in 
combination with bortezomib/dexamethasone (NCT01668719) or lenalidomide/
dexamethasone (ELOQUENT-1, NCT018916430) are ongoing. 
Anti-myeloma drugs
As described earlier novel anti-myeloma drugs including the IMiDs and proteasome 
inhibitors have improved outcome of MM patients in the last decade.5 Interestingly, 
these drugs seem to confer their effects, at least partly, trough stimulation of NK 
cell-mediated killing. 
 Thalidomide was the first drug of the IMiD group that was used, though later 
more potent and less toxic IMiDs like lenalidomide have been introduced.130 IMiDs 
mediate their anti-myeloma effects via several mechanisms. They can directly kill 
MM cells by induction of cell cycle arrest and caspase-dependent apoptosis,131 
decrease binding of MM cells to BM stromal cells,132 block angiogenesis133 and 
inhibit production of cytokines (IL-6, TNF-α).134 Furthermore NK cell-mediated 
cytotoxicity can be augmented by these drugs. 135 Hayashi et al.136 reported that 
IMiDs stimulate NK cells via increased IL-2 production by T cells. Additionally in vitro 
studies have shown that pretreatment of NK cells with lenalidomide can enhance 
ADCC against CD40-expressing MM cells if NK cells are combined with SGN-40, an 
anti-CD40 monoclonal antibody.137 Pomalidomide, a novel IMiD, which has been 
approved by the FDA recently, significantly increases serum IL-2 receptor and IL-12 
levels.138 These cytokines are important for NK cell activation and could contribute 
to increased NK cell-mediated killing.
 Proteasome inhibitors are a second group of anti-myeloma drugs. These drugs 
interact with the ubiquitin-proteasome pathway, which is responsible for the 
degradation of the majority of regulatory proteins in eukaryotic cells, including 
proteins that control cell-cycle progression, apoptosis and DNA repair.139 Inhibition 
of proteasome activity results in growth arrest and cell death due to the induction 
of an apoptotic cascade as a result of rapid accumulation of incompatible regulatory 
proteins within the cell.140 Malignant cells show increased sensitivity to proteasome 
inhibition, probably as a result of higher proteasome activity. Therefore, the proteasome 
is one of the most interesting therapeutic targets in oncology, and it is currently an 
important component of MM treatment.141 Beside direct apoptotic effects on MM 
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cells, treatment of MM cells with bortezomib can induce sensitization to NK 
cell-mediated lysis via several mechanisms. By down-regulation of cell-surface 
expression of HLA class I molecules on MM cells, NK cell activation is no longer 
inhibited, since HLA class I is an important inhibitory ligand for NK cells.142 In addition, 
bortezomib can induce expression of NK cell activating ligands like Tumor Necrosis 
Factor-related apoptosis-inducing ligand (TRIAL)-R2,143,144 DNAM-1 ligands (poliovirus 
receptor, Nectin-2, CD112, CD155) and NKG2D ligands (MICA/B, ULBPs).145,146 On the 
downside a dose-dependent suppression of NKp46-mediated and TRAIL-mediated 
cytotoxicity, as well as induction of apoptosis in NK cells treated with bortezomib 
has been described.147,148 These findings indicate that low dose bortezomib may 
support NK cell-based immunotherapy, while high dose bortezomib may disturb 
NK cell-mediated cytotoxicity. 
 A third group of anti-myeloma drugs are the histone deacetylase (HDAC) inhibitors. 
HDACs play an important role in epigenetic modulation of gene expression and 
alterations in HDAC expression have been found in many types of cancers, making 
these enzymes a attractive targets for cancer therapy.149 Clinical phase II and phase 
III studies using the HDAC inhibitors vorinostat and panobinostat in relapsed MM 
patients have gained promising results.150-152 In vitro and in vivo studies have 
reported NK cell-activating effects of HDAC inhibitors. Upon exposure to HDAC 
inhibitors, increased expression of MICA/B on lymphoma, leukemia and 
hepatocellular carcinoma cells was observed.153-155 Another in vitro study reported 
increased DNAM-1- and NKG2D-dependent NK cytotoxicity. 156 However, decreased 
expression of the activating NKp30 ligand B7-H6 has been observed in cell lines 
treated with HDAC inhibitors, reducing NKp30-dependent tumor cell recognition by 
NK cells.157  Additionally, in mice treated with HDAC inhibitors, diminished expression 
of NKG2D and NKp46 on, and decreased IFN-γ production by NK cells was observed. 
Therefore, it is essential to obtain data on the influence of HDAC inhibitors on NK 
cell-mediated killing in clinical studies in order to draw definite conclusions on the 
benefit of these drugs in NK cell-mediated myeloma therapy.
Future prospects
Survival of MM patients has improved significantly due to the introduction of new 
therapies like bortezomib and lenalidomide, however OS survival is still poor. 
Therefore additional potent therapeutic strategies are urgently needed. Currently, 
several cellular immunotherapeutic strategies are being developed to improve 
anti-myeloma immunity with reduced side effects. NK cell-based adoptive 
immunotherapy has shown promising clinical effects, without induction of severe 
adverse effects. Notably combination of NK cell adoptive transfer with antibodies 
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like elotuzumab and KIR-blocking antibodies, anti-myeloma drugs or even anti-PD1 
antibodies may further enhance anti-myeloma immunity. Furthermore, new 
strategies like genetic engineering hold great potential for the development of NK 
cells with superior tumor-reactive functionality. For instance, inhibitory KIR receptors 
might be specifically down-regulated in NK cells by the use of siRNAs. Another 
strategy would be the introduction of CARs on NK cells. Recently, Chu et al.158 
generated a CS1-specific CAR which could be expressed by a human NK cell line. 
These NK cells showed improved killing of CS1-expressing MM cells in vitro and 
in vivo. Therefore, it would be highly interesting to explore such MM-specific CAR 
expressing NK cells in a clinical trial. 
 Another interesting strategy, which can improve T cell-mediated killing of MM is 
the application of bispecific antibodies. Blinatumomab, a CD3/CD19 bispecific single 
chain antibody, can redirect T cells to CD19 expressing B-lineage acute lymphoblastic 
leukemia (ALL) cells. In a phase II study, 16 out of 21 patients with MRD or relapse 
after therapy were MRD negative after blinatumomab treatment.159 Based on the 
successes in B-ALL, development of bispecific antibodies against MM-specific 
molecules, like CS1 or CD138, would be an interesting strategy to explore for MM 
treatment. 
 Taken together, ongoing efforts to improve therapy for MM have resulted in the 
development of several promising therapies, these therapies will potentially reach 
the clinic in the coming years. An important question is how to combine and 
sequence these new therapies in the initial treatment plan of patients with MM. The 
combination of cellular immunotherapy with other therapies has the potential to 
maximize the anti-myeloma effect without significant increased toxicity. Further 
research will have to elucidate prognostic factors predicting therapeutic responses 
and side effects in patients, enabling more effective personalized treatments and 
better survival and quality of life for future MM patients.
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Summary and future perspectives
In the Netherlands, each year 5,600 patients are diagnosed with a hematological 
malignancy.1 Although the introduction of new therapies in the last decades has 
greatly improved outcome for many patients, still too many patients cannot be 
cured. In addition, most therapies have substantial side effects, resulting in severe 
short-term and long-term toxicity. Therefore, improved therapies are needed. 
Allogeneic stem cell transplantation (allo-SCT) is a potential curative therapy for 
patients suffering from hematological malignancies. In allo-SCT, patients are 
conditioned with chemo- and/or radiotherapy. This conditioning regimen is immu-
nosuppressive, and dependent on the intensity of the conditioning, less or more 
tumor eradicating. Subsequently, stem cells of a donor are infused, these stem cells 
replace the autologous hematopoiesis. The efficacy of allo-SCT is partly the result of 
the conditioning regimen, but more importantly, of the immunological reaction of 
the donor immune system against residual autologous hematopoietic cells, 
including the tumor cells. This effect is called the graft-versus-tumor (GVT) effect.2 
Since this immunological reaction is responsible for the clinical effect, allo-SCT is a 
so-called cellular immunotherapy. Although this therapy can cure patients, a 
considerable number of patients still relapse after allo-SCT. In addition, this therapy 
also may induce substantial toxicity. This toxicity is the result of the conditioning 
therapy, as well as an immunological reaction of the donor immune system against 
healthy tissues of the patient, resulting in graft-versus-host disease (GVHD). 
Unfortunately, the desired GVT effect after allo-SCT is often accompanied by GVHD. 
Therefore, improved cellular immunotherapies, that can induce a strong GVT effect 
without the devastating GVHD are needed. In this thesis, we investigated novel 
cellular immunotherapies, that can potentially separate the GVT from GVHD. This 
chapter summarizes the main findings of this research, and addresses how these 
results can be integrated in novel treatment protocols to improve outcome for 
patients suffering from hematological malignancies. 
Dendritic cell vaccination
T cells are important effectors in the GVT effect after allo-SCT. T cells can target cells 
that express a specific HLA-peptide complex. Although HLA-complexes are usually 
matched in allo-SCT, peptides derived from endogenous proteins presented by HLA 
molecules on recipient cells, can differ from those of donor origin due to genetic 
polymorphisms. Donor T cells can recognise these HLA-peptide complexes as 
foreign and hence be activated. Polymorphic peptides which can induce a donor T 
cell response are called minor histocompatibility antigens (MiHAs).3 Interestingly, 
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certain MiHAs are exclusively expressed by hematopoietic cells. As a result, boosting 
T cell responses against these MiHAs can separate the beneficial GVT from the 
devastating GVHD. In chapter 2 and 3 of this thesis, hematopoiesis restricted MiHAs 
are targeted to fight residual tumor cells after allo-SCT. Chapter 2, describes a phase 
I/II clinical trial investigating MiHA-directed dendritic cell (DC) vaccination in patients 
who relapsed after allo-SCT and at least one donor lymphocyte infusion (DLI). DCs 
were generated ex vivo from donor-derived monocytes, and were loaded with MiHA 
peptides. Subsequently, the MiHA-loaded DCs were administered intravenously and 
intradermally to relapsed patients. The DCs were infused in three portions with 
2-week intervals. The first DC vaccination was combined with a DLI, of which the 
dosage of the DLI was equivalent to the last DLI that did not lead to GVHD. We were 
able to generate sufficient MiHA-loaded DCs in all patients. In addition, the vaccines 
were well tolerated with only transient induration and erythema at the injection site, 
and grade 2 fever after the second and third vaccination. Importantly, we did not 
observe any GVHD or life-treating toxicities. We could detect an increase in the 
percentage of MiHA-specific CD8+ cytotoxic T cells in 5/9 patients. However, no 
objective clinical responses were observed. This illustrates that MiHA-directed DC 
vaccination is feasible and safe, but further improvement of this therapy is needed.
Earlier, our group found that programmed death-1/programmed death ligand-1 
(PD-1/PD-L1) interactions contribute to functional T cell impairment after allo-SCT.4 
In addition, silencing PD-L1 and PD-L2 on MiHA-loaded DCs resulted in more potent 
DCs, which showed enhanced potential to expand MiHA-specific CD8+ T cells.5,6 
To be able to translate this knowledge to clinical practice, a clinical-grade procedure 
for the generation of MiHA-loaded PD-L1/L2 silenced DCs is required. Chapter 3 of 
this thesis, describes this clinical-grade procedure. In this procedure, DCs were 
generated from donor-derived monocytes. In the culture process, PD-L1/L2 was 
silenced using lipoplexes composed of PD-L1 and PD-L2 siRNAs mixed with 
SAINT-RED lipid. Mature PD-L1/L2 silenced DCs were finally loaded with MiHA mRNA 
or peptide. We found that siRNA/SAINT-RED transfection resulted in efficient and 
long-term knockdown of PD-L1 and PD-L2, without affecting DC maturation or 
viability. Importantly, MiHA-loaded PD-L1/L2 silenced DCs could efficiently stimulate 
MiHA-specific T cell expansion and cytokine production. Currently, these vaccines 
are investigated in a project consisting of two phase I clinical trials (NTR4128/
NCT02528682). In these clinical studies, patients after allo-SCT, who did not develop 
GVHD after cessation of immunosuppressive therapy are included. In order to be 
able to develop a MiHA-specific T cell response, patients should express a hemato-
poietic-restricted MiHA, whereas their stem cell donor does not express this MiHA 
epitope. The project consists of two studies. In the first study (PSCT16 study), three 
patients were treated with non-silenced MiHA-loaded DCs. In the second study 
(PSCT19 study), ten patients will be treated with MiHA-loaded PD-L1/L2 silenced 
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DCs. So far, the first study is completed. Currently, one patient was treated in the 
second study. Patient characteristics are shown in Table 1. Patients were in complete 
remission (CR) after allo-SCT. DCs were infused intravenously in three portions with 
2-week intervals. Vaccine characteristics are shown in Table 2. The vaccines were 
well tolerated. All patients experienced grade 1 to 2 fever and flu-like symptoms 
after the second vaccination. Two patients did also experience fever after the third 
vaccination. These symptoms resolved spontaneously after 12-24 hours. One patient 
developed a superficial trombophlebitis at the site of i.v. injection, which resolved 
spontaneously. We could detect MiHA-specific CD8+ cytotoxic T cells in patient 1.1, 
1.2 and  2.1. In addition, an increase in the percentage of MiHA-specific CD8+ T 
cytotoxic T cells was observed in the bone marrow (BM) of these patients (Figure 1A). 
Although all patients were in CR before vaccination, patient 1.2 had detectable 
minimal residual disease (MRD) in the BM before vaccination. Interestingly, this 
patient became MRD negative after vaccination (Figure 1B). In conclusion, this 
ongoing clinical trial shows promising preliminary results. 
Table 1  Patient characteristics
UPN Sex Age Disease Response 
after SCT
Interval  
SCT-DC 
(months)
Time 
after DC 
vaccination
(months)
Current 
status
1.1 M 38 Follicular NHL CR 8 30 CR
1.2 M 34 AML CR 5 25 CR
1.3 M 38 Small lympohcytic 
lymphoma
CR 21 20 CR
2.1 M 75 CMML CR 7 2 CR
Table 2  Vaccine characteristics
UPN Number of DCs injected i.v. (x 106) Mean 
viability  
(%)
Mean  
PD-L1 
expression 
(%)
Mean  
PD-L2 
expression 
(%)
#1 #2 #3
1.1 18 18 16 96 99 98
1.2 19 19 19 89 96 97
1.3 22 18 20 90 99 95
2.1 19 19 17 85 21 2
514292-L-bw-Roeven
Processed on: 6-10-2017 PDF page: 208
208
Chapter 8
Figure 1   MiHA-specific DC vaccination can boost MiHA-specific T cells and 
decrease MRD
Patients who did not develop GVHD after allo-SCT and cessation of immunosuppressive 
therapy were treated with MiHA-loaded DCs. DCs were generated from donor monocytes 
and subsequently loaded with MiHA mRNA by electroporation. In patient 2.1, PD-L expression 
on the DCs was silenced using PD-L1 and PD-L2 siRNA/SAINT-RED transfection. DCs were 
administered at three time points with a two-week interval. (A) The absolute number of MiHA- 
specific CD8+ T cells in peripheral blood and the percentage of MiHA-specific CD8+ T cells in 
bone marrow was determined by flow cytometry at preset time points after vaccination.
A
BA
B
A
B
A
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Natural killer cell based therapy
Besides T cells, Natural killer (NK) cells, which are part of our innate immunity, are also 
important effectors involved in the GVT effect. Therefore, NK cell adoptive cell 
therapy (ACT) to treat acute myeloid leukemia (AML) has been explored in various 
studies.7-10 These studies showed that allogeneic NK cells have anti-AML activity, 
moreover, NK cell ACT did not induce GVHD. As a result, NK cell ACT is an attractive 
therapeutic approach to target AML. Thus far, NK cell products used in NK cell ACT 
studies were enriched from peripheral blood of haplo-identical donors, followed by 
overnight stimulation with IL-2 or IL-15. However, using these procedures, relatively 
low NK cell dosages of 3-5x106 cells/kg can be generated.  In addition, NK cell 
products contain residual T cells, which can cause GVHD. For these reasons, our 
group developed a good manufacturing practice (GMP)-compliant, cytokine based 
culture method for the ex vivo generation of a highly pure NK cell product from 
CD34+ hematopoietic stem and progenitor cells (HSPCs) derived from umbilical 
cord blood (UCB) units.11,12  This procedure allows the generation of a large amount 
of NK cells; in addition, these HSPC-NK cells are highly pure and show cytolytic 
activity against AML cells in vitro and in vivo.13 Chapter 4 of this thesis, describes a 
phase I clinical trial (PLMA25 study) investigating feasibility, toxicity, in vivo life span, 
and impact on MRD of this HSPC-NK cell product in the treatment of older AML 
patients. Patients included in this study were in morphologic CR after intensive 
chemotherapy and/or hypomethylating agents. After inclusion, patients were 
Figure 1   Continued
(B) MRD in peripheral blood and bone marrow was measured by quantitative real-time PCR 
for AML-ETO at preset time points. DC, dendritic cell, PB, peripheral blood, BM, bone marrow; 
MRD, minimal residual disease; alloSCT, allogeneic stem cell transplantation.
A
BB
514292-L-bw-Roeven
Processed on: 6-10-2017 PDF page: 210
210
Chapter 8
conditioned with lymphodepleting chemotherapy, to prevent rejection of the cells 
as well as to increase endogenous cytokine levels, which support NK cell survival 
and maturation in vivo. Subsequently, an escalating dose of HSPC-NK cells, between 
three and 30x106/kg body weight, was infused. HSPC-NK cell products contained a 
median of 75% highly activated NK cells, with < 1x104 T cells/kg and < 5x105 B cells/
kg. In this study, patients did not experience unexpected toxicity and importantly, 
we did not observe any GVHD. HSPC-NK cells were detectable in peripheral blood 
and BM until day eight after infusion. Donor chimerism up to 21% and 3.5% was 
found in peripheral blood and BM respectively. Four patients had detectable MRD 
in BM before HSPC-NK cell infusion, two of these patients became MRD negative 
after infusion, which lasted for six months. In conclusion, these results show that 
HSPC-NK cell therapy could be an adjuvant therapy to eradicate MRD in AML patients 
following intensive therapy or after treatment with hypomethylating agents (HMA), 
however, since clinical responses were not always durable, further improvement of 
this therapy is warranted. 
 Interestingly, both patients who became MRD negative after HSPC-infusion, 
were treated with HMA before inclusion in the trial. Earlier, it was reported that NK 
cells in myelodysplastic syndrome (MDS) patients treated with azacitidine show 
higher degranulation and interferon-γ (IFN-γ) production in response to leukemia 
cell lines in vitro.14 Furthermore, various preclinical studies reported that HMA 
sensitize AML cells for NK cell mediated killing by stimulating upregulation of 
activating ligands such as the NKG2D ligands.15-17 Therefore, in chapter 5, we 
investigated the impact of HMA on HSPC-NK cells; in addition, we evaluated if there 
was an improved anti-leukemic effect of HMA in combination with HSPC-NK cell 
transfer in vivo. In vitro, we found that HMA did not impair NK cell viability, nonetheless, 
azacitidine did impair NK cell proliferation and killing capacity, whereas NK cell 
proliferation, killing and IFN-γ production was preserved upon exposure to 
decitabine. In vivo, the persistence of adoptively transferred HSPC-NK cells was not 
affected by azactitine neither by decitabine, with sustained expression of activating 
receptors and remarkable KIR acquisition. While both agents exerted a significant 
effect on AML progression, only decitabine potentiated HSPC-NK cell anti-leukemic 
activity in vivo. We found that decitabine resulted in up-regulation of activating NK 
cell ligands on AML cells, in addition, decitabine enhanced mRNA expression of the 
inflammatory cytokines perforin and TRAIL in HSPC-NK cells. Finally, treatment with 
decitabine resulted in higher NK cell numbers in the BM compartment. Altogether, 
these data provide strong rationale to further explore combination of decitabine 
and HSPC-NK cell therapy in AML patients.
 Although patients in our clinical trial described in chapter 4 were at the time no 
candidates for allo-SCT due to age or co-morbidity, the introduction of non-myelo-
ablative conditioning makes allo-SCT currently available for fit older patients.18,19 
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Therefore, several patients included in that study would now be eligible for allo-SCT. 
In the PLMA25 study, we have shown that ACT with UCB-derived HSPC-NK cells can, 
at least temporary, decrease MRD. Persistent MRD prior to allo-SCT has been 
associated with increased relapse rates and decreased overall survival in 
myeloablative and non-myeloablative allo-SCT.20-22 Therefore, consolidation NK cell 
ACT before allo-SCT could be an attractive therapeutic strategy. Early NK cell 
repopulation after allo-SCT has been associated with decreased relapse rates 
without increasing GVHD incidence.23,24 As a result, NK cell ACT after allo-SCT could 
further improve outcome after allo-SCT. In this strategy, HSPC-NK cells of donor 
origin would be preferable to UCB-derived HSPC-NK cells, since these cells will not 
be rejected, so no immunosuppressive chemotherapy is needed. Hence, multiple 
NK cell infusions can be performed. In chapter 6, we investigated whether large 
numbers of NK cells from donor origin could be generated using our cytokine-based 
culture method. Unfortunately, granulocyte colony-stimulating factor (G-CSF)-mo-
bilized HSPCs have a lower expansion potential as compared to UCB-derived HSPCs. 
Interestingly, we discovered that addition of the aryl hydrocarbon receptor (AhR) 
antagonist StemReginin1 (SR1) to our culture protocol potently enhances expansion 
of CD34+ HSPCs. In addition, SR1 induces expression of NK-cell associated 
transcription factors promoting NK cell differentiation. Consequently, we can 
generate high numbers of NK cells with an active phenotype from G-CSF-mobilized 
HSPCs. These cells exert efficient cytolytic activity and IFN-γ production against 
AML and multiple myeloma (MM) cells. Interestingly, we found that HSPC-NK cell 
proliferation and function is not inhibited by cyclosporine A, an immunosuppressive 
drug often used after allo-SCT. Therefore, donor-derived HSPC-NK cells can be 
infused relatively short after allo-SCT. In conclusion, infusion of donor-derived 
HSPC-NK cells after allo-SCT is an attractive therapeutic strategy to enhance het GVT 
effect shortly after allo-SCT.
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Future perspectives
In this thesis, we explored various cellular immunotherapeutic strategies that can 
enhance GVT effects, with a limited risk of inducing GVHD. Nevertheless, tumors can 
exploit various immune evasion mechanisms to escape from immune responses. 
An overview of these mechanisms is given in chapter 7. To prevent relapse as a 
result of these immune evasion mechanisms, the anti-tumor effects of our immuno-
therapeutic strategies should be further optimized. In addition, we believe that 
combining several immunotherapeutic strategies is essential to prevent relapse due 
to immune escape. Here, we first describe how our immunotherapeutic strategies 
could be optimized, and next we will explain how these therapies could be 
combined to maximize their therapeutic potential.
In this thesis, we investigated cellular immunotherapies targeting T cells and NK 
cells, which are the main effectors inducing the GVT response after allo-SCT.  By DC 
vaccination, we activated MiHA-directed T cells in vivo. In chapter 2, DC vaccination 
was combined with DLI, the infusion of unselected donor T cells. Although DLI is an 
effective therapy,25 the main drawback of DLI is the risk of inducing GVHD. To 
prevent GVHD, infusion of MiHA-specific T cells would be a safer alternative. However, 
only low numbers of MiHA-specific T cell precursors are present in peripheral blood 
of donors. So, to be able to infuse these cells, they need to be expanded and 
enriched. In addition, circulating T cells are mostly differentiated, and while 
differentiated T cells show potent anti-tumor killing, these cells show a lower 
proliferative capacity as compared to less mature T cell population.26 To overcome 
these hurdles, our group developed a method to generate MiHA-specific CD8+ T 
cells.27 These cells were generated in the presence of an Akt-inhibitor, resulting in a 
less mature phenotype and importantly, improved anti-tumor effects in vivo. 
Therefore, infusion of ex vivo generated MiHA-specific T cells after allo-SCT would be 
an attractive approach to enhance GVT responses.
 Further boosting of tumor-directed T cells in vivo, can be achieved by DC 
vaccination. Originally, and also in this thesis, most DC vaccines were generated ex 
vivo from donor-derived monocytes. In contrast to monocyte-derived DCs, naturally 
occurring DCs consist of various subsets, which can be roughly divided into myeloid 
and plasmacytoid DCs. Recent studies have investigated the use of naturally 
occurring DC subsets loaded with tumor associated antigens (TAAs) to treat 
melanoma patients.28,29  In these studies, DCs were collected by apheresis of 
patients.28,29 Since only low numbers of DCs can be isolated from peripheral blood, 
relatively low DC numbers were infused. Surprisingly, still TAA-specific T cells could 
be detected in peripheral blood of patients after vaccination, suggesting potent 
stimulatory capacities of these vaccines. Indeed, preclinical research has suggested 
that different subsets interact synergistically to induce antigen-specific T cell 
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responses.30  As a result, infusion of naturally occurring DCs might be an attractive 
alternative to infusion of monocyte-derived DCs. Since only low numbers of these 
DCs are present in peripheral blood, our group has developed an ex vivo culture 
protocol which enables us to generate and infuse high numbers of functional 
myeloid en plasmacytoid DCs.31  We found that these DCs show superior capacity 
to expand and activate MiHA-specific CD8+ effector memory T cells. (Thordardottir 
et al. Oncoimmunology, under revision) Interestingly, these DCs also had the capacity 
to activate NK cells with high cytolytic capacity against tumor cells. These results are 
in line with earlier studies describing DC induced activation of NK cells.32-34 Hence, 
DC vaccination using naturally occurring DC subsets, can induce tumor-directed 
T cells as well as NK cells, therefore these vaccines show great promise for future 
immunotherapy, either alone or in combination with infusion of MiHA-specific T cells 
or NK cell ACT.
 Besides combining NK cell ACT with DC vaccination, a different way to improve 
the efficacy of HSPC-NK cell therapy, is to improve the killing potential of our NK cell 
products. We recently published an improved HSPC-NK cell generation protocol.35 
In this protocol, IL-2 is replaced by IL-12 in NK cell cultures. Addition of IL-12 to our 
culture protocol resulted in enhanced INF-γ production and improved cytolytic 
activity of HSPC-NK cells towards cultured and primary AML cells in vitro. Importantly, 
these cells exhibited improved anti-leukemic responses in mice bearing human 
AML cells. Further improvement of HSPC-NK cell therapy can be reached by boosting 
in vivo survival of HSPC-NK cells using cytokines. Most reported studies did combine 
NK cell ACT with IL-2 injections to stimulate NK cells expansion and survival in vivo.7-10 
However, IL-2 can induce toxicity in patients, moreover, IL-2 does promote expansion 
of regulatory T cells (Tregs), which can inhibit NK cell proliferation and expansion.36 
In our clinical trial in chapter 4, we did not administer IL-2, thereby we were able to 
separate toxicity induced by the conditioning regimen and HSPC-NK infusion from 
IL-2 mediated toxicity. However, the lack of cytokine support could be an explanation 
why NK cell numbers did not exceed 100 cells/µL, a level that has been correlated 
with achievement of CR in relapsed/refractory AML patients.8  Therefore, in future 
trials cytokine support would be desirable. Besides IL-2, IL-15 is another cytokine 
important for NK cell survival, proliferation and effector function, yet, it does not 
promote Treg expansion. Therefore, administration of IL-15 could improve therapy. 
Since the use of IL-15 is limited by its short half life and poor bioavailabiliy in lymphoid 
organs,37 IL-15 superagonist fusion protein complexes with enhanced biological 
activity have been developed.38 An example of a promising IL-15 superagonist is 
ALT-803. A phase I clinical trial, investigating this agent in patients with relapsed 
hematological malignancies after allo-SCT revealed no dose limiting toxicity.39 In 
addition, a dose dependent increase in NK cell proliferation was observed. In chapter 
5, we show that equimolar concentrations of ALT-803 increase HSPC-NK cell 
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proliferation and viability in vitro as compared to recombinant human IL-15. As a 
result, combining HSPC-NK cell ACT with ALT-803 is a promising strategy to boost 
HSPC-NK cell expansion in future clinical studies. 
 In this thesis, we focus on cellular immunotherapeutic strategies, which can be 
used to improve outcome in patients suffering from hematological malignancies. In 
chapter 7, we describe interesting novel therapies, which have been introduced in 
MM. Beside cellular immunotherapies, several promising therapeutic antibodies 
have been introduced. The first group of antibodies are the immune checkpoint 
inhibitors. These antibodies target cytotoxic T-lymphocyte associated protein 4 
(CTLA-4) or PD-1. Although a phase 1 clinical trial investigating the anti-PD1 antibody 
nivolumab in MM did not result in objective responses,40 promising results were 
found in Hodgkin’s lymphoma.41 Recently, the use of ipilimumab, which targets 
CTLA-4 after allo-SCT, has been explored. Although durable responses were 
observed, immune-mediated toxicity and GVHD occurred.42 These results illustrate 
the need for more specific therapies after allo-SCT. Other interesting antibodies, 
which can be used in MM are elotuzumab and daratumumab. Elotuzumab binds to 
CS1, a cell surface glycoprotein which is highly expressed on MM cells. Daratumumab 
binds to CD38 on the surface of MM cells. Recently, phase 3 trials investigating 
addition to these antibodies to treatment with lenalidomide and dexamethasone in 
relapsed or refractory MM patients showed promising clinical results.43,44 Since NK 
cells express CD16, which recognizes the Fc-tail of antibodies, the therapeutic 
potency of these antibodies can be partly explained by the induction of anti-
body-dependent cytotoxicity (ADCC) by NK cells. Therefore, combining these 
antibodies with NK cell ACT would be a rational therapeutic strategy. In addition to 
antibodies inducing NK cell activation via ADCC, antibodies that directly target NK 
cells have been developed. An example of such an antibody is the anti-KIR antibody 
lirilumab (IPH2101). Phase 1 studies in relapsed/refractory MM patients and older 
AML patients investigating this antibody either alone, or in combination with 
lenalidomide did not reveal auto-immunity.45-47 In the trial combining lirilumab with 
lenalidomide, 5/15 patients showed objective responses. Three of these patients 
had been treated with lenalidomide before. Unfortunately, a phase 2 clinical trial 
investigating lirilumab monotherapy in smouldering myeloma did not reveal any 
clinical responses.48 Still, we expect that combining lirilumab with NK cell ACT might 
result in clinical responses, therefore this strategy should be investigated in future 
studies. 
 To conclude, we have developed promising cellular immunotherapeutic strategies 
to improve outcome in patients suffering from hematological malignancies. We have 
shown safety and feasibility of some of these cellular immunotherapies in phase 1 
clinical trials. At the same time, we developed improved therapies at a preclinical 
level. In the near future, we will need to translate these improved therapies to the 
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clinic. At the same time, integration of these, and other novel therapies will be 
essential to provide an optimized and personalized therapy resulting in improved 
outcomes for patients. Optimal integration of multiple therapies will be challenging, 
since phase 3 clinical trials comparing different combination therapies are costly. 
At the same time, more patient and disease characteristics will be taken into account 
to determine the optimal therapy, resulting in smaller patient groups. In small 
groups, it will be more difficult to prove a survival advantage using a certain therapy. 
As a result, designing rational combination therapies is essential. We think that 
different cellular immunotherapies investigated in this thesis, could well be 
integrated in the future. Figure 2 provides a possible strategy integrating allo-SCT, 
NK cell ACT, infusion of MiHA-specific T cells and DC vaccination. In this strategy, 
patients will not receive one stem cell graft containing different cell subsets, in 
contrast, different cell populations are administered in time. We believe such an 
approach can enhance the GVT effect while minimizing the risk of inducing GVHD. 
We hope that future research will result in introduction of these therapies in the 
clinic, resulting in improved survival and quality of life for future patients.
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Hematologische maligniteiten zijn kwaadaardige ziekten van het bloedvormend 
systeem. Grofweg kunnen deze ziekten ingedeeld worden in acute leukemie, 
chronische leukemie, lymfomen en plasma cel ziekten. In Nederland worden jaarlijks 
5.600 patiënten gediagnosticeerd met een hematologische maligniteit. In de 
afgelopen decennia is een scala aan behandelingen voor deze ziekten ontwikkeld. 
Voorbeelden van behandelingen zijn: chemotherapie, radiotherapie en 
behandelingen gericht op specifieke moleculaire afwijkingen verantwoordelijk voor 
de ongeremde celgroei van de kwaadaardige cellen. De introductie van deze 
nieuwe behandelingen heeft ervoor gezorgd dat de kans op genezing van patiënten 
met deze ziekten gedurende de afgelopen decennia is toegenomen, echter voor 
teveel patiënten is genezing nog steeds niet mogelijk. Daarnaast hebben de 
behandelingen vaak ernstige bijwerkingen op korte en op lange termijn. Dit maakt 
dat er nog steeds grote behoefte is aan effectievere behandelingen met minder 
bijwerkingen. 
 Naast de eerder genoemde behandelingen voor hematologische maldigniteiten 
is immuuntherapie een mogelijke behandeling. Bij immuuntherapie wordt het 
afweersysteem ingezet om tumorcellen te bestrijden. Allogene stamceltransplantatie 
(allo-SCT) is de oudste vorm van immuuntherapie en vaak de enige genezing biedende 
behandeling voor patiënten met een hematologische maligniteit. Bij een allo-SCT 
worden patiënten voorbehandeld (conditionering) met chemo- en/of radiotherapie. 
Door deze conditionering wordt het eigen afweersysteem uitgeschakeld en tevens 
wordt, afhankelijk van de intensiteit van de conditionering, het eigen bloedvormende 
systeem (met daarin de kwaadaardige cellen) geheel of gedeeltelijk verwoest. 
Vervolgens worden stamcellen van een donor toegediend, deze stamcellen groeien 
uit tot een nieuw bloedvormend systeem waaruit ook weer een nieuw (van de 
donor afkomstig) afweersysteem ontstaat. Het genezende effect van allo-SCT is 
gedeeltelijk het gevolg van de conditionering, echter de immunologische reactie 
van het donor immuunsysteem tegen de overgebleven bloedvormende cellen van 
de patiënt (waaronder de kwaadaardige cellen), speelt ook een zeer belangrijke rol. 
Deze gewenste immunologische reactie wordt de graft-versus-tumor (GVT) reactie 
genoemd. Helaas komt de ziekte bij veel mensen ondanks de GVT op termijn terug 
(er treedt een recidief van de ziekte op). Daarnaast heeft allo-SCT vaak aanzienlijke 
bijwerkingen. Deze bijwerkingen zijn deels het gevolg van de conditionering, maar 
ook van een immunologische reactie van het donor immuunsysteem tegen 
gezonde weefsels van de patiënt. Deze omgekeerde afstotingsreactie wordt graft-
versus-host ziekte (GVHD) genoemd. Vaak gaan de GVT reactie en GVHD samen. 
Daarom is het van belang nieuwe cellulaire immuuntherapieën te ontwikkelen, die 
in staat zijn om wel de GVT reactie te versterken, maar geen GVHD opwekken. In dit 
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proefschrift hebben we een aantal vernieuwende cellulaire immuuntherapieën, die 
de GVT mogelijk kunnen scheiden van GVHD, onderzocht. De belangrijkste 
bevindingen worden hier samengevat.
Dendritische cel vaccinatie
Na allo-SCT spelen de van de donor afkomstige T-cellen en natural killer-(NK)cellen 
een belangrijke rol bij het tot stand komen van het GVT effect. T-cellen vallen cellen 
aan die een specifiek HLA-antigeen complex tot expressie brengen. Dit complex 
wordt herkend door de T-cel receptor op de T-cel. Elke T-cel heeft een specifieke 
T-cel receptor. T-cellen gericht tegen lichaamseigen HLA-antigeen complexen 
worden vroeg in hun ontwikkeling uitgeschakeld, daarom worden lichaamseigen 
cellen niet aangevallen. Lichaamsvreemde antigenen, zoals antigenen van bacteriën 
en virussen, maar ook antigenen in tumorcellen, worden wel herkend. Om ernstige 
GVHD te voorkomen, wordt bij een allo-SCT een donor geselecteerd die (grotendeels) 
dezelfde HLA-moleculen op diens cellen heeft als de ontvanger. Door kleine 
verschillen in het DNA van donor en ontvanger kunnen echter verschillende 
antigenen gevormd worden. Deze antigenen worden gepresenteerd door de 
HLA-moleculen. Donor T-cellen kunnen deze antigen herkennen als lichaamsvreemd, 
waardoor een afweerreactie tegen de cel die het antigen presenteert ontstaat. 
Antigenen die een donor T-cel reactie kunnen opwekken worden minor histocom-
patibility antigenen (MiHA’s) genoemd. Het is gebleken dat sommige MiHA’s enkel 
tot expressie komen op bloedvormende cellen. Daarom zullen T-cel reacties tegen 
deze MiHA’s een GVT effect teweegbrengen, tumorcellen zijn bij hematologische 
ziekten immers bloedvormende cellen. Echter T-cel reacties tegen deze MiHA’s 
veroorzaken geen GVHD, de MiHA’s zijn immers niet op de andere organen 
aanwezig. Het activeren van T-cellen tegen deze specifieke MiHA’s is daarom een 
mogelijkheid om het GVT effect te versterken zonder het risico op GVHD te 
vergroten. Het direct toedienen van MiHA-specifieke T-cellen is lastig gebleken, 
omdat deze cellen slechts in lage aantallen in het bloed van donoren voorkomen. 
Het is echter wel mogelijk MiHA-specifieke T-cellen in het lichaam van de patiënt te 
activeren door gebruik te maken van dendritische cellen (DC’s). DC’s zijn professionele 
antigeen-presenterende cellen (APC’s). Deze cellen kunnen door het presenteren 
van antigenen aan T-cellen een krachtige afweerreactie opwekken. DC vaccinatie 
maakt gebruik van dit principe. Bij DC vaccinatie worden voorlopers van DC’s 
(monocyten) geïsoleerd uit het bloed van de stamceldonor. Deze monocyten 
worden in het laboratorium, met behulp van verschillende groeifactoren en 
cytokines gekweekt tot rijpe cellen. Vervolgens worden ze beladen met het MiHA 
waartegen een T-cel reactie gewenst is. Deze rijpe, beladen DC’s kunnen vervolgens 
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in de vorm van een vaccinatie toegediend worden aan patiënten, met als doel de 
MiHA-specifieke T-cel reactie te versterken.
 Hoofdstuk 2 van dit proefschrift beschrijft een fase I/II klinische studie waarin 
we patiënten met een recidief hematologische maligniteit na allo-SCT en minimaal 
één donor lymfocyten infusie (DLI) gevaccineerd hebben met MiHA beladen DC’s. 
De DC’s werden toegediend op drie tijdstippen met een interval van 2 weken. De 
eerste vaccinatie werd gecombineerd met een DLI. We konden voor alle patiënten 
voldoende MiHA beladen DC’s genereren. De vaccins werden goed verdragen, 
patiënten ontwikkelden enkel tijdelijke roodheid en lokale zwelling op de plek van 
vaccinatie en graad 2 koorts na het tweede en derde vaccin. Niemand ontwikkelde 
GVHD. Bij 5 van de 9 patiënten zagen we na vaccinatie MiHA-specifieke T cellen in 
het bloed. Helaas zagen we geen objectieve klinische verbeteringen. Deze studie 
laat dus zien dat MiHA-gerichte DC vaccinatie mogelijk en veilig is, maar we 
constateren ook dat verdere verbetering van de behandeling nodig is.
 Zoals eerder beschreven, kan na allo-SCT ondanks de GVT reactie een recidief 
van de ziekte optreden. Eerder onderzoek door onze groep heeft aangetoond dat 
donor T-cellen na allo-SCT op den duur vaak een verminderde functie hebben, ze 
raken als het ware uitgeput. Deze verminderde functie is onder andere het gevolg 
van het voorkomen van het molecuul programmed death-1 (PD-1) op het oppervlak 
van de T-cellen. PD-1 gaat een interactie aan met zijn liganden: programmed death 
ligand-1 (PD-L1) en PD-L2 op APC’s en tumor cellen. Het uitdoven van een T-cel 
reactie is een natuurlijk beschermingsmechanisme in de mens. Bij een infectie is 
deze remming van de T-cel reactie immers functioneel, omdat dit voorkomt dat de 
T-cellen na een infectie geactiveerd blijven waardoor ontstekings- of auto-immuun 
ziekten zouden kunnen ontstaan. Echter na allo-SCT zorgt de remming van de 
T-cellen ervoor dat resterende tumorcellen de kans krijgen opnieuw uit te groeien 
met als gevolg een recidief van de ziekte. Ook de MiHA beladen DC’s die we in onze 
klinische studies toedienen  brengen PD-L1 en PD-L2 tot expressie. Het is gebleken 
dat het onderdrukken van de expressie van PD-L1 en PD-L2 op de DC’s zorgt dat 
hun vermogen om MiHA-specifieke T-cellen te activeren en expanderen toeneemt. 
Zonder een “Good Manufacturing Practice” (GMP) compatibele procedure om 
PD-L1 en PD-L2 op DC’s te onderdrukken, kan deze kennis echter niet vertaald 
worden naar de klinische praktijk. Daarom beschrijft hoofdstuk 3 van dit proefschrift 
een GMP-compatibele procedure waarin monocyten van donor origine gekweekt 
worden tot rijpe DC’s. Tijdens het kweekproces worden PD-L1 en PD-L2 onderdrukt 
door het toevoegen van partikels die PD-L1 en PD-L2 silencing RNA bevatten met 
daaraan toegevoegd SAINT-RED, zogenaamde siRNA/SAINT-RED transfectie. Aan 
het einde van het kweekproces worden de DC’s beladen met MiHA mRNA of 
peptiden. SiRNA/SAINT-RED transfectie resulteert in efficiënte en langdurige 
onderdrukking van PD-L1 en PD-L2 zonder de conditie of uitrijping van de DC’s te 
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remmen. De op deze wijze gegenereerde PD-L1/L2 negatieve DC’s zijn in staat 
MiHA- specifieke T-cellen efficiënt te activeren en expanderen. Momenteel wordt de 
veiligheid en werkzaamheid van deze PD-L1/L2 onderdrukte DC vaccins onderzocht 
in een fase I klinische studie. 
Natural killer cel therapie
Naast T-cellen, spelen ook NK-cellen een belangrijke rol bij het GVT effect na allo-SCT. 
NK-cellen zijn een onderdeel van het aangeboren immuunsysteem. Ze brengen in 
tegenstelling tot T-cellen, geen antigenspecifieke receptoren tot expressie, maar 
hun activatie wordt gereguleerd door de balans van hun binding aan een scala aan 
remmende en activerende receptoren. Elke NK-cel heeft tenminste één remmende 
receptor voor een zelf-HLA-molecuul. Hierdoor zijn NK-cellen onder fysiologische 
omstandigheden tolerant voor lichaamseigen cellen. NK-cel activatie kan in 
verschillende situaties optreden. Ten eerste kan er een toename zijn van activerende 
signalen, bijvoorbeeld door een infectie of een maligne transformatie. Dit wordt 
“induced-self” activatie genoemd. Ten tweede kan er in bepaalde situaties een 
afname zijn van het remmende signaal, bijvoorbeeld als tumoren expressie van HLA 
onderdrukken om aan T-cellen te ontsnappen. NK-cellen worden dan geactiveerd, 
dit wordt “missing-self” activatie genoemd. Missing-self activatie kan ook optreden 
na allo-SCT. Het is aangetoond dat een snel herstel van het aantal NK-cellen (NK-cel 
repopulatie) na allo-SCT geassocieerd is met een kleinere kans op het ontwikkelen 
van een recidief. Daarnaast lijken NK cellen ook buiten de transplantatie setting een 
GVT reactie te kunnen induceren. Daarom hebben verschillende studies onderzocht 
of toediening van allogene NK-cellen buiten de transplantatiesetting een rol kan 
spelen in de behandeling van acute myeloide leukemie (AML). Deze studies lieten 
zien dat toediening van allogene NK cellen (NK-cel “adoptive cell transfer” (ACT)) na 
conditionering met een tijdelijk afweeronderdrukkende (immunosuppressieve) 
chemotherapie remissie kan induceren bij hoog-risico AML-patiënten zonder GVHD 
te veroorzaken. Deze resultaten laten zien dat NK-cel ACT een aantrekkelijke therapie 
is om AML te bestrijden. De meeste voorgaande NK-cel ACT studies isoleerden 
NK-cellen via aferese uit het bloed van donoren, waarna de cellen overnacht 
gestimuleerd werden met IL-2 of IL-15. Het nadeel van deze procedure is dat op deze 
manier relatief weinig NK-cellen gegenereerd kunnen worden, daarbij bevatten de 
NK-cel producten ook nog achtergebleven T-cellen die GVHD kunnen veroorzaken. 
Daarom hebben wij een ex vivo kweekmethode ontwikkeld waarmee grote aantallen 
NK-cellen onder GMP omstandigheden kunnen worden gekweekt vanuit navel-
strengbloedstamcellen. Deze cellen zijn geheel vrij van alloreactieve T-cellen en zijn 
in vitro en in vivo hyperactief. Hoofdstuk 4 van dit proefschrift beschrijft een fase I 
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dosis escalatie studie waarin we de veiligheid, de in vivo overleving, vermeerdering 
en het effect op rest ziekte van dit NK-cel product bij oudere AML patiënten 
onderzochten. De patiënten in deze studie waren morfologisch in complete remissie 
na behandeling met chemotherapie of hypomethylerende middelen. De patiënten 
werden voorbehandeld met immunosuppressieve chemotherapie om directe 
afstoting van de donor NK-cellen te voorkomen en om de aanmaak van cytokines, 
die belangrijk zijn voor de overleving en rijping van de NK-cellen, te stimuleren. 
Daarna werden NK-cellen toegediend. We zagen in deze studie geen onverwachte 
toxiciteit en met name geen GVHD. We konden de toegediende NK-cellen 
detecteren in het bloed en beenmerg van de patiënten tot 8 dagen na infusie. Vier 
patiënten hadden voor toediening van de NK-cellen mimimale residuale ziekte 
(MRD), bij twee van deze vier patiënten verdween de MRD na de behandeling, dit 
effect hield zes maanden aan. Samenvattend laten deze resultaten zien dan NK-cel 
ACT een aanvullende behandeling kan zijn om MRD te bestrijden na behandeling 
met chemotherapie of hypomethylerende middelen bij oudere AML patiënten. 
Echter, aangezien het effect niet blijvend was, bleek verdere verbetering van deze 
therapie noodzakelijk.
 Het is opvallend dat beide patiënten die na behandeling met NK-cel ACT MRD 
negatief werden, voor inclusie in de studie behandeld waren met hypomethylerende 
middelen. Hypomethylerende middelen zijn in de afgelopen jaren geïntroduceerd 
en effectief gebleken in de behandeling van AML en het myelodysplastisch 
syndroom, voorbeelden van deze middelen zijn azacitidine en decitabine. Om uit te 
zoeken of azacitidine en decitabine mogelijk een positief effect hebben op NK-cel 
ACT, hebben we in hoofdstuk 5 het effect van deze middelen op ons NK-cel 
product onderzocht. Daarnaast hebben we bekeken of het combineren van 
azacitidine of decitabine met NK-cel ACT kon leiden tot een verbetering van het 
anti-leukemisch effect in vivo. In vitro onderzoek toonde aan dat azacitidine NK cel 
proliferatie en het vermogen leukemiecellen aan te vallen remt. Decitabine 
daarentegen remt deze eigenschappen niet. In vivo werd de overleving van de NK 
cellen niet geremd door azacitidine of decitabine. Zoals verwacht, hadden beiden 
middelen een remmend effect op de progressie van AML in vivo, echter alleen 
decitabine versterkte het anti-leukemisch effect van de NK-cel ACT. Decitabine 
zorgde voor een hogere expressie van activerende receptoren op de NK cellen en 
een toename van de mRNA levels van de inflammatoire cytokines perforine en 
TRAIL. Deze cytokines zijn belangrijk voor de anti-leukemische functie van de 
NK-cellen. Al met al kunnen we uit deze studie concluderen dat het combineren van 
decitabine met NK-cel therapie zinvol lijkt in de behandeling van AML patiënten.
 Zoals eerder beschreven zijn NK-cellen belangrijk voor de GVT reactie na 
allo-SCT. Dit blijkt uit het feit dat vroege uitgroei van NK-cellen (NK-cel repopulatie) 
na allo-SCT geassocieerd is met een verminderde kans op het ontwikkelen van 
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recidieven. Omdat vroege NK-cel repopulatie geen toename geeft van GVHD, zou 
NK-cel ACT na allo-SCT een aantrekkelijke therapie kunnen zijn. In deze setting heeft 
toediening van NK-cellen van donor origine de voorkeur. Donor NK-cellen worden 
immers niet afgestoten waardoor immunosuppressieve chemotherapie voor 
toediening niet nodig is. Hierdoor kunnen de NK-cellen op meerdere momenten 
toegediend worden. Bij de eerder door ons beschreven ex vivo kweekmethode 
werden NK-cellen gegenereerd uit navelstrengbloedstamcellen. Omdat het 
grootste deel van de donoren volwassen is, zullen voor de meeste transplantaties 
geen navelstrengbloedstamcellen beschikbaar zijn. In hoofdstuk 6 hebben we 
daarom onderzocht of het ook mogelijk is grote hoeveelheden potente NK-cellen te 
kweken uit granulocyte colony-stimulating factor (G-CSF) gemobiliseerde 
stamcellen verkregen uit perifeer bloed van stamceldonoren. We ontdekten dat 
deze stamcellen minder expansie lieten zien dan navelstrengbloedstamcellen. 
Echter de toevoeging van de aryl hydrocarbon receptor (AhR) antagonist 
StemReginin1 (SR1) zorgde voor een forse toename van de expansie. Daarnaast 
stimuleerde SR1 de NK-cel differentiatie. Hierdoor kunnen we nu grote hoeveelheden 
NK-cellen genereren uit G-CSF gemobiliseerde stamcellen. Deze NK-cellen zijn in 
staat om AML en multipel myeloom cellen te doden in vitro. Om te zien of deze 
NK-cellen al vroeg na allo-SCT toegediend konden worden, onderzochten we het 
effect van de immuunsuppressieve middelen mycofenolzuur (MMF) en cyclosporine 
A (CsA) op de NK-cellen. We ontdekten dat de NK-cel functie geremd wordt door 
MMF, maar niet door CsA. Omdat MMF relatief kort gebruikt wordt na allo-SCT 
zouden deze NK-cellen van donor origine al snel na de allo-SCT toegediend kunnen 
worden. Al met al is het toedienen van deze NK-cellen na allo-SCT een aantrekkelijke 
manier om het GVT effect na de stamceltransplantatie te versterken.
 Hoofdstuk 7 van dit proefschrift geeft een overzicht van de ontwikkeling van 
verschillende nieuwe immuuntherapieën voor de behandeling van multipel 
myeloom. Het is gebleken dat multipel myeloom cellen verschillende mechanismen 
kunnen ontwikkelen om aan het immuunsysteem te ontsnappen. Dit hoofdstuk 
beschrijft een aantal van deze mechanismen. Om deze mechanismen te overwinnen 
is het van belang de ziekte via meerdere wegen te bestrijden. Dit hoofdstuk laat 
daarom zien dat naast cellulaire immuuntherapieën, verschillende andere immuunt-
herapieën geïntroduceerd worden. Optimale integratie van deze nieuwe therapieën 
in de nabije toekomst zal een belangrijke stap zijn in het verbeteren van de 
uitkomsten voor hematologische patiënten. 
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Conclusie
In dit proefschrift hebben we verschillende veelbelovende cellulaire immuunthera-
pieën ontwikkeld, deze behandelingen zijn gericht op het versterken van het GVT 
effect, zonder het risico op GVHD te vergroten. De veiligheid en uitvoerbaarheid van 
een gedeelte van deze behandelingen hebben we aangetoond in fase 1 klinische 
studies. Tegelijkertijd hebben we op preklinisch niveau verbeterde behandelingen 
ontwikkeld. Deze verbeterde behandelingen zullen op korte termijn moeten 
worden vertaald naar de klinische praktijk. Daarnaast zullen deze behandelingen 
moeten worden geïntegreerd met elkaar en andere nieuwe behandelingen. Zo kan 
de effectiviteit vergroot worden waardoor ze de kans op overleving en kwaliteit van 
leven van patiënten die lijden aan hematologische ziekten in de toekomst kunnen 
vergroten. 
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Mieke Roeven werd geboren op 27 maart 1985 en groeide op in Grubbenvorst. In 2003 
behaalde zij haar VWO-diploma aan het Blariacumcollege in Blerick. In datzelfde jaar 
begon ze met haar studie geneeskunde aan de Radboud Universiteit Nijmegen. 
In het kader van haar wetenschappelijke stage verrichtte zij onder begeleiding van 
dr. H. Dolstra en prof. dr. T. de Witte wetenschappelijk onderzoek naar het fenotype 
van antigen-presenterende cellen in het beenmerg van multipel myeloom patiënten. 
In 2004 behaalde zij haar propedeuse en in 2010 het artsexamen, beide met het 
predicaat cum laude. Na het artsexamen werkte ze gedurende enkele maanden 
als ANIOS (arts niet in opleiding tot specialist) op de afdeling intensive care in het 
Radboudumc. In september 2010 startte ze met de opleiding tot internist. Het eerste 
deel van de opleiding vond plaats in het Canisius Wilhelmina Ziekenhuis in Nijmegen 
(opleider dr. A. Dofferhoff). In 2013 onderbrak ze haar opleiding om te starten met 
het promotieonderzoek zoals beschreven in dit proefschrift. Dit vond plaats onder 
begeleiding van dr. H. Dolstra, dr. N. Schaap, prof. dr. N. Blijlevens en prof. dr. J. Jansen. 
Naast haar promotieonderzoek nam ze deel aan het Radboud Institute for Molecular 
Life Sciences PhD programme. In 2014 ontving ze een American Society of 
Hematology (ASH) Abstract Achievement Award voor haar abstract op de ASH 
meeting in San Francisco. Daarnaast won ze in dat jaar een prijs voor de beste 
presentatie op de klinische dag van de Nederlandse Vereniging voor Hematologie. 
In 2015 hervatte ze haar opleiding tot internist in het Radboudumc (hoofdopleider 
prof. dr. J. de Graaf), momenteel is ze fellow hematologie in het Radboudumc.
 In haar vrije tijd hockeyt Mieke bij hockeyclub Union. Daarnaast doet ze aan 
hardlopen en in 2015 volbracht ze haar eerste marathon. Sinds 2010 woont Mieke 
samen met Tim Verhoeven. Samen hebben ze een dochtertje Anna.
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Uiteindelijk ben in toegekomen aan het laatste hoofdstuk van dit proefschrift. Ik 
moet bekennen dat ik als kind al droomde van het schrijven van een boek, ik had 
dan wel geen proefschrift in gedachten, maar een kinderboek. In navolging van 
mijn favoriete schrijfster Annie M.G. Schmidt, zou op de voorkant van dit boek staan: 
Mieke W.H. Roeven.  Hier is mijn eerste boek dan. Het is zeker geen kinderboek, maar 
op de voorkant staat Mieke W.H. Roeven. Toch klopt dat niet helemaal. Ik heb dit 
boek namelijk helemaal niet alleen geschreven. Er zijn heel veel mensen die hun 
bijdrage geleverd hebben aan het tot stand komen van dit proefschrift. Daarom wil 
ik deze mensen in dit hoofdstuk bedanken.
Allereerst wil ik alle patiënten bedanken die deelgenomen hebben aan de studies 
beschreven in dit proefschrift. Zonder jullie was dit proefschrift er niet geweest. 
Jullie hebben kostbare tijd gestoken in het deelnemen aan deze studies. Omdat het 
fase I/II studies betrof, kon ik jullie niet garanderen dat de behandeling voor jullie 
persoonlijk een positief effect zou hebben. Toch waren jullie bereid de behandeling 
te ondergaan in de hoop dat deze voor jullie en voor toekomstige patiënten een 
positief effect zou hebben. Hoewel jullie in de tekst van dit proefschrift als een 
nummer verschijnen, zijn jullie voor mij de patiënten die voor me zaten in de 
spreekkamer. Helaas zijn een aantal patiënten die deelgenomen hebben aan de 
studies op dit moment niet meer onder ons. Laten we hopen dat jullie inzet leidt tot 
betere vooruitzichten voor patiënten in de toekomst. Naast de patiënten wil ik alle 
partners en familieleden bedanken voor alle keren dat jullie met de patiënten naar 
het ziekenhuis zijn gekomen. 
Promotoren en co-promotoren, zonder jullie begeleiding was dit proefschrift er niet 
geweest. 
 Harry, wij leerden elkaar kennen tijdens mijn stage in het laboratorium. Gelukkig 
mocht ik een paar jaar later terug komen voor mijn promotieonderzoek. Ik wil je 
bedanken voor je enorme inzet deze studies, ondanks alle mogelijke obstakels die 
ik nooit had kunnen voorzien, tot een goed einde te brengen. Bedankt voor alle 
goede wetenschappelijke input, maar vooral ook voor je luisterend oor als ik het 
even niet meer wist. Hopelijk kunnen we onze samenwerking in de komende jaren 
voortzetten.
 Michel, het was ontzettend fijn dat ik de afgelopen jaren altijd binnen kon lopen 
voor alle vragen die ik had over de patiënten in onze studie en onze studies in het 
algemeen. Bedankt voor je inhoudelijke bijdrage aan alle hoofdstukken in dit 
proefschrift. En natuurlijk ook voor alle moeite om onze studies in het land te 
promoten, waardoor het gelukt is om ze tot een goed einde te brengen.
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 Nicole, jij wist een plekje voor mij te creëren op de afdeling. Hierdoor kreeg 
ik de kans om me te bekwamen in het celtherapie onderzoek. Bedankt hiervoor 
en ook voor je input voor dit proefschrift. Hopelijk kan ik ook in de komende tijd nog 
een positieve bijdrage leveren aan de afdeling.
 Joop, als professor van het laboratorium hematologie heb jij tijdens onze 
besprekingen en daarbuiten waardevolle input geleverd. Deze input heeft bijgedragen 
aan het tot stand komen van dit boekje. 
Willemijn, hoewel we tijdens onze introductie in 2003 mentorzusjes waren, werd jij 
in 2009 mijn begeleider op het laboratorium hematologie. Daar leerde je me voor 
het eerst wat een labjournaal is, hoe een pipet werkt en ga zo maar door. Ook tijdens 
mijn promotie heb ik ontzettend veel van je kunnen leren. Daarnaast was het ook 
gewoon gezellig om met je samen te werken. Volgens mij waren en zijn we een 
perfect laboratorium-kliniek team voor alle dendritische cel vaccinatie studies. Laten 
we dit ook de komende tijd nog voortzetten.
Post-docs van het laboratorium hematologie. Wat heb ik veel van jullie geleerd. 
Anniek, jij was mijn hulplijn als ik het even niet meer wist. Of het nou ging om de 
flow cytometer, een ELISA, de muizen of een statistisch probleem. Jij wist het met 
heel veel rust tot een goed einde te brengen. Je bent een geboren docent, dus ik 
ben heel blij dat je dit talent de komende tijd nog meer gaat ontwikkelen. Jeannette, 
thank you for our collaboration in the NK cell projects. You are a hard worker and 
a real expert if it concerns mouse work. Basav, je bent al een tijdje niet meer op 
het lab, toch heb jij er voor gezorgd dat de PLMA25 studie ging lopen. Bedankt voor 
dit voorwerk en natuurlijk voor je gezelschap op onze kamer! 
 Mijn mede-promovendi Soley, Tim en Lotte. Ook jullie wil ik bedanken voor de 
samenwerking en gezelligheid op het lab. Veel succes met het afronden van jullie 
proefschrift. En Tim, sorry dat ik altijd je spullen gebruikte… 
 Arwa, jij bent de enige student die in begeleid heb tijdens mijn onderzoek. 
Bedankt voor jou enorme inzet en werklust. Het was een plezier je te mogen 
begeleiden.
Janneke, wat was ik blij met jou als mede clinicus in de voor ons onbekende labora-
toriumwereld. Waar iedereen zich helemaal thuis voelde tussen de pipetten en 
celkweken, waanden wij ons in een nieuw universum. Het was heerlijk om samen 
te ontdekken hoe erg een mislukt experiment kan zijn…  Hopelijk gaan we de NK 
cellen ieder op ons gebied naar de kliniek brengen. 
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Zonder de analisten van het laboratorium hematologie was het lab voor mij nog 
steeds een vreemd universum geweest. Hanny, Frans, Rob, Marij en Marleen bedankt 
voor jullie hulp. Al in de vroege morgen kon ik met mijn vragen bij jullie terecht. 
Verder zorgden jullie ook voor een goede sfeer op het lab. En Frans en Rob, bedankt 
dat jullie me hebben geïntroduceerd bij Hit ‘91, anders was die marathon er nooit 
gekomen. Ook de analisten van de BMT Jos, Carel, Marianne en Hanna. Bedankt voor 
jullie bijdrage aan de studies en dat jullie me altijd wisten te vinden als er restmateriaal 
was. Daarnaast wil ik ook de collega’s van de moleculaire diagnostiek en IFT 
bedanken voor de hulp bij de diagnostiek van de studies en hun adviezen voor mijn 
laboratoriumwerk.
Op de afdeling hematologie zijn een heleboel mensen belangrijk geweest in het 
tot stand komen van deze studies. Ik wil beginnen met het bedanken van alle 
hematologen die patiënten geïnformeerd hebben over de studies en voor 
opgenomen patiënten in de studies gezorgd hebben. Met name Brigitte en Walter 
wil ik als leden van het SCT team bedanken. En ook Gerwin voor zijn inhoudelijke 
en bijdragende adviezen. Manita en Bart, jullie wil ik bedanken voor de hulp bij 
beenmergpuncties en het informeren van gezonde donoren. Suzanne, wat fijn dat 
jij als kenner van celtherapie naar Nijmegen gekomen bent. Laten we de komende 
tijd samen zorgen dat het onderzoek op dit gebied niet ophoudt. 
 Het datacentrum hematologie was onmisbaar voor onze studies. Olga, jij hebt 
enorm veel werk verricht in de communicatie met de CCMO, de financiën in de 
studies, het opbouwen van het studiedossier en het organiseren van overleg-
momenten. Voor onze studies was vaak een stapje extra nodig en jij was steeds 
bereid om dit stapje te zetten. Nori en Elise, bedankt voor jullie bijdrage in het data 
management. En natuurlijk vergeet ik onze researchverpleegkundigen niet: Marlies, 
Evelien, Elles en Lisanne, bedankt voor jullie hulp met de organisatie van de sampling. 
Verder wil ik alle verpleegkundigen van E10 en E00 bedanken voor de zorg die zij 
geleverd hebben aan onze patiënten.
Ook buiten Nijmegen hebben veel mensen bijgedragen aan dit proefschrift. 
Laurens, we hebben samen gewerkt aan de PSCT20 studie. Ik ben blij dat we onze 
krachten gebundeld hebben met dit resultaat. Ook Tuna Mutis en Henk Lokhorst 
moet ik hiervoor natuurlijk bedanken. Daarnaast zijn er vele collega’s in het hele land 
die patiënten naar Nijmegen verwezen hebben voor behandeling. Sommigen zijn 
als co-auteur opgenomen in dit proefschrift anderen niet. Uiteraard wil ik iedereen 
bedanken voor hun bijdrage. 
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Naast mijn promotieonderzoek, ben ik in opleiding tot internist. Deze opleiding 
zou niet mogelijk zijn zonder mijn opleiders. Ton Dofferhoff, Mark Mol, Margriet 
Oosterveld en alle andere internisten in het CWZ, bedankt jullie begeleiding in de 
eerste jaren van mijn opleiding en bedankt dat ik nog een jaartje langer in het CWZ 
mocht blijven toen de start van mijn onderzoek uitgesteld werd. Jacqueline, Jan en 
Gerald, jullie zijn een enorm betrokken opleidingsteam. Door jullie flexibiliteit is het 
mogelijk de opleiding met onderzoek te combineren. Bedank hiervoor. En natuurlijk 
wil ik al mijn collega AIOS in het CWZ en Radboud bedanken. Het is altijd fijn om 
collega’s te hebben om mee te overleggen, om op terug te vallen en natuurlijk ook 
om gezellig samen te lunchen of na het werk een borrel te drinken. Mede-fellows 
van de hematologie. We zijn tegenwoordig met velen…en dat is maar goed. Want 
het is heerlijk om zo veel fijne collega’s te hebben. 
Ik ben er van overtuigd dat de kwaliteit van je werk voor een groot deel afhangt van 
de kwaliteit van je vrije tijd. Mijn leven naast mijn werk zou niet zo mooi zijn zonder 
al mijn fijne vrienden, vriendinnen en familieleden…
Dames van union, in 2008 werd ons team opgericht. Ik kan me de eerste wedstrijden, 
waarbij we geen idee hadden wat de regels waren, nog als de dag van gisteren 
herinneren. In de loop van de jaren zijn sommige teamgenootjes vertrokken en er 
zijn er weer andere dames bijgekomen. Uiteraard zijn we ook veel beter geworden. 
Echter, het belangrijkste voor mij is dat we al die jaren een supergezellig team 
gebleven zijn. Ook na de fusie dit najaar is het een genot om met jullie op en naast 
het veld te staan, hopelijk spelen we nog vele jaren samen.
Martine, al in groep 3 werden wij klasgenootjes. Sindsdien zijn we altijd vriendinnen 
gebleven. Ik wil niet weten hoeveel uren we in onze middelbare schooltijd naast 
elkaar gefietst hebben en hoe vaak wij als eerste (en bijna enigen) in de kroeg zaten 
omdat de laatste bus van Grubbenvorst naar Venlo al zo vroeg ging. Ik ben dan ook 
heel erg blij dat jij op deze bijzondere dag naast me staat als paranimf! En na deze 
dag op naar de volgende 25 jaar vriendschap!
 Josien, samen met Martine vormden we op de middelbare school de Kwekke-
boompjes. Het was altijd gezellig zo samen op de laatste rij. Ook in de jaren daarna zijn 
we elkaar blijven opzoeken. Dames, bedankt dat jullie al zo lang mijn vriendinnen zijn. 
Laffe herders, tijdens onze studie wisten wij elkaar al snel te vinden. Als ik terugdenk 
aan alles wat we sindsdien samen beleefden loopt mijn hoofd over. Van flessenavond 
bij het Bascafé, MFV-feesten, Batavierenraces, gedenkwaardige wintersporten tot 
weekenden in Schoorl. Ieders eigen karakter maakt ons samen een fantastische 
groep. Ik hoop nog vele jaren van jullie gezelschap te genieten.
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Het MFVN zeilweekend in 2004 zal ik nooit vergeten, hier werden de mosselvrouwen 
geboren. Negen vrouwen naar mijn hart. Sinds die tijd delen we lief en leed (en er 
kwamen heel wat lieven en leed voorbij…) met name tijdens ons “maal” op de 
maandagavond. Hoewel ons maal de afgelopen tien jaar transformeerde van een 
bordje op schoot op de grond in onze studentenkamer naar zelf verbouwde groente 
uit de moestuin in een koophuis met tot 3 kinderen in bed, is het gezelschap er 
nooit minder op geworden. Ik hoop nog heel lang van jullie gezelschap te genieten. 
En lieve Bibi, wij zijn de laatste die het “schelpje” in ontvangst mogen nemen. 
Ik ben zo blij dat jij als mede-onderzoeker, mede-AIOS, mede-hockeyster en mede- 
marthonloopster op deze dag mijn paranimf wil zijn
Willie, Willem-Jan, broers en schoonzussen Verhoeven, bedankt voor de gezelligheid 
en dat ik er zo’n gezellige grote warme familie bij heb. 
 Lieve zus, je weet dat ik niet in een paar zinnen kan schrijven hoe blij ik ben dat 
ik jou als zus heb. Met jou kon ik vroeger uren spelen, door jou kan ik heel goed 
tegen plagen, jij leerde me vroeger alles over de middelbare school en liet mij voor 
het eerst zien hoe leuk het is om op kamers te gaan. En als kers op de taart zijn we 
ook nog eens bijna tegelijk moeder geworden! Hoewel we best op elkaar lijken van 
buiten, zijn we toch heel verschillend en juist daarom vullen we elkaar zo mooi aan. 
Je blijft altijd mijn allerliefste zus!
 Pap en mam, ik kan jullie nooit genoeg bedanken, door jullie ben ik geworden 
wie ik ben. Jullie hebben mij meegenomen de wereld in, altijd gesteund in het 
maken van mijn keuzes, jullie waren misschien nog wel blijer dan ik zelf als er iets 
goed ging en als het tegenzat waren en zijn jullie er onvoorwaardelijk voor me. Deze 
dag is pas compleet met jullie op de eerste rij!
 Lieve Anna, jij hield mij gezelschap tijdens het afronden van dit proefschrift. Jou 
gezellige schopjes waren een grote motivatie om dit project tot een goed einde te 
brengen. Als je later groot bent zal ik je vertellen waar het over gaat.
 Lieve Tim, jij bent al jaren mijn steun en toeverlaat. Jij hebt een enorm vertrouwen 
in het leven en ik heb enorm vertrouwen in het leven met jou! Dit project is nu klaar 
en ik ben klaar voor de rest van ons leven samen!
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PHD PORTFOLIO
Name PhD candidate: 
M.W.H. Roeven
Department: 
Hematology /Laboratory Medicine
Graduate School: 
Radboud Institute for Molecular Life Science
PhD period: 
01-01-2013 – 24-11-2017
Promotor(s): 
Prof. N. Blijlevens / Prof. J. Jansen
Co-promotor(s):  
Dr. N. Schaap / Dr. H. Dolstra
Year(s) ECTS
TRAINING ACTIVITIES
Courses & Workshops
- Introduction day Radboudumc 
- Graduate School specific introductory course 
- Course on Laboratory Animal Science
- BROK course
- NVVH Hematology Course
- Workshop presenting skills by Spies&Spreken
- Academic writing course
- Member TSP committee
- POAG Heyendaal, Artsen met aandacht
- Organizing technical forum
- Member TSP committee
- Journal club, Urinary tract infections
- Member of TSP committee
- Journal club: Cannabis in palliative care
2013
2013
2013
2013
2013
2014
2014
2014
2014
2015
2015
2015
2016
2016
- 0.5
- 2.0
- 2.5
- 1.25
- 1
- 0.25
- 3
- 0.5
- 0.25
- 0.25
- 3
- 0.5
- 0.25
- 0.5
- 1
Seminars & lectures
- NCMLS seminars
- Noon spotlight symposia
- Radboud research rounds
- Technical fora
- Seminars 4x
2013
2013
2014
2014
2014
- 0.5
- 0.5
- 0.3
- 0.3
- 0.4
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Symposia & congresses
- Radboud Frontiers
- RIO science day including laptop presentation
- Glycostem UCB progenitor and NK cell symposium
- Afscheidssymposium Theo de Witte
- NVGCT symposium + oral presentation
- NCMLS PhD retreat
- PhD retreat including poster presentation
- DHC congress including oral presentation
- Visit EBMT meeting Milan, including oral 
presentation
- Visit Dutch Tumor Immunology Meeting
- Presentation “Klinische dag hematologie” best 
presentation award
- RIO science day including laptop presentation (third 
prize laptop presentation)
- Visit ASH annual meeting including poster 
presentation, ASH Achievement Award
- Dutch Hematology congress, including oral 
presentation
- Visiting conference: Internistendagen
- Visit EBMT meeting Valencia, including oral 
presentation
2013
2013
2013
2013
2013
2013
2014
2014
2014
2014
2014
2014
2014
2015
2015
2016
- 1.0
- 0.5
- 0.5
- 0.25
- 0.25
- 0.75
- 1.0
- 1.0
- 1.25
- 0.5
- 0.75
- 0.5
- 1.5
- 0.5
- 0.25
- 1.25
TEACHING ACTIVITIES
a)  Lecturing
- Lecture for nurses about HOVON115 clinical study
- Lecture for nurses about PLMA25 study
- 2 hours of teaching and preparation of an exercise 
about Natural killer cells for medicine students in a 
course on Stem cell transplantation
- 4 hours of teaching about advanced care planning 
and defining research questions in palliative care for 
(bio)medical students
2014
2014
2015
2016
- 0.2
- 0.1
- 0.1
- 0.4
b)  Supervision of internships 
- Supervision MMD student 2014 - 2
TOTAL 31.3
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